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Globalization, Health and Diseases 
Just as individuals cannot live in isolation, nation states need to commune, exchange and 
cooperate with others. Even the most self-reliant nation states must trade in order to survive 
and maintain sustainable development. However, globalization 1 has complex and far-reaching 
effects on the world population. For example, diseases also spread across national boundaries 
via goods and people. Pharmaceuticals used in the treatment and prevention of diseases also 
flow into the global trading system and are delivered into the hands of patients or consumers all 
over the world. 
Globalization promotes national macroeconomic and social policies; regulates environments 
and institutions. Economic growth and technological advances offer incentives for the research 
and development (R&D) of new drugs or vaccines which provide disease-preventing and 
life-saving benefits. On the other hand, globalization jeopardizes the health of populations and 
highlights severe gaps in health inequity. In the struggle between the rich and the poor, the 
North and the South, the health of innocent people is too often the first sacrifice. 
A study of projected global deaths for selected cause of death, 2002-20302, predicts world 
I 
WHO, Globalization, Trade and Public Health: Tools and Training for National Action: Report of an Intercountry 
Expert Group Meeting, P.3, 2001, available at 
http://whqlibdoc.who.int/searo/2001/SEA HSD 244.pdf(last accessed on March 16, 2009) 
Globalization refers to three distinctive and interrelated phenomena: increasing cross-border flows of goods, 
services, money, people, Globalization, trade and public technology and ideas; opening of national economies and 
boundaries to such flows; and development of international institutions and rules governing these cross-border flows. 
Globalization can scale up the effective public health interventions. It can affect the national health budget, access to 
health goods and products (drugs, vaccines, medical supplies, etc.), international mobility on health care services 
and influencing knowledge on policies. Globalization can also increase the environmental and occupational hazards. 
{he movement of people brought about different life styles, and the spread of diseases. 
WHO, World Health Statistics, P.l2, 2007, available at 
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deaths will show a substantial shift from a younger age group to an older age group and from 
infectious diseases to chronic diseases. Deaths due to communicable, maternal, perinatal and 
nutritional causes are expected to decrease from 30% in 2005 to 22% in 2030, with the exception 
of HIV I AIDS3• Childhood vaccination in developed countries has resulted in fewer cases of 
childhood infectious diseases; however, this is not yet the case in developing countries. At the 
same time, the aging of the global population of developed countries will result in a significant 
increase in chronic diseases and will likely account for almost 70% of all deaths in 2030.4 
Indeed, the four leading causes of global death in 2030 are projected to be chronic heart 
disease, stroke, HIV I AIDS and chronic obstructive pulmonary disease. The total number of 
deaths attributable to tobacco use is projected to rise from 5.4 million in 2005 to 6.4 million in 
2015 and to 8.3 million in 2030. Tobacco is projected to kill 50% more people in 2015 than 
HIVIAIDS, and to be responsible for 10% of all deaths. 5 In developed countries, due to diet, 
tobacco-use and aging6 populations, there are many more people with chronic diseases than with 
infectious diseases; however, developing countries are still haunted by both chronic diseases and 
infectious diseases. 
http://www.who.int/whosis/whostat2007.pdf(last accessed on March 16, 2009) 
3 
WHO, World Health Statistics, P.14, 2008, available at 
http://www.who.int/whosis/whostat/EN WHS08 Full.pdf(last accessed on March 20, 2009) 
Although the total number of people living with HIV has increased significantly over the years, the proportion of 
infected has not changed since the end of the 1990s. In fact, the number of people who become infected every day 
(over 6800) is greater than the numbers who die of the disease (around 6000). Worldwide, 0.8% of the adult 
yopulation (aged 15-49 years) is estimated to be infected with HIV, with a range of0.7-0.9%. 
WHO, World Health Statistics, P.12, 2007, available at 
~ttp://www.who.int/whosis/whostat2007.pdf(last accessed on March 20, 2009) 
WHO, World Health Statistics, P.12, 2007, available at 
~ttp://www.who.int/whosis/whostat2007.pdf(last accessed March 20, 2009) 
UN News Centre, 'New UN estimates Predict 2.5 Billion Increase in World Population by 2050', 2007, available 
at 
?ttp://www.un.org/apps/news/story.asp?NewsiD=2184 7 &Cr=populat&Cr 1 =&K w 1 =UN+estimates+predict+ 2.5+bill 
IOn+increase+in+world+population+by+2050&Kw2=&Kw3= (last access on March 16, 2009) 
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Infectious Diseases 
In 2005, 30% of all deaths were caused by infectious disease,7 which represented more than 15 
million deaths; ofthose, 6.7 million were children, mostly in developing countries. HIV-AIDS, 
malaria and tuberculosis are the three main diseases which cause of death and claimed around 
5.7 million lives per year worldwide. 8 The vast majority of those infected are due, 
unsurprisingly, to the international trade of goods, movement of people and vectors. In addition, 
an increasing and expanding world population, environmental change and degradation, 
trans-boundary pollutants and sanitation problems, and increasingly resistant strains of viruses 
and genetic mutations have made diseases even harder to prevent and treat. Some of the viruses 
even cross the barrier of species from animals to the human population, becoming a more serious 
threat to health. 9 
The burden of diseases has influential impacts on poverty and national economies. 
Pharmaceuticals products and immunization have therefore become the most desirable and cost 
effective methods of fighting against infectious diseases. As a result of how infectious diseases 
spread beyond boundaries and sovereignty, nation states cannot deal with infectious diseases by 
themselves or by border control despite advancements in medical technology. International 
co-operation and surveillance are essential to early warning and preparation efforts aimed at 
7 
WHO, WHO World Health Statistics, 2006, available at 
rttp://www.who.int/whosis/whostat2006.pdf(last accessed on March 22, 2009). 
Maureen Birmaingham and Claudia, 'The Burden of Vaccine-Preventable Diseases', Barry R. Bloom, Paul-Henri 
Lambert edited, The Vaccine Book, P.l4, Academic Press, 2002 and WHO, 'HIV-elated TB Deaths Higher than Past 
Estimated', 2009, available at . 
http://www. who.int/mediacentre/news/releases/2009/tuberculosis report 20090324/en/print.html (last accessed on 
March 24, 2009) 
Jhere are 1.37 new TB cases in 2007 among HIV-infected people, says new global TB control report. 
Take the example of bird flu, which has been identified as common flu in bird species has now, cross the barrier as 
the H5NI and could cause infection on human populations. This dissertation also proposes that in order to have right 
to health to human bring, attentions should also by paid to pharmaceutical products to possible vectors. 
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controlling the global threat posed by the emergence and re-emergence of infectious diseases. 
Chronic Diseases 
The major cause of deaths among children is infectious diseases; by contrast, the current major 
cause of death among adults is chronic diseases. Globally, of the 58 million deaths in the world 
in 2005, 35 million were attributed to non-communicable diseases. This number is double the 
number of deaths from infectious diseases, including HIV I AIDS, tuberculosis and malaria, 
maternal and perinatal conditions, and nutritional deficiencies. 
The number of deaths caused by chronic diseases is fairly equal for men and women. Out 
of the 3 5 million of deaths, 45% occurred prematurely, 16 million were under 70 and around 
80% of deaths occurred in developing countries. 10 In addition to the high death toll, the burden 
of chronic diseases is also heavy skewed. When measuring the burden of disease by disability 
adjusted life year (DALY) 11 , approximately half of the disease burden is due to chronic disease. 
Among the chronic diseases, the leading causes are cardiovascular diseases, cancer, and chronic 
respiratory disease. 12 Unlike the death rate for chronic diseases that predominate in developing 
countries, chronic diseases contribute considerably to the disease burden of all income groups. 13 
10 
WHO, World Health Statistics, P.l4, 2006, available at 
http://www.who.int/whosis/whostat2006.pdf(last accessed on March 22, 2009) 
The rate is higher and the age of death is younger in the developing countries, where most of the world population 
lives. 
11 
WHO, Prevention Chronic Diseases: A Vital Investment, P.39, 2005, available at 
www.who.int/chp/chronic disease report/full report.pdf(last accessed on March 16, 2009) 
The method of the disability adjusted life year (DALY) is using the combination of number of year of healthy life lot 
to premature death with the time spent in less than full health. One DALY can be thought of as one lot healthy year 
of life. 
12 
WHO, World Health Statistics, P.l4, 2006, available at 
~!tp://www.who.int/whosis/whostat2006.pdf(last accessed on March 22, 2009) 
WHO, Prevention Chronic Diseases: A Vital Investment, P.61, 2005, available at 
www.who.int/chp/chronic disease report/full report.pdf(last accessed on March 16, 2009) 
The burden of infectious and chronic diseases is both loaded in middle and low courtiers. The figure might imply 
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An estimated 17.5 million people died from cardiovascular disease in 2005, representing 30% of 
all global deaths. 14 Cancer, as the second leading cause of death, claimed 7.6 million lives in 
2005 15, which is about 13% of the world's deaths, and 70% of the deaths were in developing 
countries. The high prevalence of cancer is ominously shifting from developed nations to the 
poorer, less medically equipped countries. It is estimated that by the end of 2015, the number 
of deaths caused by cancer will rise to 9 million, and could reach 11.5 million by the end of 
2030. 16 Respiratory tract diseases are diseases of the airways and other structures of the lung 
that affect the air passages, including the nasal passages, the bronchi and the lungs. 17 The top 
five chronic respiratory diseases account for 17.4% of all deaths and 13.3% of all 
Disability-Adjusted Life Years (DAL Ys). 18 An estimated 2.2 million people died from diabetes 
in 2005. 19 80% of the deaths occurred in developing countries. Almost 50% of the deaths 
occurred in people under 70, and 55% of the deaths were women?0 
Diseases affect the public health as well as individual health. The global trade in goods 
that the socioeconomic status do have some relationship between the condition of health. 
14 
WHO, Cardiovascular Diseases, available at 
www.who.int/topics/cardiovascular diseases/en! (last accessed on March 16, 2009) 
15 
WHO, The World Health Organizations Fight Against Cancer: Strategies that Prevent, Cure and Care, P.4, 2007, 
available at 
www.who.int/cancer/publicat/WHOCancerBrochure2007.FINALweb.pdf(last accessed on March 16, 2009) 
At least 7 million of people die from cancer. The number of death is even more than the total deaths of the 
combination ofHIV/AIDS, malaria and tuberculosis. Thus, chronic disease has been a real problem to the 
rc,opulation. 
WHO, The World Health Organizations Fight Against Cancer: Strategies that Prevent, Cure and Care, P.3, 2007, 
available at 
~ww.who.int/cancer/publicat/WHOCancerBrochure2007.FlNALweb.pdf (last accessed on March 16, 2009) 
WHO, Chronic Respiratory Diseases, available at 
~ww.who.int/respiratory/en! (last accessed on March 16, 2009) 
WHO, WHO Strategy for the Prevention and Control of Chronic Respiratory Diseases, 2002, available at 
~ww. who.int/entity/respiratory/publications/WHO MNC CRA 02.1.pdf (last accessed on March 16, 2009) 
WHO, 'Diabetes: Fact Sheet', 2008, available at 
www.who.int/mediacentre/factsheets/fs312/en!print.html (last accessed on March 16, 2009) 
WHO projects that death caused by diabetes will increase by more than 50% in the next 10 years without urgent action. Most 
~ootably, diabetes deaths are projected to increase by over 80% in upper-middle income countries between 2006 and 2015. 
WHO, 'Diabetes: Fact Sheet', 2008, available at 
www.who.int/mediacentre/factsheets/fs312/enlprint.html (last accessed on March 18, 2009) 
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and people spreads infectious diseases and worsens the burden of chronic diseases worldwide. 
The burdens of diseases seriously affect countries' economies and societies in both developed 
and developing countries. 
The Problem 
The effects of the globalization, urbanization, and population-aging drive social, economic and 
cultural change, especially with regards to the underlying determinants. The rapid changes of 
underlying determinants affect individual health and public health in diseases and 
pharmaceuticals. Health inequalities have expanded from the risk of infectious diseases to risk 
factors for chronic diseases. The burden21 of diseases causes poverty and hinders the economic 
development of many countries. Diseases can turn poverty into a downward spiral of 
worsening disease and poverty while the socioeconomic inequalities jeopardize a population's 
health.22 
Health and health-related issues, particularly regarding how to balance the interests of 
transnational pharmaceutical corporations by offering incentives for R&D while providing 
accessible and affordable pharmaceutical products for patients/consumers to realize the 
international human right to health, get enmeshed in the field of foreign policies and political 
21 
WHO, World Health Statistics, 2006, P.14, available at 
http://www. who.int/whosis/whostat2006.pdf (last accessed on March 22, 2009) 
Applying the widely used "DALYS" summary measure of the burden of disease (disability-adjusted life-years), 
which combines years of healthy life lost to premature death with time spent in less than full health. When compared 
with 13% by injuries and 39% by communicable diseases, maternal and perinatal conditions and nutritional 
~eficiencies combined, non-communicable diseases cause almost half of the global burden of disease. 
WHO, Prevention Chronic Diseases: A Vital Investment, P.66, 2005, available at 
w~w.who.int!chp/chronic disease report/full report.pdf(last accessed on March 18, 2009) 
~~s:~se and poverty will fall into a cycle. The burdens of disease have direct and indirect economic impact of 




Ideally, globalization would cause actors in the international community to form a global 
village and conduct trade in a cooperative and supportive manner, but in practice, the 
globalization of pharmaceuticals gets stuck in a bottleneck when it comes to distributing interests, 
thus jeopardizing the equality necessary for maintaining the health of the world population. 
Health and diseases are national and political issues falling within the obligations for which 
each state is responsible and accountable. The emerging global economy promotes and changes 
the rapid attention to the involvement of non-state actors on the global health and the 
commercialization of pharmaceutical-related science and technology. The tangle of 
globalization, international relations, and politics makes health issues even more pressing and 
certainly more complicated. 23 Issues of availability and affordability of pharmaceuticals, 
especially in developing countries, have become an urgent problem in need of practical 
solutions,24 and require a deeper understanding of the impact of globalization on human right 
and health concerns. 
Carrying a special mission, pharmaceutical products have been both the front line and last 
resort contributing to the human rights to health, and often determining life or death; however, 
23 
WHO, Globalization, Trade and Public Health: Tools and Training for National Action, P.1, 2001, available at 
http://whglibdoc. who.int/searo/200 1 /SEA HSD 244.pdf (last accessed on March 18, 2009) 
"While globalization and trade liberalization have implications for health, a consensus on the mechanisms by which 
~~ey affect the health of populations and pathways for the protection of health has remained elusive." 
Bhushan Patwardhan, Traditional Medicine: Modern Approach for or Affordable Global Health: Could more 
effective use be made of them in providing affordable treatments, P.17, 2005, available at 
~ww.who.int/intellectualproperty/studies/B.Patwardhan2.pdf (last accessed on March 18, 2009) 
Globalization has the most impact in developing countries. The disproportionate growth and the diseases, the burden 
0~ diseases has gone beyond for the reach of the population. The poverty, the burden of diseases falls into a vicious 
crrcle. 
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pharmaceutical products are also one of the goods which are the subject of global trade. All 
actors involved in the international community have to recognize the right to health in the 
context pharmaceuticals as a basic human right in order to realize the right and co-operate under 
international law. 
Examining the problems of realizing the right to health in accessible and affordable 
pharmaceutical product, this dissertation begins in Chapter 1 with the legal personality of the 
actors involved in the realization of the right to health. Chapter 2 further explores the 
uniqueness of pharmaceutical products and development of the pharmaceutical industry. 
Chapters 3 describes the development of intellectual property protection on pharmaceutical 
products. Chapter 4 then focuses on the international human rights development of the right to 
health and discusses on the relationship of the right to health to accessible and affordable 
pharmaceutical products. Chapter 5 describes n greater detail the responsibility and 
accountability of the right and how international law should adapt to the global world. Lastly, 
Chapter 6 returns to the problem of the international human right to health and proposes a 
resolution to balance the interests. 
- 8-
Section I. Subject of International Law 
Chapter One: Legal Personality of Actors Involved in the Human Right to Health 
1.1 Legal Personality 
International laws form into legal frameworks, in which state actors and non-state actors, such as 
individuals, private corporate entities, and international organizations, interplay and interact in 
the international community. Traditionally, the so called public "inter-national" law regulates 
the relationship between its primary subjects, nation states. However globalization has given 
non-state actors a growing importance into the international community under international law. 
With the vigorously growing global economy, private corporate entities which operate and 
trade globally gradually becoming transnational corporations, sell their products or service 
everywhere in the world and are able to negotiate with national governments. Their powers 
have been so influential that when their businesses constitute the major industries of a nation 
state, often they influence the negotiation of treaties and engage involvement of foreign policies 
between nation states. While non-state actors are exercising their powers and influences on the 
forming or negotiation international law, non-state actors essentially participate in rule-making 
activities. 
As subjects of the various legal systems, persons or entities can hold rights and bear 
duties,25 and whether non-state actors have the legal personality to bear obligations and are 
accountable and responsible under international law is the subject of ongoing debate. 26 The 
traditional concept of state-centered public international law has dominated the law for years. 
2s Chr' 
26 ts N. Okeke, New Subject of Contemporary International Law, P.9, P.l9, 1973 
Andrew Clapham, Human Rights Obligations of Non-State Actors, P.62, Oxford University Press, 2006 
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Due to the effects of globalization, some approaches propose to expand international law's reach 
to cover non-state actors as well as state actors, while other approaches object to claim the legal 
responsibility and accountability beyond the traditional concept of state-centered international 
law.27 
One approach insists that states are the main actors and the only obligor of human rights 
under international law. The state actors will be accountable for failing to establish legal 
systems to enforce their own laws against the non-state actors. State actors are responsible for 
regulating the non-state actors, and ensuring that they comply with and do not violate 
international law. This approach suggests that having new subjects in international law might 
diffuse accountability. 28 
A second approach addresses the increasing irrelevance and powerlessness of state actors in 
the globalized world. This theory claims that there should be legal systems and transnational 
justice to respond to globalization. This approach recognizes the importance of non-state actors, 
but it does not seek to impose duties on non-state actors as subjects of international law directly; 
state actors would still remain as the main actors in international law. According to this theory, 
the interactions between state actors and non-state actors do not create customary international 
law; only interaction between state actors can create such law. Thus, there are cases in which 
non-state actors might be bound by international agreements, but these non-state actors do not 
enter the international law making processes?9 
27 Chr' 
IS N. Okeke, New Subjects of Contemporary International Law Through Their Treaty-making Capacity, P.9, 
P.19, 1973 
28 
29 Andrew Clapham, Human Rights Obligations of Non-State Actors, P. 25-29, Oxford University Press, 2006 
Andrew Clapham, Human Rights Obligations of Non-State Actors, P. 25-29, Oxford University Press, 2006 
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This dissertation suggests the third approach postulating rights and duties through capacity 
rather than traditional concept of subjectivity. In his epic work Professor Christian Okeke 
outlines three essential elements of a qualified subject of a legal system. Firstly, that entity is 
capable of claiming benefits of the rights conferred by the law; secondly, such an entity must 
bear duties for violation of those duties; thirdly, with the capacity that entity can pose contractual 
capacity or other legal relationship with other subjects of the system, but the extent may vary 
with the nature of the person or entity.30 Daniel O'Connell also states that capacity implies 
personality, as in the capacity to do those particular acts. 31 Here, capacity refers not only the 
capacity to enjoy rights and obligations, but also the capacity to be held accountable for failure to 
fulfill those obligations. 
This approach claims to retain the importance of state actors within public international law, 
but proposes to expand and goes beyond the traditionally state-focused aspects of international 
law and subjects of international law to some non-state actors; however, this approach does not 
suggest that all non-state actors could serve as law makers. 32 International law does not 
prescribe which if any entities are entitled to an international personality, or which are 
recognized as being subject to international law. When the non-state actors serve important 
functions and hold the same power as state actors, such as the Vatican's Holy See, insurgent or 
belligerent parties, non-governmental organizations, or transnational corporations, these entities 
3o Chr' 
IS N. Okeke, New Subjects of Contemporary International Law Through Their Treaty-making Capacity, P.9, 
P.l9, 1973 and see also Emeka Duruigbo, 'Corporate Accountability and Liability for International Human Rights 
Abuses: Recent Changes and Recurring Challenges', 2008, http://www.Iaw.northwestem.edu/joumals!JIHR/v6/n2/2/ 
(last accessed on March 22 2009) 
31 ' 
Andrew Clapham, Human Rights Obligation ofNon-StateActors, P.71, Oxford University Press, 2006 
~s Klabbers concludes, personality is just like subjectivity in international law. 
C ~ndrew Clapham, Human Rights Obligations of Non-State Actors, P. 25-29, Oxford University Press, 2006 and 
hns N. Okeke, New Subject of Contemporary International Law, P.205-206, 1973 
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are said to assume into international legal responsibility and accountability. 33 
International law has already addressed the concerns regarding the duties and obligations of 
individuals both in their public and private capacities. Today, international law has also 
extended this concern to inter-governmental organizations?4 The role of non-state actors in 
today's world cannot be ignored, yet there is no international standard or framework to explain 
the rights and duties oftransnational corporations (TNCs) under international law. 
1.2 Transnational Corporations and International Human Rights Law 
The issue of whether the TNCs can be held accountable or responsible for international human 
rights depends on the status and characteristics of non-state actors under international law in the 
global world. Responding to the increasing importance and influential status of TNCs, there are 
various approaches addressing the application of these obligations to TNCs. 
Traditionally TNCs are not parties to international human rights treaties even though TNCs 
play essential roles in global trade and participate in shaping international law indirectly.35 
State actors are bound by international law to ensure TNCs' conformity to international human 
rights protection; whether nation states have power to enforce and ensure international human 
rights protection on TNCs is another question.36 The state-centered approach suggests that the 
33 Chr" 
34 IS N. Okeke, New Subject of Contemporary International Law, P.220, 1973 
C Remigius Chibueze, 'The Legal Personality of Non-State Entities in International Law: A Settled Issues?', Chima 
C en~s. Nweze edited, Contemporary Issues on Public International Law: Essays in Honor of Professor Dr. 
35 hnstzan Nwachukwu Okeke, P.l71-188, Vandeplas Publishing, 2009 
Ch Emeka Duruigbo, 'Corporate Accountability and Liability for International Human Rights Abuses: Recent 
anges and Recurring Challenges', 2008, available at 
~.law.northwestern.edu/journals!JIHR!v6/n2/2/ (last accessed on March 18, 2009) 
sm ~any ~orporations, especially multinational corporations, have more power, resources or influence than many 
a nation states in the world now. 
- 12-
extension of international human rights protection to TNCs will thereafter chip away at the 
foundation of the human rights movement, thereby accelerating the chances of its eventual 
disintegration and ruin. 37 
International human rights protection is the very fundamental protection of the dignity of 
human beings. Today, international human rights protections have new needs and demands 
because of the participation of influential and important non-state actors in the international 
community. International law and international human rights machinery and norms should 
respond to these needs and demands in order to continue offering effective and sustainable 
international human rights protections. 38 
A corporation has legal personality under the national domestic law of the state of its 
incorporation or establishment. The issue of the legal subjectivity of TN Cs to international law 
is even more complex. There has been strong resistance to including TNCs within legal 
definitions as having international legal personality, thereby acquiring responsibility and 
accountability on international human rights protection.39 There are fears that treating non-state 
actors with the same status as nation states would implicitly suggest that non-state actors are 
being endowed with the rights and obligations of nation states, and would be called upon to 
perform important and influential functions. However, the reality is that some of the TNCs are 
more influential than some nation state actors. Disregarding the status of these TNCs under 
37 
38 Andrew Clapham, Human Rights Obligation of Non-State Actors, P.32, Oxford University Press, 2006 
Andrew Clapham, Human Rights Obligation of Non-State Actors, P.32, Oxford University Press, 2006 
A~ Christine Chinkin states, "[t]here is apprehension that to transform the vision of human rights to include acts by 
~IV~te indi~iduals would disturb and undermine the entire edifice of human rights .... If human rights law is so 
39 agde that It cannot withstand such re-conceptualization, then it is barely worth preserving." 
C Remigius Chibueze, 'The Legal Personality of Non-State Entities in International Law: A Settled Issues?', Chima 
Nentus Nweze edited, Contemporary Issues on Public International Law: Essays in Honor of Professor Dr. Christian 
wachukwu Okeke, P.189-196, Vandeplas Publishing, 2009 
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international law would be very dangerous and harmful, especially with regard to the 
international human rights protection. Professor Andrew Clapham observes that "[i]f 
international law is to be effective in protecting human rights, everyone should be prohibited 
from assisting governments in violating those principals, or indeed prohibited from violating 
such principle themselves."40 
International human rights protection has traditionally been regulated by the relationship 
between the national governments, individuals and groups. With the impacts and increased 
roles of non-state actors at both the national and international level, attention must be paid to the 
responsibilities and accountabilities of non-state actors. However, to date, the practical 
meaning of the link between non-state actors, business, and human rights remains uncertain, and 
there is much debate over how and which human rights can and should apply to non-state 
actors.41 
1.3 Transnational Pharmaceutical Corporations and TRIPS 
With the recent trend towards economic globalization, pharmaceutical corporations have also 
acquired or merged beyond their national boundaries. Many of the pharmaceutical corporations 
are now composed as TNCs.42 The transnational pharmaceutical corporations are among the 
most important non-state actors in the international community, because their products and 
influences have a global impact on both public and individual health. 
40 
41 Andrew Clapham, Human Rights Obligation of Non-State Actors, P.80, Oxford University Press, 2006 
?ffice of the United Nations High Commissioner for Human Rights, Globalization-Business and Human Rights, 
avatlable at 
~://www2.ohchr.org/english/issues/globalizationlbusiness/index.htm (last accessed on March 18, 2009) 
Global 500 Industry, 2008, available at 
http:f/money.cnn.corn/magazines/fortune/global500/2008/industries/21/index.htm (last accessed on March 18, 2009) 
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Transnational pharmaceutical corporations have influential powers on the national 
government and also the international organizations, which they exert by lobbying both their 
individual and collective interests. Transnational pharmaceutical corporations and the 
interested state actors influence negotiations and jointly promote their interests on a global scale 
during the negotiation and formation the Agreement on Trade-Related Aspect of Intellectual 
Property Rights (TRIPS), 1994,43 and through the patent protection on pharmaceutical products, 
all WTO members are bound to minimum protection pharmaceutical products. 
1.4 Concluding Summary 
Transnational pharmaceutical corporations are important non-state actors on the global stage, 
exerting influence on international policy as well as impacting the life or death and well being of 
entire populations through their policies and business practices. These transnational 
pharmaceutical corporations demonstrated their power during the TRIPS negotiation and shape 
the public international law to provide legal grounds to protect their interest and inject their value 
in global economic and political policies and foreign relations. Therefore, by playing important 
roles and functions in this international community, transnational pharmaceutical corporations 
should not only be subject to international law but also bear responsibility and accountability 
international human rights. 
43 
Susan Sell, Private Power, Public Law: The Globalization of Intellectual Property Rights, P.l-2, Cambridge 
University Press, 2003 
The US-based Intellectual Property Committee (IPC) played a pivotal role in TRIPS. IPC consists of executive 
officer from main industry of the US, representing pharmaceuticals, entertainment and software industries. 
Mohamed Mmar Gad, Representational Fairness in WTO Rule-Making: Negotiating, Implementing and Disputing 
the TRIPS Pharmaceutical-Related Provisions, P.87-92, British Institute for International & Compara, 2006 
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Section II. Pharmaceuticals in International Law 
Chapter 1\vo: Pharmaceutical Status and Pharmaceutical Industry 
2.1 Introduction. 
Pharmaceutical products not only provide enormous benefits to the length of human life, but also 
improve the quality of life by relieving pain, preventing diseases and reducing the rate of death 
or disability that results from disease. From the perspective of health economics, 
pharmaceuticals reduce the cost of treating diseases. 
Pharmaceutical products are unique consumer products with special characteristics. Most 
pharmaceuticals are not substitutable because they treat different illnesses due to their special 
methods depend on patients' personal conditions. Therefore pharmaceutical products should 
not be treated as common goods and allowed to flow into the relevant markets without special 
treatment and regulations. 
Consuming Process and Decision Making in the Use of Pharmaceutical Products 
The process of consuming pharmaceutical products is very different from other consumer 
products, except the over-the-counter drugs (OTC) 44 • The consuming process of 
pharmaceuticals is: the pharmaceutical companies manufacture the pharmaceuticals, the sales 
representatives promote the drugs to physicians, the physicians45 prescribe the medicines to end 
users, and the patients pay for the prescriptions. The end user and the consumer are different 
most of the time and the physicians are agents of patients, acting as experts to choose suitable 
44 
. Th~ purchase decision of the OTC drugs is made by consumers/patients for self-medication by following the 
~Irectton on the label. The decision making of the use of prescription-only drugs is made by physicians only. 
~herefore, the demand of pharmaceutical products is not ultimately depend on patients, but physicians and the 
retail and hospital pharmacists who dispense the prescriptions. 
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pharmaceuticals. 
Normally, patients are not responsible for the decision-making process to determine the use 
of specific pharmaceuticals; physicians are responsible for prescribing medicines. 46 Patients 
make the decision to buy pharmaceutical products. Most of the time, physicians' and patients' 
decisions are influenced by the trademark, marketing promotions from the pharmaceutical sales 
persons, and advertisements. A third-party, such as hospital utilization or insurance companies' 
review, may have influence on the demand for pharmaceutical products. Monitoring third-party 
payers can help to ensure physicians appropriately prescribe their medicines.47 
Easy Reproduction 
Some of the pharmaceuticals can be reproduced easily because the ingredients and the formulas 
are disclosed under the requirements of laws and regulations. Because of this special 
characteristic, pharmaceutical companies try hard to lobby for stricter laws and regulations to 
protect their investments from infringement. Patent protection is applied as an exchange in 
which the inventors disclose the best mode of the invention; in return, the patent laws protect the 
economic profits of the patent right holders over a period of time, which is usually an exclusive 
right for twenty years.48 Pharmaceutical patent holders can then prevent potential competition. 
46 
47 Yet, the physicians usually select of high-priced, brand-name drugs when there are comparable generics. 
Rexford E. Santerre and Stephen N. Neun, Health Economics: Theories, Insights, and Industry Studies, 3'd Ed., 
~439-440, South-Western College Pub, 2003 
Rexford E. Santerre and Stephen N. Neun, Health Economics: Theories, Insights, and Industry Studies, 3'dEd., 
P.444-445, South-Western College Pub, 2003 
The effective duration of patent protection is usually shorter due to the drug administration takes a few years to 
;pprove a pharmaceutical product for commercial introduction. In US, the passage of Drug Price Competition and 
ate~t Term Restoration Act of 1984 (Hatch-Waxman Act), the effective life of a new drug patent is extended by a 
maximum of 5 years, but not beyond 14 years of effective life. 
- 17-
While pharmaceutical products are still under the protection of their patents, due to the 
inaccessibility or unaffordability of the pharmaceutical products, counterfeit or unauthorized 
reproductions of the medicines often appear in the black market. Because these medicines are 
unregulated, they are almost invariably substandard and pose serious health risks. 
2.2 Chemical Compound Medicines 
2.2.1 Present State of Chemical Compound Medicines 
Chemical compound pharmaceutical products are the maJor product of the pharmaceutical 
industry today. The majority of the users of chemical compound pharmaceuticals are in 
developed countries, for the possible reason that the chemical compound pharmaceuticals are 
more available and affordable for them. 
The largest groups of products in the world-wide market used to be antibiotics, but are now 
cardiovascular pharmaceuticals.49 All the therapeutic segments showed significant growth in 
2003 (over 20% ). 50 The IMS estimates that due to the influence of the transitional period of the 
patent expiry blockbusters and the new pharmaceuticals, the industry has seen declining costs of 
drug treatment in major therapy areas, increased uncertainty over safety, pricing and market 
access and other intellectual property issues. IMS also forecasts that the global pharmaceutical 
market will shift from the top seven markets to emerging markets 51 and from primarily 
49 
Ronald P. Evens edited, Drug and Biological Development: From Molecule to Product and Beyond, P.12, 
Springer, 2007 
In the 200 products in therapeutic market, the top was cardiovascular products, followed by central nervous systems, 
~oncology, infectious diseases, gastrointestinal diseases and respiratory areas. 
John P. Griffm and John O'Grady edited, The Textbook of Pharmaceutical Medicine, 5th Ed., P.342, BMJ Books, 
2006 
51 
Because of the profit margins are not as good as before, pharmaceutical companies start to engage in R&D in the 
~ha"?aceutical products which reflect the markets in the developing potential countries, such as China, India and 
razi\ and IMS, 'IMS 2008 Global pharmaceutical Market Forecast, 2008', available at 
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care-driven practice to specialty care-driven drugs. 52 
The Blockbuster 
Blockbuster pharmaceuticals are defined by sales levels of at least $1 billion per year, and these 
drug patents are usually held by the top 10 companies. The ten best selling drugs account for 
12% of all medicine production. 53 The blockbuster pharmaceutical market included 94 
products accounting for $186 billion US worldwide, which represent 33.8% of the total 
pharmaceutical sales in 2004. The patent expiry blockbusters have made pharmaceutical 
companies very nervous because of the difficulties in R&D of new pharmaceuticals, and the new 
pharmaceuticals cannot make up to the loss suffered by the off-patent pharmaceuticals. 54 
www.imshealth.com/web/content/0.3148.64576068 63872702 70260998 82829532,00.html (last accessed on 
March 18, 2009) 
Global pharmaceutical sales will still grow 5~6%, which is over US$735 billion in 2008, but is lower than 6~7% 
compared with sales in 2007. In the U.S and Europe's top five markets, growth of 4~5% is expected- an all time 
low for the U.S.- while Japan will see an even smaller increase of 1~2%.The seven "pharmerging" markets of China, 
Brazil, Mexico, South Korea, India, Turkey and Russia will experience growth of 12-13 percent to reach $85-90 
billion, driven by greater access to generic and innovative new medicines as primary care improves and becomes 
more available in rural areas, and as more people take out private health insurance. The seven largest markets will 
contribute just half of overall pharmaceutical growth, while seven emerging markets will contribute nearly 25 
f
2
ercent of growth worldwide. 
IMS, 'IMS 2008 Global pharmaceutical Market Forecast', 2008, available at 
YiJ>IM w.imshealth.corn/web/content/0,3148,64576068 63872702 70260998 82829532,00.html (last accessed on 
53 
arch 18, 2009) 
WHO, The World Medicines Situation, P.3, 2004, available at 
~w.searo.who.int/LinkFiles/Reports World Medicines Situation.pdf(last accessed on March 18, 2009) 
S ~onald P. Evens edited, Drug and Biological Development: From Molecule to Product and Beyond, P.12, 
prmger, 2007 
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* Blockbuster Pharmaceuticals in 2004 55 
Lipitor 11.59 Pfizer/ Astel Risperdal 3.05 J&J 
Piavix/lscover 5.39 BMS/S-A Remicade 2.90 J&J/Sch-PI 
Zocor 5.20 Merck Cozaar/Hyzaar 2.82 Merck 
Advair/Seretide 4.50 GSK Neuron tin 2.72 Pfizer 
Norvasc 4.46 Pfizer Pravachol 2.64 BMS 
Zyprexa 4.42 Lilly Singulair 2.62 Merck 
Nexium 3.88 AstraZen Rituxan/MabThera 2.62 Riche/Gen 
Procrit/Eprex 3.59 J&J Epo_gen 2.60 Arn_g_en 
Novo-insulin 3.43 Novo Nord Prevacid 2.59 T<!Q_ 
Zoloft 3.36 Pfizer Enbret 2.58 Arngen/Wy 
Effexor 3.35 Wyeth Aranes_Q_ 2.47 Am_g_en 
Celebrex 3.30 Pfizer Lovenox/Clexane 2.37 San/Aven 
Fosfamax 3.16 Merck Duragesic 2.08 J&J 
Diovan/Co-Diovan 3.09 Novartis 
Generic Pharmaceuticals 
Pharmaceutical products enjoy patent protection for a limited time, usually twenty years. Once 
the patent expires, generic competition rapidly enters the market. With the pharmaceutical 
prices and patent expiry blockbuster pharmaceuticals, generic pharmaceuticals continue to grow 
at an expected rate of 14-15%. When the patent expired, the generic products will be 
substituted for 55% of the patented prescriptions. The greater use of generics is driven by 
incentives from new government policies that encourage the use of these less expensive generic 
pharmaceuticals 56 
Essential Medicines 
The essential medicine framework is encouraged by the WHO to offer lists of the essential 
medicines which are intended to be available within the context of functioning health care 
ss 
S ~onald P. Evens edited, Drug and Biological Development: From Molecule to Product and Beyond, P.I2, 
S6prmger, 2007 
h IMS, 'IMS 2008 Global Pharmaceutical Market Forecast', 2008, available at 
~M://www.imshealth.com/web/content/0,3148,64576068 63872702 70260998 82829532,00.html (last accessed 
on arch 18, 2009) 
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systems at all times and in adequate amount, in the appropriate dosage forms, with assured 
quality, and at affordable price for individuals and the community.
57 
The essential medicines 
are in an inventory of medicines with ensured safety, efficacy, and cost-effectiveness so that they 
can treat pressing global health concerns. 
58 
2.2.2 Industry 
The development of the pharmaceutical industry started in the late 1800s with the synthetic 
versions of natural compounds in Europe. The research-based pharmaceutical industry began 
with the development of sulfanilamide in the mid-1930s and penicillin in 1938. During the 
Second World War, because of increased demand for pharmaceuticals, the production of 
pharmaceuticals changed from handcraft methods of drug preparation for individual 
prescriptions to mass production techniques. 
59 
Following the high potential profits of the pharmaceuticals, the pharmaceutical industry 
drew upon further innovation, expanding exponentially by the postwar period. Since the late 
1980s, pharmaceutical companies have been undergoing significant reconstruction towards the 
formation of larger and fewer companies through mergers, acquisitions, joint ventures and 
57 
WHO, 'Essential Medicines', available at 
~ww.who.int/medicines/services/essmedicines def/en/print.html (last access on March 18, 2009) 
WHO, 'Essential Medicines', available at 
www.who.int/medicines/services/essmedicines def/en/print.html (last access on March 18, 2009) 
The model list of essential medicines was created by the WHO expert panel in 1997, and gives member states a 
guide to adapt to the needs of various nations. The list is revised every two years to reflect current health challenges. 
Currently, 156 out ofthe 193 member states have official essential medicine lists. In 1977, the first list identified 
208 essential medicines to battle the global disease burden at that time. Today, the list comprises up to 340 · 
medicines to treat diseases by prioritizing various conditions such as malaria, HIV/AIDs, tuberculosis, reproductive 
~ealth, and chronic diseases such as cancer and diabetes. 
Rexford E. Santrees and Stephen P. Neun, Health Economics: Theories, Insights, and Industry Studies, 3'd Ed., 
P.434, South-Western College Pub, 2003 
Chemical firms, such as Lederle and Merck, found ways to produce drugs in bulk form, which were then 
:ansform~d into dosage form (e.g., powders and tablets) by drug companies, such as Upjohn. Pfizer developed a 
ermentatiOn process to allow penicillin to be produced in large quantities. 
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strategic alliances. The reconstruction of the companies offers the benefits of increasing scale 
of operations, diversities, range of the products, and concentration of the investments.60 
Currently, the global pharmaceutical market is worth US$300 billion a year and it is 
expected to increase to US$400 billion within 3 year.61 The world's top ten pharmaceutical 
companies represent at least one-third of that market. Some of the sales are more than US$1 0 
billion a year, with profit margins of about 30%.62 The top ten pharmaceutical companies are 
mostly located in the US and Europe. A few transnational pharmaceutical companies dominate 
the global production, trade and sale of medicine. Ten of the mega transnational 
pharmaceutical companies now account for almost half of all sales. 63 
The medicine production is concentrated in developed countries, with over 90% of the 
world production located in the USA, Japan, Germany, France, and the UK, which account for 
6° Kelley Lee edited, Globalization and Health: An Introduction, P.71, 2003 
The concentration deals of the pharmaceutical industry were estimated to be $80 billion US between 1994 and 1997. 
During 1996 to 2001, the figure raised up to $500 billion, with another half of2000 including the merger ofGlaxo 
Wellcome and Smith Kline Beecham (US$160 billion) and Pfizer and Warner-Lambert (US$85 billion) and IMS, 
'New Patterns Emerge in Pharma M&A', available at 
www.imshealth.com/web/content/0.3148,64576068 63872702 70261002 77707758.00.htrnl (last accessed on 
March 18, 2009) 
Since the tortuous demise ofhealthcare giant Johnson & Johnson's proposed $24 billion acquisition of medical 
device manufacturer Guidant in January 2006, the era of the mega-merger within the pharmaceutical and 
biotechnology industries appeared to be at an end. The last such deal took place in August 2004, when the 
acrimonious marriage between Sanofi-Synthelabo and Aventis was consummated. While mega-mergers no doubt 
lead to increased critical mass, as demonstrated by the global rankings of Pfizer (including, for example, Pharmacia, 
Warner-Lambert), GlaxoSmithKline (Glaxo Wellcome, SmithKline Beecham) and sanofi-aventis, many industry 
executives now acknowledge that they do not always bring a solution for every problem - particularly poor R&D 
productivity. Indeed, mergers can actually disrupt the work of researchers as pipelines are reviewed and projects 
reprioritised. GSK, for one, has since split up its R&D teams into smaller groups based on therapy areas, to 
;~courage the levels of innovation seen in smaller biotechnology rivals. 
CNN, 'Global 500 Industry', 2008, available at 
l¥ID://money.cnn.com/magazines/fortune/global500/2008/industries/21/index.htm (last accessed on March 18, 2009) 
WHO, Pharmaceutical Industry, available at 
~ww. who.int/trade/glossary/story073/en/print.html (last accessed on March 18, 2009) 
WHO, The World Medicines Situation, 2004, P.3, available at 
IDYw.searo.who.int/LinkFiles/Reports World Medicines Situation.pdf(last accessed on March 18, 2009) 
-22-
two-thirds of the value of all medicine produced.64 
* The World's Top Ten Pharmaceutical Companies65 
Company (Headquarters) Rank Sales (US $billion) 
Pfizer (US) 1 23.1 
GlaxoSmithKline (UK) 2 22.0 
Merck (US) 3 16.5 
Astra Zeneca (UK/Sweden) 4 14.3 
Bristol-Myers Squibb (US) 5 13.3 
Novartis (Switzerland) 6 12.4 
Johnson & Johnson (US) 7 12.3 
Aventis (Germany/France) 8 11.3 
Pharmacia (Sweden/US) 9 10.2 
American Home Products (US) 10 9.6 











Other lower-priced medicines exist in highly competitive countries, such as the domestic 
markets of China and India.66 Countries with innovative capability in pharmaceutical products 
grow rapidly in their bio-pharmaceutical industries. 67 The US pharmaceutical market 
performance is leading among the group. According to the annual US Pharmaceutical Market 
Performance Review, the overall sales growth in the US prescription market was 3.8% in 2007, 
and total sales reached $286.5 billion, the slower sales growth resulting from loss of patent 
expiry pharmaceuticals, fewer new product approvals, and the impact of safety issues. 68 
The market is highly competitive, with a large number of equally-sized pharmaceutical 
64 
WHO, The World Medicines Situation, 2004, P.6, available at 
www.searo.who.int/LinkFiles/Reports World Medicines Situation.pdf(last accessed on March 18, 2009) 
India, for example, has rapidly growing pharmaceuticals biotechnology market currently estimated to be worth 
over US$ 1 billion, and in 1999-2000 spent some US$ 66 million on medicines R&D, up from US$ 2.2 
~illion in 1976-1977. 
66 
Kelley Lee edited, Globalization and Health: An Introduction, P.72, Palgrave Macmillan, 2003 
WHO, The World Medicines Situation, 2004, P.3, available at 
~ww.searo. who. int/LinkFiles/Reports World Medicines Situation.pdf (last accessed on March 18, 2009) 
WHO, The World Medicines Situation, 2004, P.6, available at 
~ww.searo. who.int/LinkFiles/Reports World Medicines Situation. pdf (last accessed on March 18, 2009) 
IMS, 'IMS Health Reports U.S. Prescription Sales Grew 3.8 Percent in 2007, to $286.5 Billion', 2008, available 
at 
~w.imshealth.com/ims/portaUfront/articleC/0,2777,6319 3665 83470499.00.html (last accessed on March 18, 
2009) 
There are many factors contribute to the slower sale, from possibly Joss of patent expiry blockbusters, fewer product 
approvals, stricter safety issues and the leveling year-over-year growth from the US Medicare Part C Program, etc. 
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companies. Only a few major pharmaceutical compames normally interact within most 
therapeutic markets, which treat common diseases or illnesses. Thus, the concentration ratios 
of the therapeutic markets are more monopolistic than the structure of the pharmaceutical 
. d t 69 m us ry. 
2.2.3 Challenges 
Pre-Clinical, Clinical and Post-Clinical Trials 
Pharmaceuticals are required to prove safety, efficacy, and quality under the laws of each country 
by undergoing a series of tests and trials. The pharmaceutical candidates are subject to 
pre-clinical and clinical trials to pass examination by the regulatory authority in order to put the 
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Rexford E. Santrees and Stephen P. Neun, Health Economics: Theories, Insights, and Industry Studies, 3rd Ed., 
~436-437, South-Western College Pub, 2003 
PHRMA, Pharmaceutical Industry Profile, 2006, P.l2, available at 
~://www.phrma.org/files/2006%20Industry%20Profile.pdf (last accessed on March 18, 2009) 





Adverse Drug Reaction 
After the medicine is produced, it can still pose other safety, efficacy and quality concerns. 
Medicine treats and prevents diseases, but it can also pose great health risks and may cause 
adverse reactions in some people. Besides irresponsible use of these drugs due to human error 
(situations that can be prevented), all medicine has side effects, some of which can be quite 
damaging. The post-marketing (Phase IV) studies focus on adverse drug reactions. The 
surveillance studies involve more patients and can provide more information about side effects.72 
Substandard and Counterfeit Drugs 
Substandard and counterfeit pharmaceutical products are those whose composition and 
ingredients do not meet the correct scientific specifications. Counterfeit medicines are 
deliberately and fraudulently mislabeled as to the identity or the sources. They may or may not 
contain the correct ingredients, active ingredients, or have fake or misleading packaging. 73 
Substandard and counterfeit pharmaceuticals may occur as a result of human error, insufficient 
human resources, insufficient financial resources, or the deliberate creation of fake 
pharmaceuticals. 
Counterfeit medicines represent 10% of the global pharmaceutical trade. 74 The most 
common counterfeited medicines in developed countries recently have been cholesterol-lowering 
~!tp://www.phnna.org/files/2006%20Industry%20Profile.pdf (last accessed on March 18, 2009) 
PHRMA, Pharmaceutical Industry Profile, 2006, P.l4, available at 
~://www.phrma.org/files/2006%20Industry%20Profile.pdf (last accessed on March 18, 2009) 
WHO, 'How does WHO define a counterfeit drug (medicine)?', available at 
~ww.who_.intlm~d~cines/services/counterfeit/faqs/05/en/print.html (last accessed on March 18, 2009) and WHO, 
ounterfeit Med1cmes, Fact Sheet, 2006, available at 
~W.who.int/mediacentre/factsheets/fs275/en/print.html (last accessed on March 22, 2008) 
G WI_IO, 'Counterfeit Medicines: The Silent Epidemic, WHO convenes Stakeholders to find Global Solution to a 
rowmg Health Threat' 2006 available at 
w . ' ' 




medicines, drugs used for treatment of growth hormone deficiency, and those used for cancer 
treatment. In developing countries, the most counterfeited medicines are those used to treat 
life-threatening conditions such as malaria, tuberculosis and HIV I AIDS. Antibiotics are also 
often found among counterfeit medicines.75 The WHO estimates that 25-50% of medicines 
consumed in developing countries are believed to be counterfeit. 76 A report released by the 
Centre for Medicines in the Public Interest in the United States projects counterfeit drug sales to 
reach US$75 billion in 2010, a 92% increase from 2005.77 
The purchases and uses of substandard and counterfeit pharmaceuticals are mostly due to 
the unavailability and unaffordability of pharmaceuticals.78 When prices of medicines are high 
and a great price difference exists between genuine pharmaceuticals and counterfeit 
pharmaceuticals, there are greater possibilities for the patients/consumers to obtain 
pharmaceuticals outside the normal supply system. This condition is more serious in rural areas 
where the normal supply chain fails to reach, or in poorer areas, where the pharmaceuticals are 
75 
WHO, 'The Safety of Medicines', 2005, available at 
www. who.int/mediacentre/factsheets/fs293/en/print.html (last accessed on March 18, 2009) 
76 
WHO, 'Counterfeit Medicines' Fact Sheet, 2005, available at 
http://www. who.int/mediacentre/factsheets/fs275/en/print.html (last accessed on 22 Mar 2008) 
The unregulated market is supplied with stolen and diverted drugs, illicitly manufactured pharmaceuticals sold 
illegally on the Internet and distributed through the mail and courier services. The consumers/patients do not know 
that the lower-priced medication is not life-saving drugs, but can take lives. In Africa, the use of counterfeit vaccines 
in 1995 resulted in 2,500 deaths. The frequent use of substandard or counterfeited medicines can lead to therapeutic 
failure, drug resistance, or death in some cases. 
-During a meningitis epidemic in Niger in 1995, more than 50 000 people were inoculated with fake vaccines 
resulting in 2 500 deaths. The vaccines were received as a gift from a country which thought they were safe. 
-89 children died in Haiti in 1995 and 30 infants died in India in 1998 due to the consumption ofparacetamol cough 
syrup prepared with diethylene glycol (a toxic chemical used in antifreeze). 
-In 200 I, in South-East Asia, a Welcome Trust study revealed that 3 8% of I 04 anti-malarial drugs on sale in 
Pharmacies did not contain any active ingredients. 
-In Cambodia, in 1999, at least 30 people died after taking counterfeit anti-malaria's prepared with 
~~lphadoxine-pyrimethamine (an older, less effective anti-malarial) which were sold as artesunate. 
WHO, 'Counterfeit Medicines: The silent Epidemic, WHO convenes Stakeholders to find Global Solution to a 
Growing Health Threat', 2006, available at 
~ww.who.int/mediacentre/news/releases/2006/pr09/enlprint.html (last accessed on March 18, 2009) 
lNCB, 'INCB Warns of Counterfeit Medicines Flooding Markets', 2007, available at 
~ww.incb.org/pdf/e/press/2007 /annual-report-press-kit-2006-en-2.pdf (last accessed on March 18, 2009) 
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:I 
often unaffordable. 79 
The High Cost in Pharmaceutical R&D 
Pharmaceutical R&D is the key driver of the industry. The R&D expenditures have escalated in 
recent years. The expenses of R&D by the top ten companies in 2004 were $49.1 billion. For 
the top fifty world-wide companies, R&D spending as a percentage of total expenditures was 
19.4%, ranging from 12.2-31.2%, excluding the generic companies who primarily perform 
phannacokinetic equivalence studies and few clinical trials. During the stages of R&D, 
research spending on clinical trials cost the most, at 35.9%, followed by non-clinical drug work 





Figure "'.2 Expenses and revenues curve f'or a new drug 
81 
IMS reported that total U.S. prescription drug spending grew at 8.3 percent in 2004. IMS 
found that drugs' spending growth was 5.4 percent for 2005 and 5 percent for the 12 months 
ending July 2006.82 Pharmaceutical companies have to ensure a return on the investments 
79 
The major reason for the consumers/patients to buy counterfeit pharmaceuticals is usually the counterfeit 
pharmaceuticals are cheaper. The sick people believe that they are taking genuine medicine. The major reason for 
the manufacturer of counterfeit pharmaceuticals is that the pharmaceutical is not hard to reproduce and the marginal 
r:ofit is so high that individuals could take a risk to manufacture the fake ones. 
~onald P. Evens edited, Drug and Biological Development: From Molecule to Product and Beyond, P.15, 
~pn~ger, 2007 
82 Rick Ng, Drugs: From Discovery to Approval, P.IO, Wiley-Blackwell, 2004 
PHRMA, 'Prescription Medicine Spending Trend', available at 
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made. It is estimated that large pharmaceutical companies need 4 to 5 new drugs approved 
every year to maintain their status. However, with the low productivity of R&D, most companies 
only have 1 to 2 new drugs approved per year. 83 
Bottleneck of the Substance 
Despite the high costs of R&D, R&D productivity is declining. The slow and difficult 
production of new pharmaceuticals has scared many moguls in the industry. The dearth of new 
products continues to haunt the pharmaceutical industry. There have only been a few new 
active substances to reach the market, and even fewer have achieved blockbuster status. 84 The 
declining rate in R&D productivity is high in major pharmaceutical companies. In Europe, big 
pharmaceutical companies are launching a declining proportion of New Molecular Entities 
(NMEs); by contrast, in the US the proportion of NMEs is declining more gradually. 85 The 
annual review from the IMS showed that there are just thirty-six new active substances in 2002, 
which is a 20-year low. There are not enough new candidates to counter the patent expiration 
of the blockbusters. 86 
http://www.phrma.org/files/Prescription%20Medicine%20Spending%20Trends%202006%20FINAL.pdf (last 
accessed on March 18 2009) 
83 • ' 
84 
Rick Ng, Drugs: From Discovery to Approval, P.8, Wiley-Blackwell, 2004 
IMS, 'Is the Pharma Industry Weathering the "Perfect Storm?"', available at 
lY.Ww.imshealth.com/web/content/0.3148.64576068 63872702 70261000 71488550,00.html (last accessed on 
March 18 2009) 
85 ' 
IMS, Fewer NMEs, Premium lunch Prices, 2005, available at 
IDYw.imshealth.com/web/content/0,3148,64576068 63872702 70515404 79037268,00.html (last accessed on 
March 18, 2009) 
T~ere are three main conclusions to be drawn from this. First, leading multinationals appear to be experiencing 
diseconomies of scale in their R&D investments. Second, the contribution of licensed products to revenues has 
~ver .been more important. And, third, the industry needs a sustained improvement in R&D productivity to maintain 
86 stone growth rates- and to offset the next round of patent expiries on blockbuster products. 
IMS, 'Is the Phrma Industry Weather the "Perfect Storm"?', available at 
,W}ywM .imshealth.com/web/content/0,3148,64576068 63872702 70261000 71488550,00.html (last accessed on 
arch 18, 2009) 
?nee again the US topped the charts for those countries to first launch a product, notching up 58% of world 
.aunches. Japan outstripped Europe to become the second most popular country with 22%, and Europe accounted for 









Jlle Patent Expiry Blockbusters and Generic Competition 
Patents are the pillars that support the pharmaceutical industry, leading to a positive return of 
revenue after the drug has been approved by the regulatory authority for marketing. The 
expiration of patented pharmaceuticals also increases the generic competition in the 
pharmaceutical markets. Patent expiry blockbusters represent $17 billion in sales lost in 2007. 
Thus, pharmaceutical companies try everything they can to maintain or strengthen the legal 
safeguard for their interests. The generic pharmaceutical companies wait for the moment when 
a patent will expire (if the patent is not successfully extended) in order to capitalize on these 
gains. 
Profit Margin (cost/profit) 
As the development of new chemical entities (NCEs) fall into a bottleneck and expenses for 
R&D soar, the competition with the generic pharmaceutical companies and the parallel trade 
policy all pose challenges to profit margin. 87 Companies are responding to difficulties in the 
operating environment in their markets. Countries with pricing strategies for cost containment, 
such as the policy of price control and the use of more generic pharmaceutical products, also 
increase the competition. The profit margin for pharmaceuticals is not as high as in the past. 
Thus, it is a trend that more and more companies are investing in the new markets (the so-called 
developing markets, such as China, India and Brazil) to supply the pharmaceuticals they need. 88 
!~unched in Japan as their first market. 
IMS, 'Fewer NMEs, Premium lunch Prices', 2005, available at 
Y!FwM .imshealth.comJweb/content/0,3148,64576068 63872702 70515404 79037268,00.html (last accessed on 
arch 18, 2009) 
p~~aceutical companies are trying to avoid parallel trade by narrowing their price gap. Greater pricing pressure 
~thm the .EU is making the pharmaceutical companies to set significantly higher prices in Germany and UK. 
38 ~ater pnce preference across countries tends to bring prices closer together. 
~ M~, 'Fewer NMEs, Premium lunch Prices', 2005, available at 
-....:JY.Imshealth.comJweb/content/0,3148,64576068 63872702 70515404 79037268,00.html (last accessed on 
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2.2.4 Concluding Summary 
With the emerging and re-emerging diseases, increasing costs of R&D, the scarcity of new 
substances, the patent expiration of blockbusters, and genetic competition, the chemical 
compound pharmaceutical industry is facing the most essential and challenging moment now. 
2.3 Vaccine 
2.3.1 Present State ofVaccine 
A vaccine is a biologically derived substance that elicits a protective immunity. A vaccine 
protects against and prevents diseases by inducing immunitl9 to avoid disability, death and 
infection from the diseases against which a patient is immunized. Immunization saved over 2 
million lives in 2003 alone.90 Vaccination and immunization have been deemed the most 
successful and cost effective health intervention ever pursued.91 
Up to now, vaccination has partly controlled ten major diseases.92 Immunization is proven 
to control and eradicate diseases, such as the natural occurrence of smallpox, poliomyelitis, 
March 18, 2009) 
89 
WHO, 'Immunization against Diseases of Public Health Importance', 2005, available at 
www.who.int/mediacentre/factsheets/fs288/en/print.html (last accessed on March 18, 2009) 
Vaccines typically provide the immune system with harmless copies of an antigen: a portion of the surface of a 
bacterium or virus that the immune system recognizes as "foreign." A vaccine may also provide a non-active version 
?fa toxin - a poison produced by a bacterium - so that the body can devise a defense against it. Once an antigen 
18 detected by the immune system, white blood cells called B-lymphocytes create a protein called an antibody that is 
precisely designed to attach to that antigen. If a true infection of the same disease occurs, still more antibodies are 
created, and as they attach to their targets they may block the activity of the virus or bacterial strain directly, thus 
~ombating infection. In addition, once in place, the antibodies make it much easier for other components of the 
llOmune system (particularly phagocytes) to recognize and destroy the invading agent. Immune systems are designed 
to "remember" - once exposed to a particular bacterium or virus, they retain immunity against it for years, decades, 
~ even a lifetime - and so are prepared to defeat a later infection, and to do so quickly. 
WHo and UNICEF GIVS, Global Immunization Vision and Strategy 2006-2015,2006, available at 
~W.who.intlvaccines-documents/DOCPDF05/GIVI final EN.pdf(last accessed on March 19, 2009) 
WHo, 'Immunization against Diseases of Public Health Importance', 2005, available at 
~W.who.intlmediacentre/factsheets/fs288/en/print.html (last accessed on March 19, 2009) 





measles and maternal and neonatal tetanus. For the later development of vaccines, toxoids 
against diphtheria and tetanus were introduced in the early 1900s; the bacillus Calmette-Guerin 
vaccine (against tuberculosis) in 1927; the Salk polio vaccine in 1955; and vaccines against 
measles and mumps in the 1960s.93 Some of these diseases have been eradicated, but more 
needs to be done to fight against the emergence and re-emergence of these diseases. 
The top 20 vaccine brands account for 77% of total vaccine sales. 20 new vaccine brands 
have been filed or approved recently, and another 31 are in phase III trials.94 The emergence 
and re-emergence of new diseases in the last 20 years encouraged vaccine development.95 With 
the better understanding of the immune system and the emergence of the recombinant DNA 
technologies, new vaccines are developed by conjugate vaccines, recombinant DNA technology 
for subunit vaccines and improved delivery vaccines. 
New vaccines have been introduced with significant results. Some vaccines have been 
licensed or are at advanced stages of development. The illnesses targeted are rotavirus 
93 
WHO, 'Immunization against diseases of public health importance', 2005, available at 
:ww.who.int/mediacentre/factsheets/fs288/en/print.html (last accessed on March 19, 2009) 
4 
IMS, 'Vaccines: An Antidote to Sluggish Pharma Sales?', available at 
www.imshealth.com/web/content/0,3148.64576068 63872702 70515404 823677ll.OO.html (last accessed on 
March 19, 2009) · 
The big hitters in the vaccine world, e.g. GlaxoSmithKline, sanofi pasteur and Merck & Co, are anticipating 
vaccines becoming one of their major drivers of growth going forward. As a result, they are upping their 
commitment to the area. GSK Bio, GSK's vaccines arm, accounted for 8.4% of GSK's pharmaceutical turnover in 
2Q0.6, reporting sales up 23% to $3.4 billion. GSK Bio is set to become an increasingly important part ofGSK's 
b?s~ness and has been transformed from a tiny company with one product and $3 million in revenues, into a $2 
bilhon behemoth with six vaccines in late-stage development - GSK's vaccines business has doubled in growth over 
~e past five years and the company expects it to double again over the coming five years 
p Marin~ Lattanzi and Rino Rappuoil, 'Vaccination: Past, Present, and Future', Guido Grandi edited, Genomics 
roteom1cs and Vaccines, P.6, Wiley, 2004 
:the past two or three decades, diseases were emerge or reemerge, such as HTVL, HIV, Staphylococcal toxins, 
1 ~herichia coli 0157, Borrelia burgdorferi, Helicobacter pylori, Human herpesvirus type 6 during the year of 80-1990 and Hepatities C, Vibiro cholerae 0139, Bartonella sp., Hantavirus, Nipah virus, West Nile virus, TT 
VUrus and SARS coronavirus during the year of 1990-2000. 
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diarrhoea, pneumococcal disease, and cervical cancer (as caused by human papilloma virus). 
Progress is being made on a vaccine for the regional menace posed by meningococcal meningitis 
serogroup as well. Intensive efforts are underway to develop effective vaccmes for AIDS, 
malaria, tuberculosis, dengue, leishmaniasis, and enteric diseases, and to adapt new technologies 
to improved formulation and delivery. 96 Very recently, the concept of reverse vaccinology has 
been applied to viruses as well in the hope that this approach might be able to create new 
vaccines in the fight against AIDS. 97 
2.3 .2 Vaccine Industry 
The vaccine industry is small but growing98 compared to the pharmaceutical industry overall. 
The revenue of vaccine companies mainly comes from sales of the product. The vaccine 
business has relatively low profitability in comparison with chemical-compound pharmaceutical 
industry. Worldwide, vaccine sales are estimated to be approximately US$6.5 billion, 
representing only 2% of global pharmaceutical market sales, roughly equaling the sales of one 
successful chemical compound medicine; therefore, industrial interest in vaccines is limited.99 
In addition, the cost of putting a new vaccine into a commercialized product is also as high as 
putting a new medicine on the market, which represents US$850 million. Moreover, the 
growing concern of liability costs, regulatory costs, intellectual property rights costs, and other 
96 
WHO, 'Development of New Vaccines', 2006, available at 
~://www. who.int/mediacentre/factsheets/fs289/en/print.html (last accessed on March 18, 2009) 
p Marin~ Lattanzi and Rino Rappuoi.l, 'Vaccination: Past, Present, and Future', Guido Grandi edited, Genomics 
9toteom1cs and Vaccines, P.12-13, Wiley, 2004 
IM~, 'Vaccines: An Antidote to Sluggish Pharma Sales?', available at 
.~.Jmshealth.com/web/content/0.3148.64576068 63872702 70515404 8236771l.OO.html (last accessed on arch 18, 2009) 
The vaccine market is expected to double by 2012, from the current level ofEuro 9.7 billion, to more than Euro 18 
· Marina Lattanzi and Rino Rappuoil, 'Vaccination: Past, Present, and Future', Guido Grandi edited, Genomics 
ics and Vaccines, P.14, Wiley, 2004 
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economic factors might provide incentives for withdrawing vaccine products or discontinuing 
old vaccine production. 
As a result, vaccme companies have started to shut down or merge with one another 
similarly to the chemical compound pharmaceutical industry. 100 The chemical compound 
pharmaceutical companies even plan to have their own vaccine companies. Larger vaccine 
companies are more attracted by pharmaceutical business than vaccine business, because the 
pharmaceutical industry has grown in size and number. 101 As a result, the vaccine industry is 
now dominated by only a few companies. The larger vaccine companies have annual sales of 
vaccine products of $1 billion or greater. 102 Some of the mergers are due to the creation of one 
stronger and larger company, like the merger of Lederle Laboratories, Inc. and Wyeth 
Laboratories, Inc.; some are due to the departure from vaccines business, e.g., Eli Lilly & Co. 
and E.R. Squibb & Sons. 
The US is extraordinary successful103 in vaccine R&D due to the delicate fabric of public 
and private collaboration involved in interwoven scientific, public health and economic concerns. 
More than two-thirds of the vaccines approved in the past 25 years have been developed in the 
100 A . 
mte Batson, Sarah Glass, and Erica Seiguer, 'Economic of Vaccines: From Vaccine Candidate to 
Commercialized Product', Barry R. Bloom and Paul-Henri Lambert edited, The Vaccines Book, P.349, Academic 
Press, 2002 
~fthe 20 internationally active vaccine companies in the 1960s' less than 12 remained by the early 1990s. 
102 Stanley A. Plotkin and Walter A. Orenstein edited, Vaccines, 4th Ed., P. 51, Saunders, 2004 
103 Stanley A. Plotkin and Walter A. Orenstein edited, Vaccines, 4th ed., P.47, Saunders, 2004 
Arnie Batson, Sarah Glass, and Erica Seiguer, 'Economic of Vaccines: From Vaccine Candidate to 
P
Commercialized Product', Barry R. Bloom and Paul-Henri Lambert edited, The Vaccine Book, P.347-352, Academic 
ress, 2002 
~eAmerican companies, such as Wyeth-Lederle Vaccines, Anventis Pasteur, GlaxoSmithKline and Merck have 
s ar~d the vaccine market and have seen it rise from approximately 50% in 1998 to about 80% today. Small to 
medtum sized companies, notably Chiron and Baxter, as well as the emerging companies in Korean, India, Indonesia, 
and Other sites, vie for the remaining revenues. 
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us. 104 Currently, the vaccine industry can be found in 50 countries, and is concentrated in the 
US and Europe. Five multinational producers dominate global vaccine sales. 
Estimates of the total world market revenues are US$6 billion, the top five accounting for 
80% of the sales or US$4.8 billion US, with the remainder coming from the regional vaccines 
companies located in countries such as India or Brazil. By contrast, the same top five 
companies supply only approximately 52% of the doses, or 2.8 million of 5.4 billion doses 
worldwide, with the remainder coming from regional vaccine companies. 105 The vaccine 
companies have emerged, but the investment in the vaccine industry is shrinking, and compared 
to the pharmaceutical companies, the vaccine business is less attractive with its low profits and 
higher costs. 106 
2.3.3 Challenges ofVaccine 
Safety, Efficacy, Quality and Delivery of Vaccine 
Vaccines are usually administrated on healthy people to generate immunization. The safety 
standards are higher for vaccines, which are usually administered on infants or children, than for 
medicines which are usually used to treat diseases, because a slight adverse effect could result in 
· substantial population-attributable risks. 107 The adverse effect of vaccines could be caused by 
104 
Stanley A. Plotkin and Walter A. Orenstein, Vaccines, 4th Ed., P. 47, Saunders, 2004 and 
T~e Committee on the Evaluation of Vaccine Purchase Financing gin United States Board of Health Care Services, 
forancing Vaccine in the 21 '1 Century: Assuring Access and Availability, P. 116, 2004 
Maureen Birmingham and Claudia Stein, 'The Burden of Vaccine Preventable Diseases', Stanley A. Plotkin and 
~alter A. Orenstein, Vaccines, 4th Ed., P. 51, Saunders, 2004 
w, Maureen Birmingham and Claudia Stein, 'The Burden of Vaccine Preventable Diseases', Stanley A. Plotkin and 
T alter A .. Or~nstein edited, Vaccines, 4th Ed., P.51, Saunders, 2004 
1 
he vaccme mdustry has concentrated since 1967, when 26 different companies held vaccine licenses in the US. In 
980, 17 companies held vaccine license. In 2002, only 12 companies held vaccine licenses. Some ofthe 
~~ncentration was due to mergers, but some was due to the departure of the vaccine business. 
NealA. Halsey, 'Vaccine Safety: Real and Perceived Issue', Barry R. Bloom, Paul-Henri Lambert edited, The 
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the injection process, incomplete inactivation of the vaccine agent, replication of live vaccine 
agents, inadvertent contamination of the vaccine with other live agents, the direct effects of the 
. d h . . 108 vaccme components, an ost Immune response to vaccme components. 
Vaccines are traditionally divided into two main groups: a live organism that is in an 
attenuated (weakened) or inactivated (killed) form and that is either whole or fractionated. The 
latest vaccine technology has moved towards new dimensions in recombinant vaccines that have 
been developed through genetic manipulation and, for later DNA vaccines, cellular vaccines and 
other novel vaccines. Whereas vaccines are deemed to prevent infection, many vaccines 
actually prevent or minimize the consequences of infection. 109 
The development of vaccines first started with the identification and characterization of 
antigens. Vaccine science, innovation, and manufacturing are critical components in 
developing safe and efficacious vaccines. Licenses of new vaccines, and all other information 
concerning vaccine formulation, vaccine manufacturing, stability and sterility test and results of 
animal testing, are required by the Food and Drug Administration. 
The safety issues are not limited to the safety, quality and side-effects of the vaccine itself, 
but also to injection safety in order to avoid the transmission of blood-borne pathogens. To 
provide immunization safety is to ensure vaccine safety and quality at every stage, from the 
Va · 
108 ccme Book, P.3 71, Academic Press, 2002 
Va ~eal A. Halsey, 'Vaccine Safety: Real and Perceived Issue', Barry R. Bloom, Paul-Henri Lambert edited, The 
109ccme Book, P.375, Academic Press, 2002 
p
34
Kenrad E. Nelson and Carolyn Masters Williams, Infectious diseases Epidemiology: theory and Practice, 2"d ed., 
.. · 7-355, Jones & Bartlett Publishers, 2006 
are. novel approaches in vaccine development, including the identification of new targets, new adjuvants and 
vaccme delivery methods, as well as the development of new vaccine types and combination vaccines. 
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development stage through clinical trials, vaccine production, quality control and distribution, 
and up to the point of use. Likewise, the trials of chemical-compound medicines are quite 
rigorous. The vaccine candidate undergoes multiple trials, and the decision to progress to the 
next phase is based upon the results from the previous studies. A successful vaccine 
development normally takes about 10 or more years, but only a small proportion of the 
candidates will end up as licensed products. 110 
The manufacturing of vaccines often involves complex transformation of live biologic 
organisms into active, safe and stable immunization components. The vaccine must be 
controlled in a certain condition to maintain its safety and activities. The factors have to be 
controlled in each and every process, including manufacturing, storage and delivery. 111 Time, 
sterility and temperature are essential in each manufacturing process; any change will result in a 
different vaccine. 
Each batch of vaccine must be tested and approved individually prior to release. Vaccines 
require both a product license application and an establishment license application, while new 
chemical entities require only a product license application. The vaccine companies have to 
obtain a facility license for a vaccine, which requires full capacity for that vaccine. 112 
110 
Jens-Peter Gregsen, 'Scientific, Technical and Economic Aspects of Vaccine Research and Development', Oliver 
Kayser and R.H. Muller edited, Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications, P.66, 
Wi!ey-VCH, 2004 
~e vast majorities of the candidates remain stuck in the early development phases or is abandoned. 
S ~he Committee on the Evaluation of Vaccine Purchase Financing in the Untied States Board on Health Care 
~rvices, Financing Vaccine in the 2151 Century: Assuring Access and Availability, P.l 09, 2004 
~ te~perature-controlled environments are needed at each manufacturing step, and many vaccines must be 
Wiai;tamed with in a narrow temperature range during storage and delivery -referred to as the "cold chain." 
S .he Committee on the Evaluation of Vaccine Purchase Financing in the Untied States Board on Health Care 
~rvices, !'inancing Vaccine in the 2 1'1 Century: Assuring Access and Availability, P.l 09, 2004 
establishment license application certificates for that facilities, equipment and personnel involved in the 
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Q_evelopment ofVaccine 
Because of the emergence and re-emergence of diseases, the vaccine companies are working 
co-operatively with partners, including the governmental research branches, the Food and Drug 
Administration, the governmental disease control branches, other biotechnology companies, 
. 1 . . dNGO 113 intematwna orgamzatwns, an s. 
In order to have sustainable development of vaccines, vaccine companies need to have a 
rich environment of sponsoring by government-funded institutions and academic universities to 
carry out the R&D, strong intellectual property rights protection, and freedom to price the 
products at a fair level in relation to the value of a product to society. 114 
Vaccine development is difficult, complicated and costly both in clinical studies and process 
components, and it usually takes more than 10 years to develop a fully licensable product. The 
production of new vaccines is costly. The vaccine industry receives their revenue from the sale 
of vaccine products. The cost of vaccine production includes the R&D costs; cost related to the 
regulatory process; the ongoing regulatory costs; and vaccine plants costs 115, including the 
w:nufacturing process meet food and drug administrative regulations and current good manufacturing practices. 
B. Bret Finlay, 'Understanding Microbial Pathogenesis as a Basis for Vaccine Design', Barry R. Bloom and 
Paul-Henri Lambert edited, The Vaccine Book, P. 186, Academic Press, 2003 
~y discouraging the production of vaccine, possible ways to increase the production to meet the demands include: 
mcreased construction of facilities by the four majors; growth of regional small manufacturers in countries such as 
Brazil, Cuba, India, Korea, and Japan; partnerships between regional and major manufacturers' and development 
of new institutions to make vaccines and Stanley A. Plotkin and Walter A. Orenstein edited, Vaccines, 4th Ed, P. 50, 
Saunders, 2004 
Vaccine development starts with basic research, which is usually done in universities, biotechnology firms or the 
vaccine department ofthe pharmaceutical company. Funding for vaccine R&D is basically from govemment 113, 
profits of the sales of vaccine and risk capital. Large vaccine companies, nowadays, usually is the subdivision of 
~harmaceutical companies in average reinvest approximately 18% oftheir profit into R&D. Vaccine R&D has to 
,~ce the competition with other pharmaceutical product of the budgets and resources. 
·Its Stanley A. Plotkin and Walter A. Orenstein edited, Vaccines, 4 Ed., P. 51, Saunders 
Th Stanley A. Plotkin and Walter A. Orenstein edited, Vaccines, 4th Ed., P.47-48, Saunders, 2004 
e manufacturing plants for vaccines are very expensive, ranging from $50-200 million US, depend on the dose 
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depreciation and the marketing costs, variable costs of labor, production, equipment and facility 
for vaccines and the liability costs. The total costs to bring a vaccine to market are roughly 
similar to those for other drugs and, in some cases, can be higher. The estimated expense for 
development of a new vaccine is around US$500-800 million per year and often takes a period of 
12-15 years. 116 As a result, vaccine manufacturers charge prices to recoup the costs for each 
new vaccine while the vaccine is still under the protection of patent. 117 
As mentioned above, even though the production costs of vaccines have been increasing, 
the revenue from vaccine sales remains generally constant. The market of one vaccine may be 
prosperous or slow depending on demand. 118 The potential revenue from the vaccine is 
relatively small compared with chemical compound medicines. Whereas other types of 
medicine are usually taken for years, a vaccine is usually administrated one or four times to gain 
immunity for a lifetime. The commercial realities usually impact the R&D of those vaccines 
that are used in developed countries, leaving little investment for the R&D of vaccines to 
diseases that predominantly touch upon the poor and neglected populations. 
Donating vaccines or selling vaccines at a discounted price could help little in solving the 
enormity of the health problems worldwide. Developed countries generate about 82% of 
vaccine revenues but represent only 12% of the doses. This economic reality is pushing R&D 
~~~uirement and manufacturing complexity. 
T Stanley A. Plotkin and Walter A. Orenstein edited, Vaccines, 4th Ed., P.47-48, Saunders, 2004 and 
F~e C~mmittee on the Evaluation ofVaccine Purchase Financing gin United States Board of Health Care Services, 
mancmg Vaccine in the 21st Century: Assuring Access and Availability, 2004, P. 114-116 
. ~other estimated that a new vaccine costs $700-750 million from initial research to commercial production. 
WHo, State of the World's Vaccines and Immunization, P.9, 2003, available at 
~ho.intlvaccines-documents/DocsPDF04/wwwSOWV E.pdf (last accessed on March 18, 2009) 
V~ccines help the body to have immunizations, once had the vaccination, maybe the immunization can last for a 
time and the life time, sometimes. It is the major difference from chemical compound pharmaceuticals. 
- 38- ,I 
towards the infectious diseases in developed countries, leaving little investment for infectious 
diseases which affect mostly poor and neglected populations in developing countries. It is hard 
to expect that companies will engage in R&D for diseases that only, or predominately, impact the 
. f h ld . h . 1 . . 119 poorer regions o t e wor w1t out specm mcentlves. 
2.3.4 Concluding Summary 
With new vaccine strategies, the revolution in biotechnology also made more powerful tools to 
make new vaccines' development and research possible. Growing recognition and 
understanding of human immunity and the importance of immunization also help to accelerate 
vaccine development. 
After an efficient vaccine is developed and is able to be licensed, the work does not stop. 
The post-marketing surveillance, cost-effectiveness, bridging studies to expand the immunization 
to larger populations, impact, evaluation of different target populations and possible improved 
vaccine delivery systems or manufacturing processes to reduce costs are keys of providing safer, 
more efficient and affordable vaccination 120 to contribute to the global goal of reducing poverty. 
Cooperation by non-profit organizations, non-governmental organizations, and 
research-based and private-public partnerships helps to focus R&D on the diseases 
predominately plaguing developing countries. Yet, a number of diseases still lack the 
leadership, funding and partnership to encourage the development of vaccines. 
119 
12o Stanley A. Plotkin and Walter A. Orenstein edited, Vaccines, 4th Ed., P. 51, Saunders, 2004 
w WHo, The Initiative For Vaccine Research, Strategic Plan 2006-2009, P.l, P.5, 2006, available at: 




2.4 Traditional Medicine (TM) 
2.4.1 Current State of TM 
TM is becoming more and more popular around the world, the global market stands at US$60 
billion per year 121 , and it is steadily growing through international trade and cultural exchanges 
under globalization. The use of TM remains the primary health care in developing countries 
because chemical compound medicines and vaccines, for most developing countries, remain 
unaffordable or inaccessible. 122 In developed countries, the growing trend of using botanical 
products, traditional, alternative and complementary medicines have attracted a great deal of 
attention lately as an alternative approach to health care. 123 
Yet, TM is currently at a critical stage12\ with the lack of validation, lack of reorganization, 
121 WHO, 'Essential Drug in Brief', P.l, 2002, available at 
www.who.int/medicines/publicationslbrief/en/edb07 .pdf (last accessed on March 18, 2009) 
122 
WHO, WHO Traditional Medicine Strategy 2002-2005, P.I, 2002, available at 
http://whglibdoc.who.int/hq/2002/WHO EDM TRM 2002.l.pdf(last accessed on March 18, 2009) 
In Africa, up to 80% of the population use traditional medicine. In Asia and Latin America, populations continue to 
use traditional medicine in accordance to historical circumstances and cultural beliefs. In China, traditional medicine 
accounts for around 40% of all health care delivered. Also, the distribution of traditional medicine is not uniform as 
well and WHO, 'Guidelines on Developing Consumer Information on Proper Use of Traditional, Complementary 
and Alternative Medicine', P.l, 2004, available at 
www.paho.org/spanish/ad/ths/ev/PM-WHO-Traditional-Medicines-Consumer.pdf (last accessed on March 18, 2009) 
In many developed, high income countries, traditional and complementary medicine is becoming increasingly 
f2~pular, with up to 65% of the population reporting that they have used this form of medicine. 
WHO, WHO Traditional Medicine Strategy 2002-2005, 2002, P.2, available at 
http://whglibdoc. who.int/hq/2002/WHO EDM TRM 2002.1.pdf (last accessed on March 18, 2009) 
The concern about the adverse effect of chemical compound drugs fuels the popular use of traditional medicine. In 
addition, accompanying the aging population and the increasing population with chronic diseases, traditional 
medicine appears to be a gentler and more affordable method to manage disease. For those seeking this treatment at 
least once, the use of traditional medicine is 48% in Australia, 70% in Canada, 42% in USA, 38% in Belgium and 
{~% in France. People in developed countries are concerned about the adverse effects of chemical drugs. 
WHO, 'Report of the Inter-Regional Workshop on Intellectual Property Rights in the Context of Traditional 
Medicine', Bangkok, Thailand, 6-8 December 2000, P.20, 200 I, available at 
bl!p:f/whqlibdoc. who.int/hq/200 1/WHO EDM TRM 200 l.l.pdf (last accessed on March 18, 2009) 
According to the report, the participants have concluded the problem areas and gaps for the protection of traditional 
medicine knowledge: 
·Lac~ .of a national policy to develop traditional medicine and lack of organizational infrastructure to utilize 
traditional medicine in the national health care systems; 
• ~ac~ of any system for traditional medicines protection and equitable sharing of benefits; 
he unportance and prioritization of traditional medicine has not been fully recognized and explicitly mentioned by 
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J 
lack of standardization, lack of protection, lack of delivery infrastructure and lack of integration 
into national health care systems. With delays in developing TM and the impediments to 
conserving necessary biological diversity and genetic resources, TM is swiftly losing much of its 
efficacy. 125 Although many understand the potential of TM to successfully reduce the burden of 
diseases and contribute to public health, TM is still struggling with protection and development 
• 126 
1ssues. 
TM covers a wide variety of therapies and practices, which vary greatly from country to 
country. 127 TM is not only a system of treatment, but it also has its unique methods of assessing 
health and diagnoses. It is also a way of living, which takes into account the interactions 
between the internal states of the body and the external environment. 
various international health organizations; 
-Absence offormal or informal mechanisms for the participation of traditional healers in policy making and 
intellectual property development; 
-Lack of mechanism or strategy for equitable benefit sharing among all stakeholders; 
-Lack of policy and regulations for the protection of biodiversity and traditional medicine knowledge; 
-Lack of understanding of intellectual property rights system among stakeholders; 
-Lack of mechanism for developing linkages between traditional medicine of different countries; 
-Lack of appreciation of the potential of traditional medicine to solve the health problems of developing countries 
·Lack of understanding , awareness, communication and respect between traditional medicine and intellectual 
property rights offices; 
·Difference between the concepts and fundamentals of traditional medicine and modem medicine; 
·Limited applicability of existing intellectual property rights laws to protect traditional medicine knowledge from 
biopiracy; and 
·Inability to meet the cost of requiring, exercising and enforcing intellectual property rights for the holders of 
12~aditional medicine knowledge. 
~CTAD Commonwealth Secretariat, UNCTAD-Commonwealth Secretariat Workshop on Elements of 
National Sui Generis Systems for the Preservation, protection and Promotion of Traditional Knowledge, Innovations 
and Practices and Options for an International Framework, P. 5, 2004, available at 
~~nctad.org/en/docs/ditcted200518 en.pdf (last accessed on March 18, 2009) 
r~aditJonal knowledge is diminishing in importance around the world. It is estimated that 90% of the traditional 
•
1 estyle could be lost within the next 100 years. The loss is accelerated by modernization/urbanization and the 
~puence of western education, which also erodes the support ofTK. 
127 Questions concern safety, efficacy, quality, access and rational use. 
8 
Due to the independent development of the traditional medicine in different geographic areas and cultures, 






The term "TM" is a comprehensive term that refers to medicines and therapies that have 
been used over generations that stem from theories, beliefs and experiences in different cultures. 
Much of TM is not "ancient" or inert, but articulates a vital, dynamic part of everyday life for 
many groups or communities today. TM includes medication therapies and non-medication 
therapies. TM can be codified, taught openly, practiced widely and systematically outlined in 
written or oral form. 
TM is usually comprised of herbal medicines, animal parts, and/or minerals. There are 
some famous TM systems such as Traditional Chinese Medicine, Indian Ayurveda medicine, 
Arabic Unani medicine, African Traditional Medicine and other various forms of indigenous 
medicines. 128 Non-medication TM therapies are also very popular, such as acupuncture and 
related techniques, chiropractics, osteopathy, manual therapies, qigong, yoga, tai-ji, Chinese 
cupping, naturopathy, thermal therapy, and other manual therapies and spiritual therapies. 
There is no formulated definition for TM, but the World Health Organization (WHO) and 
World Intellectual Property Organization (WIPO) have suggested definitions for TM. WHO 
defines TM as "including diverse health practices, approaches, knowledge and beliefs 
incorporating plant, animal and/or mineral based medicines, spiritual therapies, manual 
techniques and exercises applied singularly or in combination to maintain well-bring, as well as 
to treat, diagnose or prevent illness."129 WIPO defines TM as one part of the traditional 
medicinal knowledge, which is generally transmitted from generation to generation; these 
128 
A A .variety of indigenous TM systems also developed throughout history by Asian, African Arabic, Native 
12~encan, Oceanic, Central and South American and other cultures. 
h WHo, 'WHO Traditional Medicine Strategy 2002-2005', P7, 2002, available at 
~hqlibdoc.who.int/hg/2002/WHO EDM TRM 2002.l.pdf (last accessed on March 18, 2009) 
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medicines are generally regarded as pertaining to a particular people or its territory; and are 
l . . h . . 130 constantly evo vmg m response to a c angmg envuonment. 
In TM, the term, "traditional" does not necessarily mean "ancient," but refers to the creation 
and use of such medicine and medical knowledge as part of the cultural traditions of 
communities or groups. 131 TM is a living organic form of thoughts that grew out of the 
everyday experience of life in a particular place and within a particular community. There are 
many terms often related to TM, such as "alternative medicine," "complementary medicine," 
"natural remedies," "herbal medicines," and "indigenous medicines." Some of these terms are 
used interchangeably with TM, but some of them refer to a more specific concept. 
130 
WIPO, 'Intellectual Property Needs and Expectation of Traditional Knowledge Holder, WIPO Report on 
Fact-Finding Missions on Intellectual Property and Traditional Knowledge 1998-1999', P.25, 2001, available at 
http://www. wipo.int/tk/en/tk/ffm/report/final/pdf/part l.pdf (last accessed on March 18, 2009) 
The Term, "traditional knowledge" under WIPO refers to tradition-based literary, artistic or scientific works; 
performances; inventions; scientific discoveries; designs; marks, names and symbols; undisclosed information; and 
a_ll other tradition-based innovations and creations resulting from intellectual activity in the industrial, scientific, 
literary or artistic fields. "Tradition-based" refers to knowledge systems, creations, innovations and cultural 
expressions which have generally been transmitted from generation to generation; are generally regarded as 
pertaining to a particular people or its territory; and, are constantly evolving in response to a changing environment. 
Categories of traditional knowledge can include: agricultural knowledge; scientific knowledge; technical knowledge; 
ecological knowledge; medicinal knowledge, including related medicines and remedies; biodiversity-related 
knowledge; "expressions of folklore" in the form of music, dance, song, handicrafts, designs, stories and artwork; 
elements of languages, such as names, geographical indications and symbols; and, movable cultural properties. 
E~c!uded from this description ofTK would be items not resulting from intellectual activity in the industrial, 
Scientific, literary or artistic fields, such as human remains, languages in general and other similar elements of 
"heritage" in the broad sense. In summation, TK was created, originated in, developed and practiced by traditional 
knowledge holders. Indigenous knowledge is knowledge of indigenous people; expressions of folklore are a subset 
~;tra?itional knowledge; traditional knowledge is in tum a subset of the broader concept of heritage. 
Richard Wilder, 'Protection ofTraditional Medicine', CMH Working Paper Series, P.9, 2001, available at 
~mro.who.int/cbi/PDF/TraditionalMedicine.pdf(last accessed on March 18, 2009) 
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Comrnonly used TM/CAM therapies and therapeutic techniques 
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Nc.:~th America (and Austr31ia). When refl"fring In a Ql>neral st:nse to all of these regions, the (.'Omprt.>hensJ\l<e lM/('.AM i~ u~d. 132 
There are a variety of forms of TM in different systems as shown in the chart above from 
the WHO. Interestingly, they have different names, but the treatments are similar from one to the 
other. 
These terms "CAM" and "TM" are often used interchangeably. In countries where TM is 
not part of the country's own tradition or is not covered by the health care system, TM therapies 
are usually termed as "alternative, complementary" or "non-conventional medicine."133 WHO 
Traditional Medicine Strategy 2002-2005 points out that the term TM is usually used when 
referring to Africa, Asia, Latin America, South-East Asia and or Western Pacific, whereas 
"complementary medicine" is used when referring to Europe and/or North American (and 
Australia). When referring in a general sense to all of these regions, the comprehensive 
designation of TM/CAM is used. 134 
132 
h WHo, WHO Traditional Medicine Strategy 2002-2005, P.8, 2002, available at 
~whqlibdoc.who.int/hq/2002/WHO EDM TRM 2002.1.pdf(last accessed on March 18, 2009) 
h WHO, WHO Traditional Medicine Strategy 2002-2005, 2002, P.1, available at 
~whqlibdoc.who.int/hq/2002/WHO EDM TRM 2002.1.pdf(last accessed on March 18, 2009) 
WHo, WHO Traditional Medicine Strategy 2002-2005, P.8, 2002, available at 
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When considering indigenous medicines, "indigenous" should be understood in at least two 
different ways. First, it is used to describe knowledge held and used by communities, peoples 
and nations that are "indigenous" to a particular region or area. The Convention on Indigenous 
and Tribal Peoples of 1989 (ILO Convention No.l69) mentioned some commonly used criteria, 
such as aboriginality, cultural distinctiveness and self-identification as attributes to 
"indigenousness."135 The description of the concept "indigenous" in the Study of the Problem 
of Discrimination against Indigenous Populations is regarded as an acceptable working definition 
by many indigenous peoples and their representative organizations. It explains that indigenous 
peoples are "pre-invasion and pre-colonial societies." Professor Sompong Sucharitkul points 
out that there is no general accepted definition of "indigenous peoples." 136 For the purpose of 
this dissertation, "indigenous knowledge" refers to the traditional knowledge of indigenous 
peoples and a part of a traditional knowledge category, but traditional knowledge is not 
'1 . d' 137 necessan y m tgenous. 
TM is a traditional strategy for remedying diseases and a theory about mental, spiritual and 
physical health. For people who cannot afford to purchase modem chemical compound 
pharmaceuticals, TM remains the primary resource for health care, especially in Africa, Asia and 
Latin America. Interestingly, TM is also as a resource of health care when other pharmaceutical 
h!m://whqlibdoc.who.int/hq/2002/WHO EDM TRM 2002.l.pdf (last accessed on March 18, 2009) and 
Bhushan Patwardhan, 'Traditional Medicine: Modem Approach for Affordable Global Health: Traditional Medicine: 
Could more effective use be made of them in providing affordable treatments?', P. 34, 2005, available at 
ffiYW.who.int/intellectualproperty/studies/B.Patwardhan2.pdf (last accessed on 22 Mar 2008) 
. Sompong Sucharitkul, 'The Inter-temporal Character of International and Comparative Law Regarding the 
fughts of the Indigenous Populations of the World', 50 Am. J. comp. L. 3, 2002 
. Sompong Sucharitkul, 'The Inter-temporal Character of International and Comparative Law Regarding the 
~ghts of the Indigenous Populations of the World', 50 Am. J. comp. L. 3, 2002 
F WI.PO, 'Intellectual Property Needs and Expectation of Traditional Knowledge Holder, WIPO Report on 
~mding Missions on Intellectual Property and Traditional Knowledge 1998-1999, P.23-24, 2001available at 
://www.wipo.int/tk/en/tk/ffm/report/finaVpdf/partl.pdf (last accessed on March 18, 2009) 
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products pharmaceuticals cannot offer effective treatments or to prevent diseases. For example, 
in Australia, Europe and North America, "complementary and alternative medicine" (CAM) is 
increasingly used in conjunction with chemical compound medicine and vaccines, particularly 
. d . hr . d" 138 for treatmg an managmg c omc 1sease. 
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The status of TM is different from country to country. Some countries have established 
frameworks of laws and regulations to recognize and regulate TM as pharmaceuticals (both as 
prescription medicines and over the counter medicines). In some other countries, TM is 
considered self-medication, dietary supplements, health food, functional food, etc., in no need of 
further regulation. In some countries, the use of TM is just followed as it has been by 
generations without a "traditional medicine" industry. In countries where the traditional 
medicine developed more (for example, in China or India), the industry of TM is relatively small 
compared to modem pharmaceutical companies. 
138 
WHO, Traditional Medicine Fact Sheet, 2008, available at 
IDYw.who.int/mediacentre/factsheets/fs134/en/print.html (last accessed on March 18, 2009) 
In some Asian and African countries, 80% of the populations depend on traditional medicine for primary health care. 
In many developed countries, 70% to 80% of the population has used some form of alternative or complementary 
~edic_ine _(e.g. acupuncture). Herbal treatments are the most popular form of traditional medicine, and are highly 
Iucrat~ve m the international marketplace. Annual revenues in Western Europe reached US$ 5 billion in 2003-2004. 
n.C.hma, the sales ofTM products totaled US$ 14 billion in 2005. Herbal medicine revenue in Brazil was US$ 160 
milhon in 2007 139 • 
h WHO, Traditional Medicine-Growing Needs and Potential, P.1, 2002, available at 
~hqlibdoc.who.int/hq/2002/WHO EDM 2002.4.pdf (last accessed on March 18, 2009) 
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2.4.2 Challenges 
Some modalities ofTM (for example, acupuncture, some herbal medicines and manual therapies) 
do gain some scientific validity from random clinical trials; however, most TM is still struggling 
with the challenge of great prejudice and ignorance. 
Due to the variation of TM systems, which are developed in different countries and cultures, 
there is no parallel development of international standards and appropriate methods of evaluation. 
The lack of research data, the lack of acceptable standards for clinical trials, the lack of support 
from health care policies, the lack of adequate or acceptable methodology140 for evaluating TM, 
and the lack of international laws and regulations have given inadequate protection and 
discouraged the development of TM. 
Countries might have different regulations on TM/CAM and herbal medicine based on the 
difference in definition of TM/CAM and herbal medicines. In addition, in some countries, 
animal and mineral materials may be present in herbal medicines. 141 TM is unregulated in most 
countries. 142 WHA also points out that the major challenges to the use of TM include the lack of 
organized networks of traditional practitioners, and of solid evidence of the safety, efficacy and 
140 
The need for having standards and methodologies is so TM might become more acceptable by the scientific 
community 
141 . 
WHO, National Policy on Traditional Medicine and Regulation of Herbal Medicines, Report of a WHO Global 
Survey, P.l, 2005, available at 
lmp://whqlibdoc.who.int/publications/2005/9241593237.pdf (last accessed on March 18, 2009) 
Some counties have different regulations or laws on TM/CAM or herbal medicines. TM/CAM often refers to a 
broad set of health-care practices that are not party of a country's own traditional and are not integrated into the 
dominant health-care system. Other terms sometimes used to describe there health care practices include "natural 
medicine," "non-conventional medicine" and "holistic medicine." Herbal medicine often refers to plant-derived 
?laterials or preparations with therapeutic or other human health benefits, which contain either raw or processed 
~gredients from one or more plants. In some traditions, material of inorganic or animal may also be present. 
S WHo, National Policy on Traditional Medicine and Regulation of Herbal Medicines, Report of a WHO Global 
urvey, P.25, 2005, available at 
h!to;LLwhqlibdoc.who.int/publications/2005/9241593237 part3.pdf(last accessed on March 18, 2009) 
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quality of traditional medicines. The need for measures to ensure proper use of traditional 
medicine and to protect and preserve the traditional knowledge and natural resources is 
necessary for its sustainable application, and for training and licensing of traditional 
• • 143 
practitioners. 
The legal situation of TM vanes from country to country. There are some possible 
regulatory categories for herbal medicine: prescription medicines, over-the-counter medicines, 
self-medication, dietary supplements, health food, functional foods, and others. 144 
In some countries where TM status is well established, TM can be sold as either medicine or 
food/dietary medicine, while in other countries, TM is regarded as a food or dietary supplement 
and therapeutic claims are not allowed. In some developing countries, where TM has been 
widely used as more folk-knowledge, there is hardly any legislative criteria to conform TM into 
formal drugs legislation. 145 
143 
WHO, Resolution of the Executive Board of the WHO, 111 th Session, Agenda Item 5. 7, Traditional Medicine, 
Jan 24, 2003, available at 
http://whqlibdoc.who.int/eb/2003/EBI I I Rl2.pdf (last accessed on March 18, 2009) 
144 
WHO, National Policy on Traditional Medicine and Regulation ofHerbal Medicines, Report of a WHO Global 
Survey, P.29, 2005, available at 
ht!p://whqlibdoc.who.int/publications/2005/9241593237 part3.pdf (last accessed on March 18, 2009) 
-·Prescription medicines: medicines/drugs that can only be purchased with a prescription. 
··Over the counter medicines: medicines/drugs that can be purchased without a prescription from a physician. 
•· Self medication only: medicines/drugs permitted for self medication purposes only. 
··Dietary supplements: a dietary supplement is a substance which contains, for instance, a vitamin, a mineral, a herb 
or other botanical or an amino acid. A dietary supplement may be intended to increase the total daily intake of a 
concentrate, metabolite, constituent, extract or combination of these ingredients. 
•• Health food: health foods could be products that are presented with specific health claims and therefore regulated 
differently from other foods. 
··Functional foods: like health foods, functional foods may be products which are offered with specific health 
claims and therefore regulated differently from other foods. 
~;?ther: products classified differently from the above mentioned categories. 
h WHo, Regulatory Situation of Herbal Medicines: A Worldwide Review, P.1, 1998, available at: 
~hqlibdoc. who.int/hq/1998/WHO TRM 98.l.pdf (last accessed on March 18, 2009) 
The various legislative approaches for herbal medicines fall into one or other following categories: 
• Same regulatory requirement for all products; 
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Countries might adopt different approaches and definitions toward TM herbs and TM 
products containing herbs, mineral or animal parts, to regulate their use. 146 The lack of an 
internationally recognized standard in legislation and regulation of TM makes the protection of 
TM and the TM users more difficult. 
In order to promote R&D in TM, recognition of the role and importance of TM will be the 
first step. Then, after standardizing the safety, efficacy and quality control, guidelines for 
rational use will be the second step to gaining public trust that TM is effective as medicine. 
Thirdly, the nation states shall establish national policy in regulating TM and the TM 
practitioners. 
Standardization 
Inadequate standardization of medicinal plants, unacceptable preclinical toxicology studies and 
inappropriate and poorly designed clinical trials have held back the research and development of 
TM and consequently have delayed the use ofTM and medicinal plants to host new drugs. 
Countries might adopt different approaches towards licensing, dispensing and marketing 
herbs, medicinal plants and products in order to ensure their safety, quality and efficacy. 
·Same regulatory requirements for all products, with certain types of evidence not required for herbal/traditional 
medicines· 
• Exempti~n from all regulatory requirements for herbal/traditional medicines; 
·Exemption from all regulatory requirements for herbal/traditional medicines concerning registration or 
marketing authorizations; 
·Herbal/traditional medicines subject to all regulatory requirements; and 
·Herbal/traditional medicines subject to regulatory requirements concerning registration or marketing 
authorizations 146 • 
8 
WHo, 'National Policy on Traditional Medicine and Regulation of Herbal Medicines, Report of a WHO Global 
h ur:ey', P.? 1, 2005, available at 





Although 25% of modern medicine is made from the same plants that make up TM, a relatively 
small number of TM materials, especially plant species, have been studied in detail. With the 
growing demand to develop traditional medicine and therapies, getting the best evidence for 
safety, efficacy, quality and rational use has been the most challenging task for TM. 
Standardization is necessary for TM and herbal preparations in order to ensure that they 
contain the correct amount of the right substances without impurities. Only then can the 
medicine claim a therapeutic effect and not induce any toxic effects due to possible 
contamination. 
TM is comprised of about 90% medicinal plants, animals and minerals. Without ensuring the 
safety of TM, the credibility of TM cannot be built. Medicinal plants comprise thousands of 
species of plants. Besides the extracts from botanicals, the active ingredients and the chemical 
interaction between them in TM, especially in multiple substances formulas, have not been 
clinically proven. 147 
Nevertheless, some TM, such as manipulative therapies and behavioral stress-reduction 
techniques, can effectively provide relief for chronic diseases. For example, acupuncture and 
some herbal medicines and manual therapies were proven to help patients in studies. 
147 
M: ~h~shan Patwardhan, 'Traditional Medicine: Modem Approach for Affordable Global Health: Traditional 
edtcme: Could more effective use be made of them in providing affordable treatments?', 2005, available at 
~.who.int/intellectualpropertv/studies/B.Patwardhan2.pdf (last accessed on March 18, 2009) 
ome of the chemicals are directly responsible to contain several chemical ingredients while others are directly 
~~ponsible for therapeutic activities, some are responsible for balancing toxicity, and some are required as carriers. 
b though some of the ingredients and/or chemical reactions might be harmful or not effective as they are claimed to 
. e, because TM has been practiced and continually used for generations, the harm might not be clinically significant. 
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Acupuncture has been scientifically proven to relieve some pain and nausea. Artemisia 
aroma, one Chinese medicine which has been used in China for almost 2000 years, has been 
found effective in resisting malaria. Plant Sutherlandia Microphylla is used to treat HIV I AIDS 
patients, and is used as a tonic, to increase energy, appetite and body mass in people living with 
HIV/AIDS.
148 
In general, there is a lack of research data, a lack of adequate acceptable research 
methodology and a lack of clinical evidence to support the widespread claims of TM. 149 
Because TM systems are developed in different cultures, within different regions, and have no 
parallel development standards and methods, problems arise regarding interpretation and 
application of TM. 
As Professor Chaudhury indicates, "the challenge of the twenty-first century will be to 
carry out clinical evaluation of herbal remedies within the framework of rigid clinical 
pharmacological principles without trampling on the concepts of the traditional systems of 
medicine."150 This should be the goal to furthering the development ofTM. 
Evaluating the active ingredients in TM is extremely difficult because some of the species 
do not exist today. 151 In order to maximize the benefit of TM, consumers have to overcome the 
148 
WHO, 'Traditional Medicine' Fact Sheets', 2008, available at 
h!m.;l/www.who.int/mediacentre/factsheets/fs 134/en/print.html (last accessed on March 18, 2009) and WHO, 
Traditional Medicine Strategy 2002-2005, P.22, 2002, available at 
~whglibdoc.who.int/hq/2002/WHO EDM TRM 2002.1.pdf(last accessed on March 18, 2009) 
h ~HO, !'raditional Medicine Strategy 2002-2005, P.3, 2002, available at 
~whghbdoc. who.int/hq/2002/WHO EDM TRM 2002.1.pdf (last accessed on March 18, 2009) 
h ~anjit Roy Chaudhury, 'Research and Evaluation of Traditional Medicine', P.5, 2005, available at 
~www.searo.who.int/LinkFiles/Meetings documentl5.pdf(last accessed on March 18, 2009) 




policy, safety, efficacy, quality, access and rational use issues. This needs to be done on both a 
national and an international level. On a national level, nations should have regulations and 
registration systems for TM in order to adopt policies and funds to support research and 
development. Furthermore, countries and communities should exchange and share the 
information and results of existing TM knowledge. Networking and having an international 
registration system worldwide will aid the development of international standards for safety, 
efficacy and quality of TM. 
Efficacy 
Efficacy 1s one of the most debated issues in the TM, which is at the core of the 
pharmaco-economics of TM. Evaluation of efficacy may be affected by philosophical, cultural, 
technical, methodological and practical aspects. Some of the TM and therapies have been 
demonstrated and acknowledgt:;d worldwide (for example, acupuncture, herbs like Artemisia 
annua and St. John's wort). Plant extracts 152 have a variety of pharmacological effects, 
including anti-inflammatory, vasodilatory, anti-microbial, anti-convulsant, sedative and 
anti-pyretic effects; however, very few randomized, controlled studies have been carried out to 
investigate the effects of TM practitioners' everyday work. 153 Recently, many countries and 
animals is necessary to understand the active ingredients. The crucial problem is some plants and animals, which 
use~ in TM, do not exist nowadays. Moreover, the proprieties of plants and animals could vary the active ingredients, 
Which are influenced by time, weather, and environmental factors as well. Even a single medicinal plant could have 
more than several hundred natural constituents. Therefore, in order to ensure the safety, quality, efficacy and rational 
~e, the need to set up methodologies and evaluation on TM is urgent. 
M ~h~shan Patwardhan, 'Traditional Medicine: Modem Approach for Affordable Global Health: Traditional 
edicme: Could more effective use be made of them in providing affordable treatments?', P.46-50, 2005., available 
at 
~.wh~.int/intellectualproperty/studies/B.Patwardhan2.pdf (last accessed on March 18, 2009) 
1 
inkgo b!loba, Uncaria tomentosa, Echinacea Spp., Withania somnifera, Traditional species, including black pepper, 
1~fg pepper, ginger and turmeric. 
Bhushan Patwardhan, 'Traditional Medicine: Modem Approach for Affordable Global Health: Traditional 
:Could more effective use be made of them in providing affordable treatments?', P. 45, 2005, available at 
. ........,..!.!.:..lX!li!.JJl!Ll!:!~~J!illlm:l~r!X®tflli~li1!hl@Tillll!!Jl,llitl. (last accessed on March 18, 2009) 
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organizations have started creating new mechanisms to induce and regulate quality control and 
standardization of botanical medicine. 154 Aside from evaluating the adverse effects in 
preparation, post-marketing surveillance will provide useful information. 
In order to commercialize TM, correctly identifying and supplying the raw materials 
without altering the claimed active ingredients has become challenging. In addition to 
biodiversity issues 155, the standardization for assurance ofthe "active marker" is a prominent part 
of quality control. 
Efforts are underway to have standardized TM to establish evidence that proves the safety, 
efficacy, good quality and rational use of TM. Some of the randomized control clinical trials 
have established clinical efficacy in Rheumatoid and Osteoarthritis, Hapatoprotectives, Diabetes, 
Hypolipedemic agents, Asthma, Parkinson's disease and many other disorders. 156 
Quality Control 
The assurance of quality in TM is another safeguard against the risks of using TM. The growth, 
cultivation, collection, storage, distribution, processing and marketing of the materials are 
important, as each part of the process has a great impact on the quality of the product. Not only 
. Including the World Health Organization, European Scientific Cooperation of Phytomedicine, US Agency for Health 
Care Policy and Research, European Pharmacopoeia Commission, Department of Health UK, Common Wealth of 
Australia, Department of Indian System of Medicine. 
154 
Bhushan Patwardhan, 'Traditional Medicine: Modem Approach for Affordable Global Health: Traditional 
Medicine: Could more effective use be made of them in providing affordable treatments?', P.63, 2005, available at 
~ww.who.int/intellectualproperty/studies/B.Patwardhan2.pdf (last accessed on March 18, 2009) 
55 
Due to the time and environmental factors, a lot of species in plants and animals do not exist nowadays. How to 
ensure the biodiversity is for the sustainable development ofTM. How to find the substitutes for TM formula is 
another block for TM development. 
156 
Bhushan Patwardhan, 'Traditional Medicine: Modem Approach for Affordable Global Health: Traditional 
Medicine: Could more effective use be made of them in providing affordable treatments?', P.115, 2005, available at 
~W.who.int/intellectualproperty/studies/B.Patwardhan2.pdf (last accessed on March 18, 2009) 
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is it necessary to ensure the identity of the right raw material, but the right quality of the 
elements that compose the material must be considered so that contamination, alteration or 
spiking does not occur. However, only a few countries have regulations, national policies or 
registration systems for TM. Due to the extensive use of botanicals and other raw materials in 
TM, quality control has become a tough task. The quality of TM products may be 
contaminated or vary tremendously in the context of safety and quality. 157 Addressing the 
needs for standardization and quality control is the next step to assure the safety ofTM. 
The lack of passport data for raw materials, identification, and pharmacology is another 
problem related to quality control. There is no clear labeling standard or requirement for TM, 
and many of the herbal medicines, which are sold as over-the-counter medicines or food 
supplements, have little or no advice about the adverse effects or appropriate uses. 
The safety and quality control of raw medicinal plant materials and finished products 
depends on many factors, such as the genetic factors or extrinsic factors of the environment, 
collection methods, cultivation, harvest, post-harvest processing, transportation and storage 
practices. This can be ensured by following the WHO guidelines on good agricultural and 
collection practices (GACP) for medicinal plant materials. 158 Quality control of TM has to 
157 
Bhushan Patwardhan, 'Traditional Medicine: Modem Approach for Affordable Global Health: Traditional 
Medicine: Could more effective use be made ofthem in providing affordable treatments?', P.63, 2005, available at 
~ww.who.int/intellectualproperty/studies/B.Patwardhan2.pdf (last accessed on March 18, 2009) 
While in the most part of the use ofTM, the main sources of the botanicals and raw materials are from nature and 
~~t from planned cultivations. 
WHO, 'WHO Guidelines on Good Agricultural and Collection practices (GACP) for Medicinal Plants', P.2, 
2003, available at 
bniwwhglibdoc. who.int/publications/2003/9241546271.pdf (last accessed on March 18, 2009) 
The guidelines will contribute to the quality assurance of medicinal plant materials used as the source for herbal 
medicines, which aims to improve the quality, safety and efficacy of fmished herbal products; guide the formulation 
of national and/or regional GACP guidelines and GACP monographs for medicinal plants and related standard 
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ensure the Good Manufacturing Practice (GMP) of starting materials, including correct 
identification of species of medicinal plants, special storage, special sanitation and cleaning 
d C' • • l 159 metho s 10r vanous matena s. 
Rational Use 
There are considerably more regulations and laws regarding the safety, efficacy and quality 
control of TM than provisions on rational use. Besides information accessible by the 
consumers, nation states should be the gate-keepers for safeguarding and providing regulations 
and legislation related to the medicine itself and TM practitioners. 160 Rational use is correlated 
to safety and assured quality, and one cannot neglect the risk associated with the use of TM. 
The interaction between TM and other pharmaceutical products is another important issue as 
well. Measures are needed to avoid chemical conflict when consumers combine the two forms 
of treatment. Therefore, proper use is another important factor when developing and 
researching TM to provide the scientific information and guidance for the public to get more 
rational use of TM. 
operating procedures; and encourage and support the sustainable cultivation and collection of medicinal plants of 
rs~od quality in ways that respect and support the conservation of medicinal plants and the environment in general. 
160 
Quality control of finished herbal medicinal products, particularly mixed herbal products, is more difficult. 
WHO, Guidelines on Developing Consumer Information on Proper Use of Traditional, Complementary and 
Alternative Medicine, 2004, P.7-9, available at 
]illp://www.paho.org/spanish/ad/ths/ev/PM-WHO-Traditional-medicines-Consumer.pdf (last accessed on March 18, 
2009) 
To ensure the proper use ofTM, there are some general consideration should be addressed on: 
-Quality control of herbal medicines; 
-Development of reliable treatment guidelines; 
-Training and qualified practice for TM practitioners 
-Collaboration between health care providers and TM practitioners; 
-Communication between TM consumers and their health care providers and TM practitioners; 
-Organization ofTM practitioners; and 
-Regulatory and Mechanisms for Information and Advertisement. 
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Development of TM -
TM has been the primary health care for many people in the world. There are many difficulties 
to overcome for further development in TM. The lack of recognition of the value of TM has 
presented obstacles to its advancement. Moreover, the lack of bio-diversity and stability of the 
TM materials contributes to the slow development of TM. Although intellectual property rights 
also offer protection to TM, TM has difficulties in passing clinical trials, businesses have little 
incentive to invest in TM, and the treatments consequently fail to obtain market approval. Or 
for some other medicines, the products do not fit into the requirements of patent protection. 
Thus, there are few financial sources investing in TM, and little incentive for R&D and 
personnel. 
2.4.3 Concluding Summary 
TM has been widely used and has many positive features in its diversity, flexibility, accessibility, 
affordability, and the individualization. 80% of the population in most developing countries 
regularly uses TM. The development of TM will benefit populations in developing countries 
the most, because of the accessibility and affordability of the pharmaceuticals to fulfill their 
health care needs. Furthermore, researchers might be able to use TM to invent and develop 
more efficient and effective pharmaceuticals to benefit the world's population. 
2.5 Pharmaceutical Prices 
2.5.1 Introduction 
Health is something you cannot put a price on, and yet money still determines health in the 
context of pharmaceuticals. Pharmaceuticals account for a major portion of health expenditures, 
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and although it has been argued that medicine-as-commerce is at the heart of the problem, many 
factors contribute to the problems surrounding access to pharmaceuticals. 
Access to pharmaceuticals depends heavily on the availability and affordability of 
pharmaceutical products. Pharmaceuticals are as goods for trade, so the pharmaceutical prices 
are most affected by globalization. Although global trade increases the trade in 
pharmaceuticals, most of the pharmaceutical products are traded internationally with protection 
under intellectual property rights across countries. There are vast disparities between the 
developed and developing countries in this regard. 161 
2.5.2 Chemical Compound Pharmaceuticals 
The reproduction of chemical compound pharmaceuticals is not difficult for personnel in the 
field. The cost of the ingredients is not high and the manufacturing processes are not difficult. 
It is the discovery, development, testing, and gaining regulatory approval for a new medicine that 
is time-consuming, risky and costly. Pharmaceutical companies represent one of the most 
research-intensive industries among the many industries. 
lhe North and the South 
The worldwide pharmaceutical market is divided into the North and the South when it comes to 
the accessibility and affordability of pharmaceuticals. The worldwide pharmaceutical 
marketplace is composed of four geographic areas: the US, Europe (European Union), Asia 
161 
h WHo, Medicines Price Information, available at 
~ww. who.int/medicines/areas/access/ecofin/en/print.html (last accessed on March 18, 2009) 
n response to the World Health Assembly Resolution WHA54.11, WHO is working with partners to make existing 
drug price information more widely available in order to improve equity in access to essential medicines in health 
systems and to provide support to member states. 
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(Japan, China, Australia) and the rest of the world. Currently, the developed countries account 
for 11-12% of the global burden from all causes of death and disability, but just under 90% of 
do 162 health expen 1ture. 80% of the world's medicines are consumed by populations concentrated 
in the US, Europe and Japan. 163 By contrast, developing countries account for just 17% of 
imports and 6% of exports of pharmaceutical products. 
h . lSl b R * P armaceutica a es 'Y 0 2003164 egwn m 
Region Sales ($billion) % Global Sales 
North American 229.5 49 
European Union 115.4 25 
Rest of Europe 14.3 3 
Japan 52.4 11 
Asia, Africa, and Australia 37.3 8 
Latin America 17.4 4 
Total 466.3 100 
Among the competitive therapeutic markets, large pharmaceutical companies possess more 
ability to price their products above the marginal costs of production and generate economic 
profits. In addition, because of the first-mover advantages, even after the patent expires, the 
companies will still have a brand-name, which they price above costs to dominate the market 
over generics. Meanwhile, promotions and advertisements from large companies also help to 
reinforce the habit of buying such a product by both physicians and patients. 165 
2.5.3 Vaccines 
Immunization has revolutionized the world, especially when it comes to the health of children. 
162 
Anand S Dutta, 'Discovery ofNew Medicines', John P. Griffin and John O'Grady edited, The Textbook of 
~~armaceutical Medicine, 5th ed., P.7, BMJ Books, 2006 
164 Kelley Lee edited, Globalization and Health: An Introduction, P.72, Palgrave Macmillan, 2003 
165 C. Ralph Buncher and Jia-Yeong Tsay edited, Statistics in the Pharmaceutical Industry, 3'd ed., P.346, CRC, 2005 
f: Go~dwill established during the period of patent protection extends the physician and/or patients continue to 
avor higher-priced products, even after the patent has expired. 
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Immunization can help prevent childhood death and reduce the toll of disability and illness. 
Despite the overall success of immunizations, almost 11 million children under the age of five 
die each year because of the lack of vaccination to prevent diseases. Immunization has not 
been sustained in most of the developing countries. In some countries, fewer than one in three 
children are immunized during their first year of life. 
The accessibility and affordability of vaccines vanes both among regions and among 
products. The off-patent vaccmes, such as the traditional vaccines like measles, bacilli 
Calmetter-Guerin (BCG), diphtheria-pertussis-tetanus (DPT), Tetanus toxoid (TT), and oral polio 
vaccine (OPV), are widely accessible by an average 50~80% of infants each year. Due to 
increasingly efficient production resulting from time, economics, and competition, off-patent 
vaccines are sold at very low prices and provide low marginal rates of return to producers. 166 
Newer vaccines, such as hepatitis B and Haemophilus influenza type B (Hib ), which have 
been available in developed countries for many years, have been introduced into developing 
countries very slowly due to the price of the vaccines. Although these vaccines were provided 
at a far lower price167 to developing countries than to developed countries, the vaccine prices are 
still making the drugs prohibitively expensive to people in developing countries. 168 
166 • 
Arnie Batson, Sarah Glass, and Erica Seiguer, 'Economic of Vaccines: From Vaccine Candidate to 
P
Commercialized Product', Barry R. Bloom and Paul-Henri Lambert edited, The Vaccines Book, P.350, Academic 
ress, 2002 
167 
168 The vaccine prices introduced in developing countries have been contained by measures by differential pricing. 
Arnie Batson, Sarah Glass, and Erica Seiguer, 'Economic of Vaccines: From Vaccine Candidate to 
P
Cornrnercialized Product', Barry R. Bloom and Paul-Henri Lambert edited, The Vaccines Book, P.350, Academic 
ress, 2002 
\Vhe? comparing with the traditional or off patent vaccines, which range from $0.05-0.15/dose, the prices of newer 
vaccmes are still unaffordable to the majority of the population. 
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The accessibility and affordability of these drugs are big problems in both developed and 
developing countries. The vaccine industries are just like any other business sectors; the market 
demand dictates the potential earnings from a product. The price of vaccines is a critical 
component of accessibility and affordability of a vaccine. If the vaccine price is too high, the 
higher price will cause problems to government budgets, clinicians, hospitals and consumers. 
Immunization will surely decrease if the payers are unable to afford the treatments. By contrast, 
if the vaccine price is too low, due to government discounts 169, price caps or the purchasing 
power of consumers or small markets, it will discourage investment by vaccine companies. The 
economics of vaccines have become the major obstacle to vaccine development. Nevertheless, 
vaccines prices are just like any other goods, affected by the volume, market demand, and the 
purchasing power of the buyer. 
The high profit of vaccines is influential for large companies and for venture funding of 
small companies because potential sales determine the desirability of an investment decision. 
The public expectation is for low vaccine prices. 
Nonetheless, the gaps between those who have and who do not have access to vaccines has 
widened in the past two decades. The main reason for the lack of access to live-saving vaccines 
is that they are unaffordable; however, there are other factors that contribute to the problem. In 
many developing countries, lack of an adequate health care service to provide medical services 170, 
169 
Large group or government can usually negotiate discounts to up to 15% and for the small clinics and hospitals 
f7~Y for the list price. Historically, the discount was up to 75%. 
WHO, State of the World's Vaccines and Immunization, P.14, 2003, available at 
~.wh.o.int/vaccines-documents/DocsPDF04/wwwSOWV E.pdf (last accessed on March 18, 2009) 
1
evelopmg countries account for 93% of the world burden of diseases, but only 18% of its income and only 11% of 
g obal spending on health. 
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lack of the capacity to deliver the vaccines, the inadequacy of diseases surveillance and reporting 
systems cause the burden of diseases and application of the cost-effective vaccines to fight 
against the diseases-these all factor into the complexity of the problem. 171 
It is true that developing countries are in tremendous need of vaccines, but from the point of 
view of the companies, the demand is relatively small. 172 Low and uncertain demand for a 
product discourages the industry from investing. 
Because the vaccine development and manufacturing are very costly, the decision makers in 
developed countries have to appropriate the budget in the interests of the people for vaccine 
purchase. The licensed pneumococcal conjugate vaccine provides an example. Four 
recommended doses exceed $200 if purchased in a private retail market. The vaccine price is 
beginning to impinge on decisions of those who do the recommending of the vaccination. 
Therefore, even though the vaccine is effective, the vaccine price makes people more reluctant to 
purchase it. 173 
Accessibility and affordability of vaccines are even worse for developing countries. Those 
most in need of the vaccines are the least able to afford or develop them. Developing countries 
171 
WHO, State ofthe World's Vaccines and Immunization, P.7, 2003, available at 
-ffi:Vw.w~o.int/vaccines-documents/DocsPDF04/wwwSOWV E.pdf (last accessed on March 18, 2009) 
Am1e Batson, Sarah Glass, and Erica Seiguer, 'Economic of Vaccines: From Vaccine Candidate to 
Commercialized Product', Barry R. Bloom and Paul-Henri Lambert edited, The Vaccines Book, P.347, Academic 
Press, 2002 
The terms of market and demand is usually used very differently. The potential market for vaccines in developing 
countries is very large; however, the actual market is the portion of this need that translates into demand or 
Purchased doses at a give price. Thus, the market for a manufacture is the revenue generated by sales of products. 
~!though the potential need of vaccine may be large in developing countries, the actual demand is much smaller 
17~cause of those who need the vaccine are often least able to pay for it. 
p B Brett Finlay, 'Understanding Microbial Pathogenesis as a Basis for Vaccine Design', Barry R. Bloom and 
aul-Henri Lambert edited, The Vaccine Book, P. 186, Academic Press, 2003 
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are mostly haunted by infectious disease. With limited health budgets and poor infrastructure, 
governments are unable to purchase the vaccine for their peoples. 
Even though transnational pharmaceutical companies sell vaccines through a two-tiered 
pricing system (prices in developed countries are high, as in Western Europe and the US, and a 
large volume of vaccines is sold to developing countries at a significantly lower price), 
immunization is still not sustainable in most developing countries. 
The lack of demand 174 is the cause of both the inaccessibility and unaffordability of 
vaccines. From the perspective of the industry, the freedom to price vaccines is restrained. 
Most of the vaccines are sold to governments at discounted prices. Prices for developed countries 
are high. 175 Setting the price of vaccines is even tougher in countries with price controls, such as 
in Western Europe and Japan. Controls are even more pressured regarding the sales to 
developing countries, or sometimes the vaccine donations. The downward price pressures 
discourage investment. 
Even though vaccines have given important benefits to the population, the vaccine supply 
system is surprisingly fragile. At the moment, only four major vaccine manufacturers are able 
to adhere to modem standards and their total capacity is inadequate for future demand. Currently, 
174 
From the perspective of the vaccine industry, the need for vaccines is different than the demand for vaccines. 
The market is located at the consuming capacity. When the market can cover up the costs and generate profits, then 
~;re is a demand. 
S ~he Committee on the Evaluation of Vaccine Purchase Financing gin United States Board of Health Care 
e~tces, Financing Vaccine in the 21 '1 Century: Assuring Access and Availability, P. 108-109, 2004 
Try~g to strike a balance between multinational pharmaceutical companies and developing countries, large, 
lllulttnational pharmaceutical companies sell the vaccine in a two-tired pricing system. Means, prices in developed 
~ountries are higher than the vaccines sell to developing countries. For those vaccines revenue generate from 







the new vaccmes sell for dramatically high prices. 176 On the other hand, pnces of the old 
vaccines are more stable; this stable pricing may be disrupted by the development of new 
combinations of individual vaccines and of existing vaccine combinations. 
2.5.4 TM 
In many developing countries, TM is the primary health care. The considerable use of TM can 
be shown by statistics: 40% of people in China and Colombia, 71% of people in Chile and up to 
80% of those living in some African countries use TM. In some developed countries, TM has 
also been regularly used by about 70-75% of the population. 177 
TM should be the most accessible and affordable pharmaceutical in countries where TM is 
the primary health care 178, when compared with the chemical compound medicines and vaccines. 
TM is usually harvested from plants, animals or minerals on a national level. However, it 
cannot be assumed that TM is always a cheaper option. In some countries, governments 
subsidize the chemical compound medicines and vaccines used by the pharmaceutical industry, 
but not the TM industry. As a result, some TM is more expensive than the chemical compound 
medicines and vaccines. 179 
176 
The Committee on the Evaluation of Vaccine Purchase Financing gin the United States Board of Health Care 
Services, Financing Vaccine in the 21st Century: Assuring Access and Availability, P. 128, 2004 
Varicella vaccine is at a federal contract price of$32.70 per dose. One new pediatric pneumococcal vaccine is at 
M3.50 per dose and the list price is $58.00 in the US. 
Gerard Bodeker, Fredi Kronenberg, and Gemma Burford, 'Policy and Public Health Perspectives on Traditional, 
Complementary, and Alternative Medicine: An Overview', Gerard Bodeker and Gemma Burford edited, Traditional, 
2
Complementary and Alternative Medicine: Policy and Public Health Perspectives, P.l 0, World Scientific Publishing, 
006 
178 • 
179 Pnmary health care in most countries in African region, Latin America and several Asian countries. 
Gemma Burford, Gerard Bodeker, and Chi-Keong Ong, 'Financing Traditional, Complementary, and Alternative 
~faith ~are Services and Research', Gerard Bodeker and Gemma Burford edited, Traditional, Complementary and 





Moreover, the problem of biodiversity of the raw material of TM, has posed problems to 
reproducing TM, making the TM inaccessible and unaffordable in some situations. 
In most countries, TM services are not insured, so patients and consumers have to pay out 
of pocket. According to the survey for Global Atlas among the WHO members, only 58 out of 
121 surveyed states (27%) are known to have public financing for TM, whether full or partial. 
The reimbursement of the TM services is often restricted to specific therapies or certain 
. f . . 180 categones o practitiOners. 
2.5.5 Factors Contributing to Pharmaceutical Prices 
There are a number of factors that contribute to the price when pharmaceuticals become 
internationally traded goods. In addition to the R&D and the market approval and other 
marketing expenses, tariffs and taxes, as well as the global intellectual property protection on 
pharmaceuticals, are key factors in driving up the market price. 
2.5.5.1 Tariffs and Other Charges 
Tariffs and other charges are revenue sources for governments, though at the same time they are 
barriers to trade. Sometimes governments may use tariffs or other charges to protect their 
domestic pharmaceutical industries against foreign competition; however, the tariffs and charges 
add to pharmaceutical prices for the end-users-the patients. The WHO recommends that the 
listed essential medicines should not be subject to tariffs, but some countries still levy tariffs and 
180 
Gerard Bodeker, Fredi Kronenberg, and Gemma Burford, 'Policy and Public Health Perspectives on Traditional, 
Complementary, and Alternative Medicine: An Overview', Gerard Bodeker and Gemma Burford edited, Traditional, 
2
Complementary and Alternative Medicine: Policy and Public Health Perspectives, P.l6, World Scientific Publishing, 
006 
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other charges on essential medicines. 
2.5.5.2 Global Intellectual Property Protection 
Intellectual property rights protection, as the safeguard of and incentive for the investment in 
pharmaceutical products, plays an important role in both the domestic and global trade of 
pharmaceutical products. 
Due to the enormous loss of profits as a result of off-patent pharmaceuticals, pharmaceutical 
companies face considerable countervailing pressures to maintain and promote their sales with 
patent protection to recoup their costs and make profits. Pharmaceutical companies adopt 
measures to prolong patent life or delay the generic products entering the markets, measures that 
wind up driving the command prices well above the manufacturing costs. 181 
TRIPS ensures. the minimum patent protection of pharmaceutical products globally. There 
are also concerns about how the TRIPS agreement affects pharmaceutical prices, because with 
the implementation of TRIPS, all WTO member states have to provide patent protection for 
product and processes following the content in TRIPS. Since the patent offers the patent 
holders (primarily the pharmaceutical companies) exclusive rights, the pharmaceutical prices 
then will be set according to the market. 
2.5.5.3 Cost Containment Measures 
In facing the problems of unaffordable pharmaceuticals, governments use cost-containment 
18} 
WHO, The World Medicines Situation, P.38, 2004, available at 
~searo. who.int/LinkFiles/Reports World Medicines Situation. pdf (last accessed on March 18, 2009) 
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measures to ensure the availability of pharmaceutical products. 
~rallel Imports 
Parallel imports or grey market pharmaceuticals are genuine pharmaceutical products imported 
into one country without the authorization of the patent holder. National governments may 
have different policies regarding parallel imports. The pharmaceutical prices from the grey 
market are much cheaper than those sold under license. 
Compulsory Licensing 
Governments may use compulsory licensing to allow the use of patented pharmaceutical 
products without the patent holder's consent on the ground of public interest; for example, 
national emergency, anti-competitive practices or non-commercial use may qualify for a public 
interest exception to the patent rules. 
Drug Donation 
Some large pharmaceutical companies engage in the support of health development through 
private-public partnerships. In a number of cases, international corporations and foundations 
have contributed drugs or products free of charge to help in disease eradication. 
SmithKline Beecham has made a US$500 million commitment to WHO of its drug 
albendazole, used to treat lymphatic filariasis (elephantiasis). American Home Products has 
provided a non-toxic larvicide and the DuPont Company have contributed free cloth water filters 
for the eradication of guinea-worm disease (dracunculiasis). The Japanese Nippon Foundation 
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has enabled the WHO to supply blister packs containing the drugs needed for multi-drug therapy 
(MDT) of TB in sufficient quantities to treat about 800,000 patients a year in some 35 
countries. 182 Novartis, in a framework established with the WHO, offers public sector 
purchases in developing countries a special price for its anti-malarial medicine Coartem 
(artmether+lumefantrine ). 183 
Differential Pricing (Tiered Pricing) 
The term "different," "tiered," "preferential," "discounted pricing" and "market segmentation" is 
used to describe the practice of charging lower prices in different markets. 184 By using 
differential pricing, companies can charge a low price in developing countries to promote 
accessibility and affordability, while still charging developed countries higher prices to recoup 
their expenditures. However, the different pricing measures do not necessarily result in greater 
affordability or availability. The measure of differential pricing has been applied in other 
sectors for years. It is often integral to widespread use of products, but safeguards must be 
instituted in order to prevent the importation of grey market goods. 
£.rice Controls 
Price control is a government policy that intervenes directly with the pharmaceutical industry in 
order to control costs. Usually, with a nationally run healthcare system, the government acts 
like a monopolist in selecting which pharmaceuticals will be subject to reduced prices185, a 
182 
WHO, 'Pharmaceutical Industry', available at 
~W.who.int/trade/glossary/story073/en/print.html (last accessed on March 18, 2009) 
WHO, The World Medicines Situation, P.70, 2004, available at 
~w.searo. who.int/LinkFiles/Reports World Medicines Situation. pdf (last accessed on March 18, 2009) 
WHO, 'Access to Medicines', available at 
~.who.int/trade/glossary/story002/en/print.html (last accessed on March 18, 2009) 
Kevin A. Hassett, Price Control and the Evolution of Pharmaceutical Markets, P.4, 2004, available at 
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decision based on national health budgets by implementing pharmaceutical price controls. 
pharmaceutical companies strongly oppose the government price control and claim that the price 
control policies discourage the investment in new R&D, and may in certain cases negatively 
h . f d . 186 impact t e mterests o consumers an patients. 
Pharmaceutical pricing is free in a few countries such as the US, Germany and Denmark. 
Some countries apply the individual price fixing systems, such as Australia, Austria, Belgium, 
Finland, France, Greece, Hungary, Italy, Japan, Korea, Mexico, Norway, Spain, Sweden and 
S . 1 d 187 w1tzer an . 
2.5.6 Concluding Summary 
The market of pharmaceuticals is led by the invisible hands of self-interest. 188 From the 
perspective of the pharmaceutical industries, profits guide the markets. Whenever the market 
price of pharmaceuticals exceeds their costs, there are profits. The market force is the 
mechanism driving the R&D of pharmaceuticals. The profits provide an incentive for the 
current companies or others to produce more pharmaceuticals to enter into the market. As a 
consequence, more pharmaceuticals will be invented or produced to provide for their priority 
markets (those places where consumers or patients are willing to pay the most). 
~w.who.int/intellectualproperty/news/en/Submission-Hassett.pdf (last accessed on March 18, 2009) 
The government interventions in the control of pharmaceutical prices usually include price, volume, and spending 
controls 
186 • 
Phrma, What Goes into the Cost of Prescription Drugs, P.1 0-11, 2005, available at 
ffit-W.phrma.org/files/Cost of Prescription Drugs.pdf (last accessed on March 18, 2009) 
Jaume Puig-Junoy edited, The Public Financing of Pharmaceuticals: An Economic Approach, Edward Elgar 
Publishing 2005 188 , 
Jack Hirshleifer, Amihai Glazer and David Hirshleifer, Price Theory and Applications: Decisions, Markets, and 
Information, 7th Ed., P.l8-19, Cambridge University Press, 2005 
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2.6 Conclusion 
pharmaceutical products work wonders m improving the quality of human life. 
pharmaceuticals not only extend human life but also contribute in many ways to making human 
life more enjoyable. So although pharmaceuticals can be seen as preventing disease or as 
life-saving instruments, whether or not the market-based theory shall be applied to 
pharmaceuticals as a commodity is an important question in need of resolution. 
However, the pharmaceutical companies need financial resources to work these wonders. 
The human capital and productivities are one main factor in the competition in the international 
marketplace, and in attracting investments. Healthy populations make for a better working 
force, higher household income and increased domestic savings. Globalization can have a 
positive influence, making the pharmaceuticals accessible and affordable. It is essential to 
'·' 
make the economic benefits extend to all countries, especially those in need. The possible 
.·.i 
i! 
adverse effects on globalization must be minimized. "Globalization will have a positive impact 
only if a country can successfully compete in the global environment." 189 
Meanwhile, the pharmaceutical products and R&D processes need protections to safeguard 
the interests of producers and consumers. As a result of lobbying to safeguard pharmaceutical 
products, the system of global intellectual property has succeeded in protecting investment by the 
pharmaceutical companies and, as the companies claim, to offer incentives for the development 
of new and better pharmaceuticals. The extension of TRIPS to define pharmaceutical products 
as goods in trade turns a new page in the complicated history of the global trade of 
189 
E WHo, Globalization, Trade and Public Health: Tools and Training for National Action: Report of an Intercountry 
Xpert Group Meeting, P.4, 200 I, available at 




Chapter Three: Intellectual Property Rights Protection and 
Pharmaceutical Products 
3.1 Intellectual Property Rights Protection on Pharmaceutical Products 
Long before the legal definition of intellectual property rights, these rights were understood as 
being conferred on creations or inventions of intelligence. The protections are usually given to 
the creators or owners of an exclusive right over the use for a period of time, with some 
exceptions in a variety of cases. 
The protection of intellectual property has progressed over time. The evolution of the 
protections given to such property can be divided into three periods: the territorial, international 
and global response to the needs for protection of scientific and technological development. 
The territorial period is characterized by the protection of rights within the territory of the 
nation state. As trade across national borders increased, states sought ways to protect rights to 
their intellectual property through agreements and treaties. The primary territorial protections 
were national in nature, and the international protections, such as treaties, tolerated some level of 
differences among states, and the process of forming international standards for protection was 
stilllimited. 190 
As globalization emerged as an economic paradigm, there was an urgent need to standardize 
Protection of the interests of scientific and technological developments. Negotiations to more 
comprehensively set minimum standard protections for intellectual property started during the 
190 
L Ian Fletcher, Loukas Mistelis and Marise Cremona edited, Foundations and Perspectives oflntemational Trade 




GATT, which acknowledged that the ineffective protection of scientific and technological R&D 
and inventions could pose a barrier to trade. 
Since pharmaceutical products are a cornerstone of advancement in science and technology, 
the pharmaceutical industry was eager to require international or even global protections for 
pharmaceutical products in order to incentivize continuous R&D as well as sustainable 
investment. Because of the special essential characteristics of their products, including the 
ability to prevent and cure diseases, it has been difficult to reconcile these products within the 
IPR system. 
The high cost of R&D coupled with the relatively low cost of manufacturing existing 
pharmaceuticals has resulted in an industry-wide push to strengthen legal protections for the 
intellectual property rights underlying these products. This behavior is a rational response by 
an industry motivated by the need to maximize their return on investment. During the 
. expansion of intellectual property rights in the international arena, these industry players focus to 
an even greater extent on securing stronger global protections for their interests. 
3.1.1 National Era 
The concept of a patent system originated in Europe. In Renaissance Italy, 1474, the concept 
Was first used as an incentive to attract foreign engineers with a 1 0-year monopoly on their 
Works and devices. 191 In 1624, the English Statute of Monopolies changed the focus of patent 
laws, with a goal of granting the true owner a monopoly rather than simply encouraging 
191 
. Graham Dutfield, Intellectual Property Rights and the Life Science Industries: A Twentieth Century History, 






invention. In the US, the first patent law came about in 1790, implementing Article 1, Section 8 
of the Constitution, which empowers Congress to promote the progress of science and useful arts 
by securing for limited times to inventors the exclusive rights to their inventions. 192 Later, 
Germany also established its Patent Act in 1877. 193 At this time, most of the national patent 
Jaws were based on several rationales from natural law, contract law, reward and incentive 
d. d h 194 para 1gms, an prospect t eory. 
The Industrial Revolution saw growing concerns by inventors seeking to protect their 
interests to avoid domestic and foreign free riders, and the result was a development trend to 
base the protection of their scientific and technological intelligence and invention on private 
property rights. These trends, coupled with the need to protect intelligent labor, have spread 
across the globe, from Europe to America, and eventually into Asia. 195 
During the 191h century, the number of patent applications in each country skyrocketed as 
the availability of foreign investment and the expansion of trading and markets brought to 
inventors and corporations the pressure of protecting their interests beyond national boundaries. 
Originally, the system for the patent "granting" power was at the discretion of the rulers. 
The patent was considered to be a "privilege." The historical accounts of patent protections 
show that the uses of patent laws have been to balance the interests of both inventors and users of 
192 
US Constitution Article 1, Section 8, 
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the products on a public policy basis. However, the later international and global development 
of patent systems has shifted the conceptual basis for patent protection from that of a "privilege" 
to that of a "right;" in this emerging system, countries have lost their discretion to grant 
protections within their sovereign territories, but instead are obligated to protect patents under 
. d . . 11 196 the treaties an mtematwna aws. This fundamental shift in the nature of patent protections 
turned the system on its head, and along the way it has created obstacles and problems that are 
still not fully resolved. 
The patentability of pharmaceutical products was different in each nation state. 
Pharmaceutical products have not been explicitly stated as within the subject matter of national 
patent laws, but by the interpretation of the laws, the laws give patent protection to some 
pharmaceutical products. At first the Statute of Monopolies granted patent protection for "the 
sole working or making of any matter of new manufacture," and this was later interpreted by the 
courts to include substances formed by chemical compounds or other processes. US patent law 
under the Patent Act of 1970, 1973 offers patent protection to "any new and useful process, 
machine, manufacture, or composition of matter, of any new and useful improvement thereof." 
The pharmaceutical chemical compounds therefore, by interpretation, fit into the definition of 
"composition" and can be given patent protection. By contrast, the French Patent Act of 1844 
explicitly excluded pharmaceutical products from patent protection for public policy reasons. 197 
196 
Susan Sell, Private Power, Public Law: The Globalization oflntellectual Property Rights, P.5, Cambridge 
University Press 2003 
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For the pharmaceutical industry, the 19th century was a truly a breakthrough era, especially 
in the extraction and purification of the active ingredients of plant-based drugs. The modem 
phannaceutical industry emerged in Germany in the late 19th century. The interest groups of the 
chemical industry lobbied hard for national patent laws to protect their investment. 198 
Bayer and Hoechst were the pioneer firms in the application of synthetic chemistry and drug 
discovery. The German chemical companies became dominant in the pharmaceutical industry 
prior to World War I. The successful model of the patent system caught the attention of other 
countries, many of which came to agree that the patent system was necessary and essential to 
protecting their assets, and could also be used to raise capital and protect inventions by their 
citizens and companies. 199 The lobbying for international patent protection of pharmaceutical 
products started in· the late 20th century.200 
3.1.2 International Era: The Paris Convention 
As pressures grew to internationalize protections, many patent abolitionists argued that the patent 
system would become a barrier to free trade and should therefore be abolished; the supporters of 
the patent system rejoined that without patent protections, intellectual property theft would 
deprive inventors of the fruits of their research, development, and labor. After many years of 
controversy and extensive debates, the policy of adapting rather than abolishing the patent 
198 
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p~arrnaceutical test data. 
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system was favored by policy makers. 
Patent law was developed during the 19th century in most economically and technologically 
advanced countries, such as Great Britain, the U.S., France, and Germany, and the resultant 
patent laws were different from each other. It was quite difficult for inventors to secure 
effective protection of their interests once the invention crossed international boundaries or was 
sold in foreign countries. At the same time, the industrial revolution brought a resultant 
increase in trading between countries, exacerbating the need to prevent piracy with strong 
international standards for patent protections. 
The proposal of having an international patent protection system encountered much 
opposition. Nevertheless, the Paris Convention of 1883 was signed and became the first major 
international treaty on the protection of industrial property. The controversy over patent 
protection temporarily ended in compromise, by the terms and perspective of the powerful 
national states and the influences of non-state actors in this multinational treaty. 201 The 
institution merged with the Berne Convention in 1970, and was transformed and administered by 
the World Trade Intellectual Property Organization (WIPO). 
The Paris Convention has been revised six times since 1883, with the intent to progressively 
r-v•uuu:: and strengthen the rights of intellectual property despite the anti-patent trend moving 
Europe to the rest of the world. Again, the commercial interests and political pressure 
Christopher May and Susan K. Sell, Intellectual Property Rights: A Critical History, P.95, Lynne Rienner 
-vu.~ueN 2005 
the negotiation of Paris Convention, non-state actors, private sectors, had played a prominent role. The private 
used the influences and lobby nation states to provide a more protective regime. 
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emerged triumphant. The Paris Convention requires the signatory states to offer certain explicit 
fundamental intellectual property protections to comply with a set of international norms. 
Substantively, the most important achievements of the Paris Convention are the national 
treatment, the right of priority, and rules relating to local manufacture. 
National treatment requires that a signatory state to grant a foreign patent owner the same 
rights and remedies offered to the state's own citizens. The right of priority gives an applicant 
six months from the date a patent is first filed in a member country to seek patent protection in 
other signatory states. 
Until that time, there was no international standard or harmonizing of national laws for the 
granting of patents, and each nation state applied its own patent law to the granting or denying of 
patent protection. The Paris Convention made no reference to compulsory licensing, contained 
no standards addressing the gap between the patent laws in each country, and left to each country 
to decide to which industrial sectors they wanted to extend patent protections. 
In the case of pharmaceutical products, the Paris Convention has never explicitly required 
giving patent protection to chemical substances, including pharmaceutical products, nor has it 
specified the duration of the protection to be offered. Due to the concern of the states, 
Pharmaceutical products remained as an area which many countries generally excluded from 
Patentability, for public policy reasons?02 
202 
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Moreover, although the Paris Convention has been supported by some countries, many 
developing countries were particularly reluctant to sign the convention. The signatory states of 
WIPO were far from constituting global participation. 
As mentioned above, the pharmaceuticals industry has been developed rigorously since the 
19th century. The industry has been defined by mergers and acquisitions among the top 
companies in the industry in the 20th century. The resulting market is dominated by 
transnational pharmaceutical corporations based in the U.S. and Western Europe. 
As the demand for pharmaceutical products grew, the transnational pharmaceutical industry 
and pharmaceutical industry-based countries lost confidence in the patent protection of 
pharmaceuticals under the Paris Convention, because it contained no explicated international 
standard protection to include pharmaceutical products, weak enforcement, and no dispute 
settlement mechanisms. As late as 1988, 49 Paris Convention signatories still excluded 
pharmaceutical products, and 1 0 signatories excluded pharmaceutical processes from patent 
protection. 203 
To protect their interests, pharmaceutical industry-based countries used bilateral, regional 
agreements or sanctions to make other countries compromise to offer more similar patent 
Protection to secure their interests, or used investment agreements to encourage other nation 
states to bargain their right to refuse protections away. For example, the U.S. used Special 301 
203 
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as a threat of trade sanction on those countries which did not offer efficient protection of their 
products. The purpose of this tactic was to influence other states to modify their inefficient 
intellectual property rights systems to be more consistent with the American approach. 
Disregarding all the measures and still dissatisfied with the result, the pharmaceutical and 
chemical industries went further to lobby for stronger intellectual property protections from an 
international level towards a global level. 
3.1.3 Global Era: The TRIPS Agreement 
As global trade increases, the pharmaceutical industry claims that it has lost growing amounts of 
its prospective profits by putting more investment in R&D without a corresponding increase in 
its legal protections. The pharmaceutical industry seeks to use its power to influence a more 
efficient global system to protect its profit in the global market. 
After the successful negotiation of the General Agreement on Tariffs and Trade (GATT), the 
negotiations turned to addressing new issues, such as investment, trade in services, and 
protection of intellectual property rights, driven almost exclusively by private actors. In the 
negotiations, pharmaceutical industry representatives took a leading role, along with other 
private actors such as the software and entertainment industries. As these industries influenced 
the evolution of patent protections, they created a system of stronger protections that help their 
bottom line, but may become an obstacle to free global trade?
04 
The intellectual property system was finally incorporated into formal trade negotiation at 
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the 1986 Punta del Este Ministerial Declaration. Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) was introduced in the 1994 to establish minimum standard 
requirements for intellectual property protection rather than harmonization of each member 
state's national law. The TRIPS Agreement came into effect on January 1, 1995. Though it 
establishes minimum standards of protection, it has allowed countries some latitude in defining 
the scope and duration of their protections, but it has helped to narrow the differences and gaps 
that created tension in cross-borders trading. 
Another breakthrough concept in TRIPS was to recognize that intellectual property rights 
are private rights and TRIPS regulations are minimum standards set for public policy reasons to 
balance the interests of the inventors and the users. All WTO member states are fully bound by 
the TRIPS agreement. However, TRIPS allows countries to have different transitional periods 
oftime to fully comply with the TRIPS provisions depending on the status of the countries?05 
During the negotiation, pharmaceutical industries-based countries, as one of the maJor 
negotiating groups, used their influential powers to persuade others that the counterfeiting of 
pharmaceutical products and the lack of protection for pharmaceutical products have become 
barriers to international trade. The international patent protection for pharmaceutical products, 
they argued, is insufficient and ineffective. 
As mentioned above, the Paris Convention did not require any specific field to be covered 
205 
··. For developed countries, the transitional period is one year following the entry ofthe WTO, i.e. until I Jan 1996. 
Developing countries are allowed to delay their transitional period for four years, which is 1 Jan 2000. Least 
developed countries are granted a longer transitional period of a total of eleven years, i.e. till 1 Jan 2006, with the 
Possibility of an extension. 
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by the rights of patent protections, nor did it specify a minimum durational requirement. 
Therefore, the field and duration of protection was determined by the signatory states. 
TRIPS sets mmtmum requirements for positive legislative action, but it does not bar 
member states from taking certain actions?06 TRIPS obligated member states to implement 
patent protection to at least the minimum standard set forth in the agreement. It is considered a 
major boon to the pharmaceutical industry by providing protection to technology in any field, 
including pharmaceutical science and technology. Moreover, patent protection in the 
technology field was set at a minimum duration of 20 years, with effective enforcement 
mechanisms. 
3.1.4 Concluding Summary 
The development of intellectual property has progressed from the national and international 
levels to the global level. TRIPS is only the latest step in an ongoing political process by which 
intellectual property law is becoming increasingly standardized across the globe. There is not 
yet a fundamental agreement on how to protect "knowledge-based property." 
The role of the industry, as non-state actors, in influencing the development of these treaties 
and norms demonstrates that law is not based on science, but on normative ideology, tightly tied 
to power.207 The pharmaceutical industry will be one of the private sectors which benefit the 
most from TRIPS. The relationship between intellectual property rights, innovation and public 
206 Christopher May and Susan K. Sell, Intellectual Property Rights: A Critical History, P.l63, Lynne Rienner 
Publishers 2005 
207 ' Paul Farmer, Pathologies of Power: Health, Human Rights and the New War on the Poor, P.235, University of 
California Press, 2003 
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health has always been the focus of debate. The primary goal of pharmaceutical industry is to 
protect and maintain the funding and incentive mechanisms for the development of new 
pharmaceutical products. The pharmaceutical industry asserts that the system of intellectual 
property rights is to safeguard the end-product, pharmaceuticals, in the return on investment 
rather than the amount invested?08 
With the development of technology and international law, the emerging dominant themes 
in intellectual property law- privatization, deregulation, expansion of incentives to 
entrepreneurial behavior, structure adjustment programs, and related pressures from international 
financial institutions and developed countries- have had mixed, and sometimes adverse, effects 
on the enjoyment of economic and social rights?09 
3.2 TRIPS, Public Health and Pharmaceutical Products 
The greatest achievement made by the pharmaceutical industry in its efforts to secure 
international protection for its products came when TRIPS obligated WTO member states to 
extend patent protection to all field of technology, which included pharmaceutical products, 
within their national intellectual property protection laws. TRIPS defines minimum standards 
for the core elements of these protections, including subject matter, definitions of rights, 
pennissible exceptions, and a minimum durational period. 
208 
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TRIPS adds a substantial number of obligations on each member state dealing with areas of 
the law which are not addressed or specified from prior international agreements, and in some 
cases replaced provisions that were inadequate or ineffective. Moreover, it included a set of 
enforcement procedures and dispute resolution practices to give teeth to these new obligations. 
TRIPS binds member states as part of the single package of the WTO Agreement, and 
imposes minimum standards of protection. It also mandates that citizens of different states be 
given equal treatment by law to that given to the nation's own citizenry. However, TRIPS 
offered transitional arrangements for developing countries, and built in some flexibility in 
reaching the minimum standards, tolerating some variations by member states. 
3.2.1 General Provisions 
The TRIPS Agreement also embraces the three general provisions under GATTS: national 
treatment, most-favored-nation (MFN) status, and transparency. TRIPS provides its members 
with fundamental rules for national treatment in Article 3210 and most-favored-nation treatment 
offoreign nationals in Article 4. 211 
In its scheme of national IP protections, WTO member states cannot discriminate against 
foreigners by offering them less favorable protection than it accords its own nationals with 
regards to the incorporation of the minimum protections for intellectual property rights from 
210 
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TRIPS into their national laws, policies and regulations.212 Member states must provide both 
the substantive standards for protection and the availability, acquisition, scope, maintenance, 
enforcement and use of the intellectual property. 
The most-favored nation provision forbids discrimination between member states as stated 
. A . 1 4213 m rt1c e . With regard to the protection of intellectual property, any advantage, favor, 
privilege or immunity granted by a WTO member state to the nationals of another member state 
should be accorded immediately and unconditionally to the nationals of all other member states. 
The enforcement of intellectual property rights related to pharmaceutical products has to be 
effective in preventing infringement by member states under the WTO law, providing that the 
procedures are fair and equitable, not complicated, costly, or entailing unreasonable time limits 
or unwarranted delays; each case must be decided on merits, supported by evidence, and 
available to parties without undue delay; and the parties shall have opportunity to ask for judicial 
review of the administrative decision or lower court's ruling. The details of the enforcement 
provisions are in Article 41 - Article 62, including the rules to obtain evidence, injunctions, 
provisional measures, damages, other remedies, and penalties? 14 
3.2.2 Patent Protection for Pharmaceutical Products 
Before the round of TRIPS negotiations, more than 50 countries did not offer patent protection to 
212 
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. 1 215 pharmaceut1ca s. It was a major achievement of the pharmaceutical industry to extend 
patent protection to pharmaceutical products in these countries. 
Besides the general obligations of national treatment and most favored nation standards, 
TRIPS sets minimum standards for intellectual property protections in copyright, trademarks, 
geographic indications, industrial designs, patents, layout-designs (topographic) of integrated 
circuits, undisclosed information, and the anti-competitive practices in contractual licenses. For 
pharmaceutical products, the most relevant and essential protection is the patent protection in 
Article 27 -Article 34. 
The key breakthrough for pharmaceutical products is in TRIPS Article 27, which defines 
patentable subject matter?16 Article 27.1 requires member states to make patents available for 
any inventions, 
... [P]atents shall be available for any inventions, whether products or processes in all 
field oftechr10logy, provided they are new, involve an inventive step and are capable of 
industrial application ... patents shall be available and patent rights enjoyable without 
discrimination as to the place of invention, the field of technology and whether the 
product is imported or locally produced. 
Article 27.1 makes patent protection available to inventions of products and processes in all 
field of technology. The absence of exclusion for pharmaceutical products and processes 
established these products and processes as within the scope of patentability, provided they meet 
215 
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all other requirements for patentability.217 
The standard for patentability reflects and mirrors the terms in national patent laws in some 
member states; however, the provision does not define the terms of "inventions," "new,218" 
involvement of "inventive steps" and "capable of industrial application." The intention might 
be for a future change in science and technology. Some countries have a more liberal 219 
interpretation of the terms. Some scholars suggest that member states can interpret these terms 
to restrict the number of patents issued. 
Despite this perceived victory for the pharmaceutical industries, TRIPS Article 27.1 was 
one of the major concessions made to developing countries during the negotiation. The 
exchange that established IPR protection will actually help the economy of these countries, and 
in the case of pharmaceutical products, the patent regime should have offered more incentives for 
R&D to benefit consumers or patients, especially for people in developing countries. However, 
the application of the global patent systems has not had the intended results. Patent systems 
217 
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offer incentives to profitable markets, but do not stimulate more R&D for diseases existing in 
developing countries. The pharmaceutical products have become even more inaccessible and 
unaffordable ever since. 
TRIPS Article 29 requires that patent application be disclosed by the state of the art, in other 
words, the best mode of the invention. The language of that article requires disclosure in a 
manner sufficiently clear and complete for the invention to be carried out by a person skilled in 
the art and may require the applicant to indicate the best mode for carrying out the invention 
known to the inventor at the filing date or, where priority is claimed, at the priority date of the 
application. 
TRIPS allows member states to exclude patentability from an invention when it is necessary 
to protect order or mortality within their territory, including to protect human, animal or plant life 
or health, or to avoid serious prejudice to the environment, provided that such exclusion is not 
made merely because the exploitation is prohibited by their law. 
TRIPS Article 27.2 provides flexibilities to WTO member states in their possible 
interpretation to structure their national patent system for pharmaceutical products. Some argue 
that pharmaceutical products should be excluded from patent protection under Article 27 .2, for 
reasons to protect human health, but others argue that Article 27.2 should be read into two parts. 
First, it says that member states can exclude patentability from commercial exploitation of the 
Invention, when it is necessary to protect order public or mortality; it then provides examples as 
including to protect human, animal, or plant life or health. 
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Pharmaceutical products have essential impacts on human health, and the legitimate 
commercial exploitation of pharmaceutical products does not necessarily pose a threat to public 
order, but it is the exclusionary effect of the pharmaceutical patent system and the marketing 
strategies of the pharmaceutical invention for profit which results in inaccessible and 
unaffordable pharmaceutical products, and which leads to the impacts on human health. 
Professor Carlos M. Correa agrees that TRIPS Article 27.2 is a sub-provision of public order and 
morality, but it does not provide grounds to refuse the application of a patent system to 
pharmaceuticals. 220 
Moreover, in TRIPS Article 27.3, member states may also exclude patentability from 
diagnostic, therapeutic and surgical methods for the treatment of human and animals, plants and 
animals other than micro-organisms, and essential biological processes for the production of 
plants or animals other than non-biological and microbiological processes. However, members 
shall provide for the protection of plant varieties either by patent or other effective sui generis 
systems, or the combination thereof. 
TRIPS Article 28, Article 30 and Article 33 confer on the patent owner exclusive rights for 
at least 20 years, but subject to exceptions. The product patent owner has the right to prevent 
third parties from making, using, offering for sale, selling or importing these products without 
The process patent owner has the right to prevent third parties without consent 
from using the process, and from the acts of using, offering for sale, selling or importing for 
these purposes the product obtained directly by that process. Additionally, the patent owner has 
' 220 
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the right to assign, or transfer by succession, the patent, and to conduct licensing contracts. 
WTO member states are bound by the WTO laws as a single package when they become 
members. Each WTO member state is required to provide patent protection for all inventions in 
any field of technology by fully complying with the TRIPS agreements, with no different 
treatment based upon the development status of the member states, only allowing transitional 
arrangements for states in Article 65 and Article 66.221 
In the case of pharmaceutical patent, generally, new members joining WTO after 1995 have 
agreed to fully comply with TRIPS as soon as they join. For developing countries not 
providing product patents in pharmaceutical products, a transition period in which to comply was 
extended from January 1, 2000 through January 1, 2005. The transitional period had a big 
impact on developing countries, including India, Brazil, South Africa, Thailand and Egypt, 
which are most important producers of the pharmaceutical products still under patent protection 
in other developed countries. 
Least-developing countries were given a transitional period until January 1, 2006. It was 
later agreed by members on November 30, 2005 to extend the deadline for patent protection for 
Pharmaceutical products until January 1, 2013, or the date a country is no longer considered a 
least-developing country, whichever occurs first. The Doha Declaration on TRIPS and Public 
Health extended the deadline for least-developing countries to fully comply with the patent 
22! 
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protection in pharmaceuticals until 2016. 
3.2.3 Parallel Import/Grey Market and Exhaustion of Rights 222 
Parallel import/grey market goods are product sold by the patent owner or with the permission of 
the patent owner more cheaply in one country and imported and sold into another country 
without the patent holder's permission. Though it is an unauthorized distribution of a good or 
service, such goods are not illegal per se, and are not considered counterfeit, but they are an 
unauthorized exportation, which may create problems when traded beyond borders. The 
parallel importation of pharmaceutical products was one of the major issues in accessibility and 
affordability of pharmaceutical products. 
Applying the legal principle of "exhaustion" to parallel imports is important here, because 
once a protected product has been sold, the patent holder generally has exhausted his right to 
control the product. There are three exhaustion schemes: national, regional and international. 
Under a national exhaustion scheme, the exclusive right is exhausted when the product is sold 
under the authority of the right holder. In a regional exhaustion scheme, the effect of 
exhaustion extends beyond the borders to other countries which have agreements. 
The most complicated issue arises in the situation of exhaustion in the international scheme, 
When the pharmaceutical products are involved in the parallel trade from one country into 
no agreement between the countries. Pharmaceutical industries, especially 
transnational pharmaceutical corporations, argue that the prevalence of grey market 
222 Grey market is different from black market, which involves the distribution of product or service that is illegal 
to distribute. 
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pharmaceuticals reduces their profits and has adversely affected the R&D of new drugs and 
sustainable price controls as well as the administrative regulation to ensure the safety of the 
pharmaceutical products. State governments, public health administrations and patients will 
buy the pharmaceutical products from the cheapest available source. Grey market 
pharmaceutical products thus increase the accessibility and affordability of pharmaceuticals. 
Therefore, some countries still allow parallel importing of pharmaceuticals. On this issue, each 
wro member state has different laws and regulations on whether they allow parallel 
importation. 
TRIPS has addressed this issue in a specific provision in Article 6223, which states the 
exhaustion of right: "[ f]or the purpose of dispute settlement under this Agreement, subject to the 
provisions of Art 3 and 4 nothing in this Agreement shall be used to address the issue of the 
exhaustion of intellectual property rights." This language provides that TRIPS simply does not 
deal with the issue of parallel importation, except for those overlaps with the violation of 
national treatment and most-favored-nation treatment which can raise the issues of exhaustion of 
intellectual property rights in the WTO dispute mechanism. It is up to each member's 
discretion whether or not to have a national exhaustion regime, under which right holders can 
take action against parallel imports, or an international exhaustion regime, under which they 
cannot take action against parallel imports. 
The current practice of parallel importation depends on the national law of each country. 
Some countries allow parallel importation if the products are sold domestically and then sold into 
223 
WTO, TRIPS, 1994, Article 6, available at 
~.wto.org/english/docs e/legal e/27-trips.pdf(last accessed on March 19, 2009) 
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foreign markets only by the consent of the patent holder. Other countries have adopted the 
theory of 'implied license,' that a purchaser of the pharmaceutical products has an implied 
license from the patent holder for reasonably contemplated purposes. Exhaustion of rights is 
presumed if the patent holder abstained from imposing restrictions in the original sales 
224 
contract. 
3.2.4 TRIPS Exceptions/Flexibilities 
TRIPS requires minimum standards for IPR protection, but at the same time offers flexibilities to 
WTO member states as the result of compromise during the negotiation. During the negotiation 
of TRIPS, several exceptions and flexibilities were established in order to balance the private 
interests by offering incentives for R&D and the public interest in accessibility and affordability 
of inventions. In addition, the use of the exceptions/flexibilities cannot unreasonably prejudice 
the legitimate interests of the patent owner and the legitimate interests of third persons. 
TRIPS Article 30 states that 
[m]embers may provide limited exceptions to the exclusion rights conferred by a patent, 
provided that such exceptions do not unreasonably conflict with a normal exploitation of the 
patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking 
account of the legitimate interests of third parties. "225 
The wording of the flexibilities was general, which reflects the difficult compromise during the 
negotiation of this provision. According to Article 30, referred exceptions must be 'limited,' 
' not unreasonably conflict with a normal exploitation of the patent,' 'not unreasonably prejudice 
the legitimate interests of the patent owner,' and '[take] into account the legitimate interests of 
224 
Carlos M. Correa, Trade Related Aspects of IPR: A Commentary on TRIPS Agreement, P. 82-83, Oxford 
·.• R~iversity Press, 2007 
, WTo, TRIPS, 1994, Article 29 Exceptions to Rights Conferred, available at 
~wto.org/english/docs e/legal e/27-trips.pdf(last accessed on March 19, 2009) 
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third parties.' 
In TRIPS Article 30, the most relevant flexibilities to the pharmaceutical products are the 
legitimate acts done privately and for a non-commercial purpose; use for experimental or 
teaching purposes; seeking regulatory approval for marketing before the expiration of the patent 
(usually refers as BOLAR exceptions); and compulsory licensing?26 
The experimental exception is to permit a person to invent, perform, test or improve on the 
existing pharmaceutical patented product. In the US, the experimental exception is only 
allowed without authorization from the pharmaceutical patent owner when it is limited to 
scientific purposes. In Europe or other countries, the experimental exception is even allowed 
for commercial purposes. By contrast, many developing countries have not explicitly referred 
to this exception. 227 
The regulatory exception, usually called the 'BOLAR exception' or 'early working 
exception,' is another exception for pharmaceutical products which allows the exceptional use of 
patented pharmaceutical products for regulatory purposes, mostly by the generic pharmaceutical 
companies for the purposes of obtaining market approval before the patent expires so they will 
be able to put their products into the market as soon as the patent expires. In order to 
compensate the loss of the exclusion rights of years due to the administration process for 
pharmaceutical products, the original pharmaceutical patent could be extended up to five years 
226 
Carlos M. Correa, Trade Related Aspects ofiPR: A Commentary on TRIPS Agreement, P.302-303, Oxford 
University Press 2007 
227 ' 
Carlos M. Correa, Trade Related Aspects ofiPR: A Commentary on TRIPS Agreement, P.304-305, Oxford 
University Press, 2007 
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from the time they processed their products for market approval. 228 
Many countries have adopted this 'BOLAR' concept into their national laws to benefit the 
consumers, who are able to purchase accessible and affordable pharmaceutical products from 
generic drug companies as soon as the patent expires. 
Compulsory licensing is another exception/flexibility related to pharmaceutical products. 
The term of 'compulsory licensing' is not used in the TRIPS provisions. TRIPS Article 31, Other 
Use Without Authorization of the Right Holder, describes the application of compulsory 
licensing as "[ w ]here the law of a Member allows for other use of the subject matter of a patent 
without authorization of the right holder, including use by the government or third parties 
authorized by the govemment."229 In other words, compulsory licensing is one of the uses under 
228 Carlos M. Correa, Trade Related Aspects ofiPR: A Commentary on TRIPS Agreement, P.304-305, Oxford 
University Press, 2007 
The exception is called after a US case of Roche Products Inc v. BOLAR Pharmaceutical Co, which US court denied 
BOLAR's right to use of the pharmaceutical product for the purpose to obtain FDA approval process before the 
patent expiry of the patent. This issue was settled in a later US Drug Price Competition and Patent Term Restoration 
Act, 1984, which allow the non-patent owner, usually generic drug companies to use of the patented pharmaceutical 
product for the purposes of initiation of procedures for the marketing approval from FDA before the patent expired. 
Generic drug companies then can place their product into the market as soon as the patent expired. In the 
compensation of the lost patent term protection of the patented pharmaceutical product, the patent protection for the 
original patent owner could be extended up to five years. 
229 
WTO, TRIPS, 1994, Article 31 Other Use Without Authorization of the Right Holder, available at 
~ww.wto.org/english/docs e/legal e/27-trips.pdf(last accessed on March 19, 2009) 
Where the law of a Member allows for other use1 of the subject matter of a patent without the 
authorization of the right holder, including use by the government or third parties authorized by the 
government, the following provisions shall be respected: 
(b) such use may only be permitted if, prior to such use, the proposed user has made efforts to obtain 
authorization from the right holder on reasonable commercial terms and conditions and that such efforts have 
not been successful within a reasonable period of time. This requirement may be waived by a Member in the 
case of national emergency or other circumstances of extreme urgency or in cases of public noncommercial 
use. In situations of national emergency or other circumstances of extreme urgency, the right holder shall, 
nevertheless, be notified as soon as reasonably practicable. In the case of public non-commercial use, where 
the government or contractor, without making a patent search, knows or has demonstrable grounds to know 
. that a valid patent is or will be used by or for the government, the right holder shall be informed promptly; 
(c) the scope and duration of such use shall be limited to the purpose for which it was authorized, and in the 
case of semi-conductor technology shall only be for public noncommercial use or to remedy a practice 
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Article 31 when the government allows the use of the patented invention without the patent 
holder's permission or authorization under some conditions for protecting the patent right 
holder's interest. 
The concept of compulsory licensing is aimed at striking a balance between the rights 
holder and the user. Compulsory licensing is used to promote the accessibility and affordability 
of pharmaceutical products and to offer incentives for R&D in pharmaceutical products. 
Compulsory licensing of pharmaceutical products is only applicable when several conditions are 
met. 
The person or company must first make efforts to obtain voluntary licensing under 
reasonable commercial terms; if it fails with reasonable efforts within a reasonable period of time, 
then the person or company can pursue compulsory licensing, 230 limiting the scope, duration and 
use of the authorization231 to domestic markets only.232 If a compulsory license is issued, 
adequate remuneration must still be paid to the patent holder. 233 
detennined after judicial or administrative process to be anti-competitive; 
(f) any such use shall be authorized predominantly for the supply of the domestic market of the Member 
authorizing such use; 
(k) Members are not obliged to apply the conditions set forth in subparagraphs (b) and (f) where such use is 
pennitted to remedy a practice determined after judicial or administrative process to be anti-competitive. The 
need to correct anti-competitive practices may be taken into account in determining the amount of 
remuneration in such cases. Competent authorities shall have the authority to refuse termination of 
~uthorization if and when the conditions which led to such authorization are likely to recur; 
0 
WTO, TRIPS, 1994, Article 31 (b), available at 
~W.wto.org/english/docs e/legal e/27-trips.pdf(last accessed on March 19, 2009) 
1 
WTO, TRIPS, 1994, Article 31 (c), available at 
~W.wto.org/english/docs e/legal e/27-trips.pdf (last accessed on March 19, 2009) 
WTO, TRIPS, Article 31 (f), available at 
~.wto.org/english/docs e/legal e/27-trips.pdf (last accessed on March 19, 2009) 
WTO, TRIPS Article 31 (h), available at 
~W.wto.org/english/docs e/legal e/27-trips.pdf (last accessed on March 19, 2009) 
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However, the pre-requisite of first attempting to get voluntary license may be waived 
temporarily in the situations of national emergency, other extreme urgent conditions, public 
non-commercial/government use, or anti-competitive practices. However, in emergency and 
urgency conditions, the patent holder must still be notified as soon as is practicable. In the case 
of public non-commercial or government use with knowledge of a valid patent, the government 
or contractor should inform the right holder promptly.234 
3.2.5 Concluding Summary 
The global patent regime m TRIPS has opened the door to patent protections for the 
pharmaceutical industry. TRIPS introduces norms and standards for all member states to follow. 
Though the norms and standards will be monitored and enforced by the WTO dispute settlement 
mechanism, the application is difficult and the effects of the patent system to pharmaceuticals 
have impacted the accessibility to affordable pharmaceutical products. 
3.3 TRIPS Issues in Pharmaceutical Products 
WTO member states, especially states with no patent protection for pharmaceutical products, 
were concerned about the accessibility of affordable pharmaceutical products during the TRIPS 
negotiation. However, in order to join the WTO and take advantage on the free trade agreement 
to promote their domestic economies, WTO member state has to agree to be bound by TRIPS. 
As a compromise based on those concerns, the negotiation included a balancing principle for the 
protection of intellectual property rights which is reflected in TRIPS Article 7, with the goal that 
TRIPS can balance the interests. 
234 
WTO, TRIPS Article 31 (b), available at 
~W.wto.org/english/docs e/legal e/27-trips.pdf(last accessed on March 19, 2009) 
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TRIPS Article 7 states235, 
The protection and enforcement of intellectual property rights should contribute to the 
promotion of technological invocation and to the transfer and dissemination of technology, to 
the mutual advantage of producers and used of technological knowledge and in a manner 
conducive to social and economic welfare, and to a balance of rights and obligations. 
TRIPS Article 7 spells out that the object of TRIPS is to balance both rights and obligations 
of the inventors and users of technological knowledge in a manner conducive to social and 
economic welfare. TRIPS tries to strike a balance between encouraging creation and invention 
and the interests people have in accessing the intellectual property. Several TRIPS flexibilities 
were offered to balance these interests during the negotiation; nevertheless, the application of 
flexibilities to pharmaceutical products has proven difficult. 
3.3.1 Exclusive Effect of Patented Pharmaceutical Products 
Tracing its history, the concept of intellectual property has shifted in the twentieth century from a 
"privilege" to a "right." In the old patent system, it was recognized as a "grant of privilege" 
and the sovereign states had the discretion to determine the grant. 236 The later shifting from 
"privilege" to "right" changed the formal concept and left the sovereign states obligated to 
recognize these protections as a right, and the shifting character of the patent system increases 
the tension between competition and rights. 
The patent system has often been criticized for its exclusive character. The exclusive 
235 
WTO, TRIPS, 1994, Article 7, available at 
~://www.wto.int/english/docs e/legal e/27-trips.pdf (last accessed on March 19, 2009) 
6 
Susan Sell, Private Power, Public Law: The Globalization oflntellectual Property, P.5, Cambridge University 
Press, 2003 
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aspect of patent protection especially affects pharmaceutical products. The term monopoly237 
might not really apply to the patent system, but the nature of the pharmaceutical products, which 
is very different from that of other industrial property, makes the patented pharmaceutical 
products more exclusive than other industrial property. 
This is because every pharmaceutical product is umque and not replaceable by other 
products, and sometimes it is the uniqueness and inability to be replaced which makes its use a 
life or death decision for the patient. Product differ from others in their pathology, chemical 
reactions, and suitable intake for patients. Due to the patent protections given to 
pharmaceutical products, many new pharmaceuticals are still under patent protection, and the 
pharmaceutical companies make every effort to extend that protection 238 • The new 
pharmaceuticals are deemed to be more effective in one way, so are construed as better than 
existing products. 239 Not only the physicians but also patients are hoping to have more 
effective treatments, but because of the cost and inaccessibility of the pharmaceutical products, 
physicians and patients are excluded from access to the products and choose other products, or 
give up treatment. 
237 
Philip Grubb, Patent for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of Global Law Practice 
and Strategy, 4th Ed., P.7, Oxford University Pres, 2005 
Philip Grubb points out that, monopoly should not be used to patent system because patent as a new invention, 
cannot take any right from public which public previous had. 
238 
Carlos M. Correa, 'Protection and Promotion of Traditional Medicine implications for Public Health 
in Developing Countries', P. Ill, 2002 
http://www.southcentre.org/index.php?option=com content&task=view&id=74&Itemid=67 (last accessed on March 
19,2009) 
This dilemma is particularly serious in the area of public health, as increased prices mean reduced access to 
redicines which in some cases determines life or death. 
39 
Patent expired pharmaceutical products, or so called generic drugs, are more accessible compare with the drugs 
still under the patent protection in the term of affordability. But most of the patented drugs are newer drugs (which 
are created or invented recently), and most of the time, more effective drugs. In most of the criticism on the 
unaffordable and inaccessible of pharmaceutical products, patients are really in hush needs for patented drugs mostly, 
but not for the generic drugs. And those patented drugs may cure or decrease the pain for the new disease, SARS, 
AIDS or cancer. However, these drugs are all still under patent protection, in other words, still very expensive. 
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The protection of the patent system does create exclusive effects, but it is also the temporary 
exclusive character which gives the incentives to investment. Cornish also agrees that "the 
exclusive rights to prevent other people from doing things are at least monopolistic in a legal 
sense, if not necessary in an economic one." Sell also points out that intellectual property rights 
per se do not constitute a monopoly, but the effect of the application of the exclusive rights raises 
monopoly power in a form of monopoly rent to the innovator. The patent right owners have the 
opportunity to raise the price. 240 
The use of the patent system to foster R&D in new drugs and balance the access of 
medicine has becomes an important task. With no effective patent protection and enforcement, 
pharmaceutical companies would be unable to insure their investment and unwilling to spend 
capital to do R&D; without ongoing R&D, fewer new drugs will be created and invented. 
However, many consumers and patients cannot afford the pharmaceutical products, and are 
forced to buy gray market medicine or counterfeited medicine. The gray market and 
counterfeited pharmaceutical products might be much cheaper, but some of the products might 
not have the same ingredients and some of the ingredients might damage the health. Moreover, 
the grey market pharmaceutical products are not examined by the Food and Drug Administration, 
and there is little consumer protection if damages occur. Therefore, there has to be a balance 
between the enjoyment of the right and the fair application of the right. 
240 
Susan Sell, Private Power, Public Law: The Globalization oflntellectual Property, P.l3-14, Cambridge 
University Press, 2003 
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3.3.3 The Use of TRIPS Flexibilities: DOHA Declaration on TRIPS and Public Health and Later 
Development 
Due to the need to clarify the use and interpretation of TRIPS flexibilities as it relates to the goal 
for the citizens of WTO member states to benefit from increased opportunities and welfare241 , the 
DOHA Declaration on TRIPS had stepped forward to settle some important parts of the TRIPS at 
the DOHA Ministerial Conference in 2001 in recognition that" ... no country should be prevented 
from taking measures for the protection of human, animal or plant life or health or of the 
. t ,242 env1ronmen .... 
In the DOHA Declaration, members adopted a separate declaration on TRIPS and Public 
Health in recognition of the public problems.Z43 The WTO member states agreed on the need 
for and the importance of implementing and interpreting TRIPS' role in supporting public health. 
The WTO members also recognized that intellectual property is important to the development of 
new medicines, but at the same time, they were also concerned about the effects on the prices of 
pharmaceutical products. It was agreed that TRIPS does not and should not prevent members 
from taking measures to protect public health. It was affirmed that TRIPS should be interpreted 
and implemented in a manner supporting members' right to protect public health, and in 
particular to promote both the access to existing medicines and the creation of new medicines for 
241 
WTO, Doha Declaration, 2001, Paragraph 2, available at 
it-WW.wto.int/english/thewto e/minist e/minOl e/mindecl e.pdf(last accessed on March 19, 2009) 
2 
WTO, Doha Declaration, 2001, Paragraph 6, available at 
~W.wto.int/english/thewto e/minist e/minO 1 e/mindecl e.pdf (last accessed on March 19, 2009) 
WTO, Doha Declaration, 2001, Paragraph 17, available at 
~W.wto.int/english/thewto e/minist e/minO 1 e/mindecl e.pdf (last accessed on March 19, 2009) 
WTO, Declaration on the TRIPS Agreement and Public Health, 2001, available at 
~W.wto.int/english/thewto e/minist e/min01 e/mindecl trips e.pdf(last accessed on March 19, 2009) 
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Some of the TRIPS flexibilities have been clarified. Each member has the right to grant 
compulsory licenses and is free to determine the grounds for granting such licenses, including 
what constitutes national emergency or other extreme urgency. Moreover, the issue of parallel 
importing in exhaustion was also affirmed in that each member state is free to determine the 
scope of exhaustion of rights and exhaustion of rights decisions cannot be challenged under the 
WTO dispute panel unless the issue is subject to the MFN and national treatment provisions of 
TRIPS Article 3 and Article 4. The transitional period was extended for the least developed 
countries until 2016. 
The remaining question was how to promote accessibility to existing pharmaceuticals by 
adopting TRIPS flexibilities regarding compulsory licenses for countries that do not have the 
manufacturing ability to produce pharmaceutical products and offer them domestically. 
This issue was partially resolved on August 30, 2003, when the General Council decided to 
allow countries with no manufacturing capacity to import patented pharmaceutical products from 
other countries under compulsory licenses provided certain conditions were met. 245 
TRIPS Article 31 (f)246 , "the compulsory licensing for domestic supply only" provision will 
he waived by application of the August 30, 2003 decision to the extent that the production of 
pharmaceutical products and export to eligible importing countries. 
245 
WTO, Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, 
Decision of the General Council of30 August 2003,2003, available at 
~w. wto.int/english/tratop e/trips e/implem para6 e.htm (last accessed on March 19, 2009) 
46 
WTO, TRIPS, 1994, Article 31 (f), available at 
h!m://www.wto.int/english/docs e/legal e/27-trips.pdf (last accessed on March 19, 2009) 
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The decision contains three waivers. First, the exporting countries' obligations to supply 
the compulsory licensed pharmaceutical products to domestic use only are waived. Second, the 
importing countries' obligations for remuneration to the patent holder are waived. Exporting 
countries will pay the remuneration. Third, exporting constraints are waived for developing 
countries, so they can export within a regional trade agreement.247 
The application ofthe August 30, 2003 decision is that the eligible importing countries have 
to provide notification to the TRIPS Council of information of the specific names and quantities 
of the pharmaceutical products and the exporting countries which have been issued compulsory 
licenses, regarding the specific requirements by the importing countries and the distinguishable 
features of exporting compulsory licensed-pharmaceutical productions from the original patented 
pharmaceutical products. The importing and exporting country governments are also required 
to post all the information on the designated website248 on which the licenser will post additional 
information, such as the quantities being supplied to each destination and the products' 
distinguishing features, in order to prevent these pharmaceutical products from being diverted 
into the wrong markets. 249 The posting on the webpage is an informational notification to other 
member states ofthe use of the "paragraph 6" system; WTO's approval is not required. 
247 
WTO, TRIPS and Pharmaceutical Patents, 2006, available at 
www.wto.int/english/tratop e/trips e/factsheet pharmOO e.htm (last accessed on March 19, 2009) 
During the time for Aug 30 2003's decision, at least half of the WTO member states were categorized as developing 
countries at that time. 
248 
WTO, TRIPS and Public Health: Dedicated Webpage for Notification, available at 
~ww.wto.int/english/tratop e/trips e/public health e.htm (last accessed on March 19, 2009) 
This webpage is dedicated for notification of the 30 August 2003's decision for members using the Doha "Paragraph 
6" system for using compulsory licensing of pharmaceutical products. 
249 
WTO, Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, 
Decision of the General Council of30 August 2003, 2003, available at 
~ww.wto.int/english/tratop e/trips e/implem para6 e.htm (last accessed on March 19, 2009) 
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When a compulsory license is granted under the "paragraph 6 system," adequate 
remuneration in accordance with TRIPS Article 31 (hi50 shall be paid to the exporting member, 
taking into account the economic value to the importing member. The remuneration of the 
pharmaceutical products shall be waived by the eligible importing member to the patent owner 
h . . 'd b h . b 251 when t e remuneration Is pm y t e exportmg mem er. In this case of two compulsory 
licenses, it is suggested that double payment to the patent right holder be avoided by considering 
that the potential importing member is usually short of resources; therefore, it is preferable for 
the exporting member to make payment of the adequate remuneration, taking into account the 
economic ability of the importing member. 252 
All WTO member countries are eligible to import under this decision, but 23 developed 
countries are listed in the decision as announcing voluntarily that they will not use the system to 
import?53 Another 10 countries about to join the EU said they would only use the system to 
import in national emergencies or other circumstances of extreme urgency, and would not import 
once they had joined the EU?54 Additionally, 11 countries said they would only do so in national 
emergencies or other circumstances of extreme urgency. 255 
250 
WTO, TRIPS, 1994, Article 31, Other Use of the Authorization of the Right Holder, available at 
http://www.wto.int/english/docs e/legal e/27-trips.pdf (last accessed on March 19, 2009) 
251 
WTO, Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, 
Decision of the General Council of 30 August 2003, 2003, available at 
~ww.wto.int/english/tratop e/trips e/implem para6 e.htm (last accessed on March 19, 2009) 
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Katharina Gamharter, Access to Affordable Medicines: Developing Responses under the TRIPS Agreement and 
EC Law, P.192-193, Springer , 2004 
253 
Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Japan, 
Luxembourg, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom and the 
us. 
254 
As to the countries are Czech Republic, Cyprus, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovak 
~epublic and Slovenia. 
55 
As to the countries are Hong Kong China, Israel, Korea, Kuwait, Macao China, Mexico, Qatar, Singapore, 
Chinese Taipei, Turkey, and United Arab Emirates. 
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The August 30, 2003 decision created the so called "paragraph 6 system" which was later 
incorporated into the amendment of the TRIPS in 2005?56 Several workshops to help officials 
of WTO member states learn about the use of patent flexibilities for the health purposes have 
been held Geneva since 2005. 257 
Canada is the first member state to notify the Council of Information of its use of the special 
provisions of the paragraph 6 system's compulsory license to export patented pharmaceutical 
products to Rwanda in 2007.258 
The Doha Declaration and the August 30, 2003 decision did confirm the public health 
concepts and solve some technical problems regarding the application of the TRIPS flexibilities; 
however, these are difficult in practice. 
3.3.4 TRIPS, Traditional Medicine (TM), Traditional Medical Knowledge (TMK), Vaccines and 
New Pharmaceutical Technology 
As previous mentioned, most of the TRIPS patent-related provisions were adapted from WIPO 
and other IPR conventions, especially designated to apply to industrial property. In 
pharmaceutical products, the application fits properly with the new chemical compound entities 
pharmaceutical products, but there are problems when applying one system to various 
pharmaceutical products, including TM, TMK, vaccines, and new pharmaceutical technology, 
~ . 
WTO, Amendment of the TRIPS Agreement, 2005, available at 
!Y-Ww.wto.int/english/tratop e/trips e/wtl641 e.htm (last accessed on March 19, 2009) 
57 
WTO, 3rd Geneva Workshop Helps Officials Use Health Patent Flexibilities, 2007, available at 
~ww.wto.org/english/news e/news07 e/trips wp 7dec07 e.htm (last accessed on March 19, 2009) 
8 
WTO, Patent and Health: WTO Receives First Notification Under "Paragraph 6" System, 2007, available at 
~W.wto.org/english/news e/news07 e/public health july07 e.htm (last accessed on March 19, 2009) and 
WTO, Canada is First to Notify Compulsory License to Export Generic Drugs, 2007, 
~W.wto.int/english/news e/news07 e/trips health notif oct07 e.htm (last accessed on Dec 3, 2008) 
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due to the different nature of these pharmaceutical products. 
The protection of TM and TMK has been a very difficult issue for TRIPS. The main 
problem is that the patent system is designated to protect novel invention, whereas the TM and 
TMK are old wisdom from traditions. The current concept of IPR is not applicable to TM and 
TMK. 
First, there is the composition issue: there are varieties of forms of TM. 90% of TM is 
composed of biological ingredients, including plants and animal parts, as well as minerals. The 
natural materials may be made and used in their original wild form or processed into 
preparations or mixtures. In this context, intellectual property right protection for products 
based on generic resources may pose problems, because the natural materials are usually not 
patentable, though depending on national law, some countries do allow patents on the discovery 
of natural materials. 259 
Also, TM and TMK encompass great varieties of methods for diagnosis and treatment, 
including physical, mental and spiritual therapies. The treatment and diagnosis methods are not 
patentable in most countries, and many countries do not even apply patent law to intangible 
mental and spiritual therapies. 
259 
WTO, TRIPS, 1994, Article 27.3 (b), available at 
lmp://www. wto.int/english/docs e/legal e/27-trips.pdf (last accessed on March 19, 2009) 
Allows governments to exclude some kinds of inventions from patenting, i.e. plants, animals and "essentially" 
biological processes (but micro-organisms, and non-biological and microbiological processes have to be eligible for 
Patents). However, plant varieties have to be eligible for protection either through patent protection or a system 
created specifically for the purpose ("sui generis"), or a combination of the two. 
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Secondly, the ownership or possession rights to TM/TMK pose an additional problem. 
Without the prior consent of the owner/holder of the TM/TMK, the appropriation will be 
biopiracy. However, by its nature most TM/TMK may be possessed by individuals without 
others' contributions, or by people's knowledge collectively possessed and asymmetrically 
distributed among individuals within a group, even though such individuals may not be aware 
that others share the same knowledge. 
TM is usually developed and held collectively, and often the original holders of the TM 
inventors are not determinable. Sometimes, this knowledge may be kept as confidential and 
passed to certain people or certain classes of people within the group, and may be accessed by 
restrictions; some ofthe knowledge may be shared with others, and become public domain. 
By contrast, the current patent law seeks to protect one or a small discrete number of 
inventors. Determining who is legally entitled to the right of TM/TMK or the use of genetic 
resources can be a difficult task. Some of the generic resources, TM, and TMK have been 
transferred from the countries of origin by the trade of goods, the movement of people, 
colonization and war, and even globalization. 
Moreover, most TM/TMK has been disclosed in written or oral forms and widely used, 
documented or researched for generations. It does not fit the novelty requirement in the current 
concept of patent system. 
One major problem with the development of TM is that most of the TM/TMK relies on 
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Jiving traditions rather than upon second-hand accounts of the value and use of certain methods 
or treatments. Upon the lack of conservation, some of the generic resources have become scarce 
or disappeared entirely. This makes protection and development ofTM/TMK more difficult. 
The United Nations Convention on Biological Diversity (CBD) in 1992 was the first 
convention recognizing the need for international cooperation towards the important goal of 
conservation and the sustainable use of biological diversity for meeting the needs for food, health 
and the future. Member states started trying to set up principles defining these bio-resources as 
the sole property of sovereign states, which should have the freedom to use and trade them, but 
in a sustainable manner to prevent destruction, extinction, or alienation of biological resources. 
CBD Article 8 (j)260 states as its goal the in-situs conservation and protection of traditional 
knowledge. It also provides a scheme for granting incentives at the local level to encourage 
indigenous and local communities to have rights to knowledge, innovations and practices, 
subject to national legislation. State governments must provide participatory mechanisms for 
the exercise of these rights so that communities can share the benefits from the 
commercialization of their resources. 
Regarding access to biological resources, CBD Article 15261 , Access to Genetic Resources, 
26° Convention on Biological Diversity, Art 8 G), 1992, available at 
htm://www.cbd.int/convention/articles.shtml?a=cbd-08 (last accessed on March 19, 2009) 
Each Contracting Party shall, as far as possible and as appropriate ... 
9) Subject to its national legislation, respect, preserve and maintain knowledge, innovations and practices of 
mdigenous and local communities embodying traditional lifestyles relevant for the conservation and sustainable use 
Of biological diversity and promote their wider application with the approval and involvement of the holders of such 
knowledge, innovations and practices and encourage the equitable sharing of the benefits arising from the utilization 
•. ~~such knowledge, innovations and practices. 
Convention on Biological Diversity, Art 15, 1992, available at 
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establishes property rights, from open access to materials at the international level, to a common 
property resource at the national level, for genetic resources. Sub-provisions of Article 15 
provide the designing mechanisms to regulate access. 
Though CBD has provided some legal recognition for traditional knowledge, there are 
problems with its provisions. 262 The major problem of CBD is that the provisions impose a 
weak, fragile obligation on the proprietors, mostly pharmaceutical companies, to ensure the 
exchange of genetic resources and the associated traditional knowledge are acquired under the 
auspices of the Convention with payment of guaranteed equitable returns. The convention 
lacks contextualization to local eco-political circumstances and its integration across local, 
regional, commercial and environmental frontiers has been lax.263 The lack of clarity of the 
http://www.cbd.int/convention/articles.shtml?a=cbd-15 (last accessed on March 19, 2009) 
262 
Padmashree Gehl Sampath, Regulating Bioprospecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, P. 36, United Nations University Press, 2005 
CBD Article 8U) calls for respect, preservation and maintenance of traditional knowledge that is associated to 
biodiversity at the national level and contains an obligation to support and further advance TK in the context of 
conserving biological diversity. It does not contain a legal basis for creating individual rights nor any legal 
protection in the sense of establishing,-exclusive, enforceable proprietary rights over the traditional knowledge. 
Though CBD has recognized TK and provided mechanisms and broad-based measures on biological diversity, it 
does not specifically prioritize the measures nor does it provide details, thus leaving member states with a lot of 
flexibility to implement its framework. 
Moreover, the CBD embodies the concept of benefit sharing in both general and specific ways through several 
provisions, but there are still big gaps in between. Although countries will be compensated for the use of genetic 
resources, the Convention does not codify the relationship between the generation of revenues through such 
activities and biodiversity conservation in a direct way. Secondly, the Convention does not define "appropriate" 
compensation for the use of genetic resources. Lastly, though specific forms of benefit-sharing are mentioned, the 
Convention does not provide guidelines as to which form of benefits should be shared under what circumstances, 
Which leave a lot of rooms for countries to deliberate amongst themselves and Sohpia Twarog and Promila Kapoor 
edited, UNCT AD, Protecting and Promoting Traditional Knowledge: Systems, National Experiences and 
International Dimensions, P. 99, 2004 
~unctad.org/en/docs/ditcted 10 en.pdf (last accessed on March 19, 2009) 
Another major difficulty in CBD and so do to other international treaties lies in the fact that, CBD obligations bind 
states as contracting parties but confer no rights and obligations on private entities such as research institutes, 
Pharmaceutical companies and indigenous communities and without specific and effective national laws and 
~egulations, governments have little power to enforce the provisions in the Convention. Currently, the access and 
enefit sharing left to contracts between the bioprospectors, mostly firms and scientific institutes, and public 
authorities in the sources countries. This contractual approach has several disadvantages which against the original 
~~rpose of the Convention. 
Padmashree Gehl Sampath, Regulating Biopropecting: Institutions for Drug Research, Access, and 
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terms in CBD and the diverse political ambitions of member countries has led to reduced 
. fh .. 264 implementatiOn o t e provlSlons. The biodiversity issues are made even more complicated 
due by the relationship between TRIPS and CBD. 
In the case of vaccines, vaccines may be protected by patent, trade-secret/know-how, or 
. 1 d . £ . 265 und1sc ose m ormatiOn. The traditional way to patent vaccines is by patenting the vaccine 
itself in the form of organism with specific modification; antigen by the sequence, DNA, or 
purified form; or in conjugate, in the adduct, linkage method or carrier protein?66 In order to 
prolong the exclusive benefits of patents, just as with chemical pharmaceutical products, the 
vaccine companies patent new vaccines using methods to extend the life of patents on vaccines 
by patenting the expression system of organisms, the regulatory sequences, and the fusion 
partners; the platform technology, such as DNA vaccines and vectors; other purification process; 
the formulation in adjuvant, excipients, and process to boost up the immunogenicity, stability, 
reactogenicity; and the delivery devices, such as nasal, aerosol, flapulette, patch or cartridge, to 
provide efficient and comfortable drug delivery.267 
There are several problematic issues in the application of TRIPS provisions to vaccines. 
Benefit-Sharing, P.3, United Nations University Press, 2005 
264 
Padmashree Gehl Sampath, Regulating Biopropecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, United Nations University Press, P.45, 2005 
"One ofCBD's problems lies in the way in which its worthwhile goals are to be implemented. They are vague, 
ambiguous or impotent. As a result, it is very ambitious attempt to integrate 'previously distinct policy goals' in the 
CBD is on the verge of a failure. Key provisions such as Article 8 G), Article 15 and Article 16 are being used out of 
context and in isolation from the rest of the Convention. Many of reasons lie in the politics that divide 
genetic-resource-rich source (yet developing) countries and technology-rich (but developed) countries." 
~Th . 1 e knowhow/trade secret and undisclosed informatiOn have problems on how to secure y protect the IPRS 
~uring transfer of technology. 
66 
WHO, Martin Friede, 'IP Parameters to Vaccines', 2004, available at 
~ww.who.int/intellectualproperty/events/en/WHO-Friede.pdf (last accessed on March 19, 2009) 
7 
WHO, Martin Friede, 'IP Parameters to Vaccines', 2004, available at 
lY.!Yw.who.int/intellectualproperty/events/en/WHO-Friede.pdf (last accessed on March 19, 2009) 
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WTO member states have different views on vaccines with regards to TRIPS. Some countries 
believe vaccines are pharmaceutical products under TRIPS, but some countries do not treat 
vaccines as pharmaceutical products under TRIPS.268 Additionally troublesome, vaccines have 
more biological substance than chemical compound pharmaceutical products. Vaccines either 
involve live or killed bacteria, live attenuated virus, or genetically manipulated antigens?69 If 
TRIPS allows biological substances to be covered by the patent system, it may be contrary to the 
basic concept of patentable subject matter. 270 
Another issue involved is the ownership of the vaccine, since the vaccmes are mostly 
biological substances, and whether anyone is eligible to claim as the patent holder is an open 
question. Dr. Jonas Salk was interviewed on the evening on April 12, 1955 when he announced 
the development of a polio vaccine, as to the question of who owns the patent of the vaccine, he 
responded, "Well, the people, I would say, there is no patent. Could you patent the sun?"271 
3.3.5 Concluding Summary 
Patent law is not incompatible with pharmaceutical products, but the application of the patent 
system affects their distribution and supply. TRIPS was negotiated based on the balancing 
principle, and also provides some balanced flexibilities, but some of the flexibilities are difficult 
268 
Dr. SS. Jodhav, 'Intellectual Property Rights & Vaccines in Developing Countries', 2004, available at 
~ww.who.int/intellectualproperty/events/en/S.Jadhav.pdf (last accessed on March 19, 2009) 
For example, Japan insisted that the Doha declaration about pharmaceutical products did not cover vaccines and 
vaccine should not be included. However, EU agreed that vaccine were very much covered under pharmaceutical 
products. Sri Lanka argued strongly that vaccines were not part of the pharmaceutical sectors; therefore, Doha 
~eclaration should not apply to it. India argued that vaccine should be included in pharmaceutical sectors. 
69 
Dr. SS. Jodhav, 'Intellectual Property Rights & Vaccines in Developing Countries', 2004, available at 
~w.who.int/intellectualproperty/events/en/S.Jadhav.pdf(last accessed on March 19, 2009) 
0 
WTO, TRIPS, 1994, Art 27, available at 
WID://www.wto.int/english/docs e/legal e/27-trips.pdf (last accessed on March 19, 2009) 
1 
Dr. SS. Jodhav, 'Intellectual Property Rights & Vaccines in Developing Countries', 2004, available at 
~w.who.int/intellectualproperty/events/en/S.Jadhav.pdf (last accessed on March 19, 2009) 
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to practice in reality. Additionally, it is difficult to apply the concept of patent provisions to other 
pharmaceutical products, such as TM/TMK, vaccines, or other new technology. 
3.4 Conclusion 
The trade framework in global patent protection has progressed from preventing free riding to 
providing incentives for R&D, and benefitting the population as a whole by allowing them to 
enjoy the fruits of pharmaceutical science and technology. Applying global patent systems to 
pharmaceutical products should further new innovation of drugs and promote the public health. 
However, the application of the patent system has made it difficult to realize this goal due to the 
conflicts between the accessibility and affordability of pharmaceutical products, lack of R&D in 
diseases predominantly in developing countries, and in those pharmaceutical products which are 
not fully protected under the current patent law system. The precious value of pharmaceutical 
products and their unique function of preventing, curing and improving the health and life of 
human beings must be taken into account, as the application of global patent systems is causing 
impacts on human health and life. Health should not be jeopardized by money, but by applying 
the global patent system, money has taken a dubious role in determining the bounds of the 
human right to health. 
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Chapter Four: Right to Health as a Basic Human Right 
4.1 The Development of Human Rights 
Human rights are the rights that every human being in the world posses irrespective of race, 
religion, political belief, legal status, economic status, language, color, national origin, gender, or 
ethnicity, and which are applicable to all individuals and groups on the basis of equality and 
non-discrimination. Human rights are freedoms and entitlements that protect the inherent 
dignity and equality of every human being. Professor Sompong Sucharitkul states that there are 
at least three dimensions of legal order or systems in promoting, protecting and preserving 
human rights as universal or global, regional or interregional, and internal or national. 272 The 
human rights norms were first developed at the national level, and then progressed towards the 
international level. The international human rights principle and norms are the result of 
negotiation and compromise among nation states, and were later embodied in international legal 
instruments on various fundamental issues as minimum international standards. 
The development of human rights has transitioned from civil and political rights to economic, 
social and cultural rights. The civil and political rights are typically referred to as first 
generation rights, whereas the economic, social and cultural rights are usually referred to as 
second generation rights. Today, the development of human rights is moving towards new 
dimensions, to the so-called third and fourth or later generations of human rights. This 
classification273 scheme has been criticized as misleading, since a generation typically implies a 
type of revolution in which a new generation is the offspring of another. The term "generation" 
272 
Sompong Sucharitkul, 'A Multi-Dimensional Concept of Human Rights in International Law', 62 Notre Dame L. 
Rev.305 1987 
273 
The human rights as been categorized into generations as first, second, third geneFation of human rights or even 
forth generation rights recently. 
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also suggests a hierarchy in international human rights norms, but the human rights norms are 
universal, indivisible, interdependent, interrelated, co-existent and mutually supportive of each 
wave of rights without hierarchy. 
Nevertheless, the classification is still used for common understanding of different categories 
of human rights. The classification of a generation of human rights describes different 
categories of the human rights in terms of the time in which they developed. The 
later-developed human rights remain indivisible, interdependent and interrelated to the previous 
generations of human rights in the progressive steps to respect, fulfill and protect the rights. 274 
4.1.1 The Development of Human Rights in Nation States 
These rights originated and were codified from the human rights protection in nation states 
during the eighteenth and nineteenth centuries. 275 The developed substance of human rights at 
the national level was later strengthened by a complementary international set of rules. 
Accordingly, the civil and political rights are usually referred to as "negative" human rights 
or civil liberties, which enjoin nation states to abstain from interfering with individual rights, 
such as the freedom of security of person or freedom of speech. The civil and political rights 
have been included in most of the constitutional texts since eighteenth century276 
274 
Christian Tomuschat, Human Rights: Between Idealism and Realism, P.2425, Oxford University Press, 2003 
Without enjoying the right of the first generation, the human being would remain subject to the whims and fancies of 
the rulers by whom he/she is confronted. Likewise, rights of the second generations, such as the right to social 
security, do not become superfluous on account of the emergence of rights of the third generation. On the contrary, it 
may be said from the very outset that step by step, the next generation leaves the path of legal entitlement be 
~~coming heavily enriched with political elements. 
276 
Christian Tomuschat, Human Rights: Between Idealism and Realism, P.24-25, Oxford University Press, 2004 
Christian Tomuschat, Human Rights: Between Idealism and Realism, P.24-25, Oxford University Press, 2004 
The development of human rights which is originated or codified to nation level, for example, the Virginia 
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From the beginning of the twentieth century, a number of rights have developed as another 
class of fundamental rights in the constitution at a national level. 277 The economic, social and 
cultural rights are usually referred to as "positive" human rights, which compel societies and 
nation states to assume the responsibility for social questions and problems. 
Governments have been charged to respect, fulfill and protect civil and political rights as 
well as social, economic and cultural rights. Governments were more willing to commit 
themselves to the civil and political rights and abstain from violating those rights. However, as 
to the economic, social and cultural rights, due to available resources, nation states were more 
reluctant to commit themselves to incorporating positive social welfare benefits into their 
constitutions278 because the steps of progression are not mandatory and there is no strong 
infrastructure to ensure the development of rights. 
4.1.2 International Development of Human Rights Norms 
With the development of national human rights protection norms, nation states formed a 
consensus on the necessity of codifying the human rights norms for a minimum international 
human rights standard. The international human rights norms are protected by a variety of 
methods, including international human rights treaties and instruments and customary 
international law. 
Declaration of Rights of 1776, first 12 Constitutional Amendment of United States, the Declaration des Droits de 
I' Homme et du Citoyen of 1789, Belgian constitution of 1831, which had a considerable influence on constitutional 
~evelopments. 
7 
Christian Tomuschat, Human Rights: Between Idealism and Realism, P.26, Oxford University Press, 2004 
The Soviet Constitution of 1917 paved the way by setting a number of social and economic rights, and the German 
~eimar Constitution of 1919 are examples to entrenching furtherance new rights during the twentieth century. 
8 
Christian Tomuschat, Human Rights: Between Idealism and Realism, P.27-29, Oxford University Press, 2004 
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Based on the trend of constitutional human rights development in nation states, the United 
Nations embarked upon drafting international human rights instruments to strengthen human 
rights norms. The UN first drafted the Universal Declaration of Human Rights (UDHR) in 
1948 as a common standard of achievement for all peoples and nation states, and planned to 
engage in negotiations for more human rights protections in depth. However, during the time 
following the Second World War, due to the tension between the western and socialist countries, 
there arose a question of whether to unite the civil and political rights and the economic, social 
and cultural rights into one convention or let them remain as two sets of conventions. Moreover, 
there was the question of whether the unity between the civil and political rights and economic 
and social rights should be split into two or more separate pieces. 
The western states and the socialist states insisted on their own standards, while the socialist 
countries favored the inclusion of economic and social rights in the text first because of mistrust 
of the civil and political rights, the western states insisted on the inclusion of civil and political 
rights first while favoring non-inclusion of economic and social rights.279 
The two sides tried to find ways to codify human rights protection in their list of priorities. 
At the result, the two sides came up some concessions280 for the International Covenant on Civil 
and Political Rights (ICCPR) 1966 and its two Optional Protocols, and the International 
Covenant on Economic, Social and Cultural Rights (ICESCR) 1966. The compromise between 
~:9 Christian Tomuschat, Human Rights: Between Idealism and Realism, P.28, Oxford University Press, 2004 
° Christian Tomuschat, Human Rights: Between Idealism and Realism, P.28, Oxford University Press, 2004 
The compromise solution was much damaged to the socialist countries, but not the western countries. For the 
. s~cialist countries, but accepting the civil and political rights which undermined the bases of the communist 
, dictatorships; for the west countries, no one was against providing the economic and social services to the 
· Populations, but the problems remain on the essentially the legal method of regulation. 
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the western states and socialist states has been criticized as one of the major political pitfalls 
while the full recognition of the civil and political rights and the economic and social rights 
remained unchanged until the definitive adoption of the two Covenants. 281 The two 
international covenants together with the UDHR formed into the so-called "International Bill of 
Human Rights." 
After the adoption of the International Bill of Human Rights, a series of international human 
rights treaties or instruments have adopted and conferred the protections and developments in 
more specific areas or groups, regional human rights protections282 and non-binding instruments. 
International human rights instruments lay down obligations and duties for state parties and some 
non-state actors283 to assume under international law. 
Through the ratification of international human rights treaties, state parties have to 
· undertake domestic measures and legislation compatible with their treaty obligations and duties. 
State parties are accountable for the violation of the human rights obligations by non-state actors 
within their jurisdictions, while the human rights obligations and duties of non-state actors is 
another issue which needs further research. 
Some international human right norms are developed from multitude of non-binding 
~81 Christian Tomuschat, Human Rights: Between Idealism and Realism, P.31-32, Oxford University Press, 2004 
82 
Christian Tomuschat, Human Rights: Between Idealism and Realism, P.34, Oxford University Press, 2004 
There are several regional human rights protection instruments in the America Continent. For example, the 
American Declaration of the Rights and Duties of Man, the American Convention on Human Rights (ACHR), 1969; 
African Charter of Human and People's Rights (Banjul Charter, AFCHPR), 1981, but there is no regional human 
~!Fts instrument in Asia so far, due to the political complexities and difficulties 
Andrew Clapham, Human Rights Obligations of Non-State Actors, P.91, Oxford University Press, 2006 
When European Union may yet become a party to the European Convention on Human Rights and Protocol14 to 
that treaty has already been adopted by the state of the Council of Europe in order to make it possible. 
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recommendations or resolutions. Though the soft laws are non-binding, they are often used for 
some specific human rights guarantees and influences on the development of law. Under some 
circumstances, soft law may form into customary international law and may be given firmer 
binding power. 
Aside from international human rights instruments, international human rights are protected 
under the international customary law. According to the Statute of the International Court of 
Justice Article 38 284 , the source of international law includes international conventions, 
international custom, as evidenced by a general practice accepted as law, the general principles 
recognized in civilized nations, judicial decisions, and the teachings of the most highly qualified 
publicists of the various nations, as subsidiary means for the determination of rules of law. 
There are two essential criteria which must be fulfilled to form customary international law. 
First, there must be some unambiguous and consistent practice by states; secondly, the state must 
have followed that practice out of legal obligations. In the landmark case of customary 
international law, the North Sea Continental Shelf case did not identify the application of 
customary international law into the field of human rights. However, the Nicaragua judgment 
points out that in the formation of customary international law, the methodology must closely 
284 
Statute of the International Court of Justice, Article 38, available at 
http://www. icj-cij .org/documents/index.php?p 1 =4&p2=2&p3=0&PHPSESSID=cd3 I 8d9c693 d2ae6ec2c3 963 fc64ac 
&#CHAPTER II (last accessed on March 19, 2009) 
1. The Court, whose function is to decide in accordance with international law such disputes as are submitted to it, 
shall apply: 
a. international conventions, whether general or particular, establishing rules expressly recognized by the contesting 
states· 
b. int~rnational custom, as evidence of a general practice accepted as law; 
c. the general principles of law recognized by civilized nations; 
d. subject to the provisions of Article 59, judicial decisions and the teachings of the most highly qualified publicists 
of the various nations, as subsidiary means for the determination of rules of law. 
2. This provision shall not prejudice the power of the Court to decide a case ex aequo et bono, if the parties agree 
thereto. 
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verify to what extent states should present their practices as fully corresponding to the 
international rule of law or whether they can simply deny charges brought against them while 
possibly hiding or concealing conduct when there is violation or abuse under customary rules. 
In the field of international human rights protection, customary international law must have 
primary, universal characteristics proclaimed in various international instruments. The practice 
of human rights protection and the implementation and development of international human 
rights instruments have formed the backbone of customary international law in human rights 
protection. The protection of civil and political rights has formed into customary international 
law because more nation states have adopted them into the text of their constitutions. For 
example, the rules of prohibiting arbitrary killing, slavery, torture, detention, and systematic 
racial discrimination are now recognized as customary international law. Other rights, 
including the right to self-determination, freedom of opinion, equality rights, and the right to fair 
trial have now entered the realm of customary international law. 
Due to the special characteristic of economic, social and cultural rights as positive rights, 
governments are reluctant to include them into their constitutional texts. Until now, there have 
been some potential candidates for the rights recognized under international law: the right to free 
choice of employment, the right to form and join trade unions, and the right to free primary 
education, subject to a state's available resources?85 Whether the human rights protections in 
economic, social and cultural rights have formed into customary international law often receives 
little attention. 
285 
Andrew Clapham, Human Rights Obligations of Non-State Actors, P.86, Oxford University Press, 2006 
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An interesting facet of customary international law is that it binds every one within the 
international community. It usually applies to hold non-state actors accountable. Obligations 
arise due to the general application and the international legal order considering certain rights 
and duties important for the legal order to follow. 
4.1.3 Concluding Summary 
The protection of international human rights is a trend of progression. Although there are 
different kinds of human rights, the ultimate goal of the protections is to respect, fulfill and 
protect human dignity. With the codification of international human rights, the international 
community has taken steps towards further realization of these rights. 
4.2 The Development of the Human Right to Health 
Health is among the most pressing concerns facing decision-makers in countries across the world. 
The concept of health is very broad and subjective. The definition is always cultural and affected 
by many socio-economic factors. The term "right-based approach to health"286 is now being 
used to characterize a wide range of activities. A human rights perspective on health could 
generate new insights and effective measures as guidance at the global level. Nevertheless, 
health is the most fundamental right and is indispensable from other human rights. Without 
health, other human rights would be difficult to realize. 
Health and human rights have rarely been linked in an explicit manner, but the linkage 
between health and human rights is so closely interrelated, complex and essential that as the 
,
286 
WHO, 25 Questions &Answers on Health & Human Rights, P.16-17, 2002, available at 
. h!m://www.who.int/hhr/NEW378710MSOK.pdf(last accessed on March 19, 2009) 
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WHO observed "[w]ithout health, other rights have little meaning."287 
Promotion or violation 




As shown in the diagram, human rights have a particularly close relationship with health, 
and their overlap includes the right to health, non-discrimination, privacy, water, education, 
information, food, housing, and the right to enjoy scientific progress and its applications. 
Violation or neglect to any one of these human rights could have serious, negative health 
consequences, such as harmful traditional practices, slavery, torture, inhuman and degrading 
treatments, and violence against women and children. 289 
The recognition of the relationship between public health and human rights can lead to more 
effective policies. The establishment of health policies and programs can either promote or 
violate human rights protection290, so governments have to be careful when designing and 
287 
James G. Hodge, Jr., Nicole Valentine and Helena Nygren-Krug, 'The Domain of Health Responsiveness-A 
Human Rights Analysis', P.4, 2003, available at 
http://www.who.int/hhr/Series 2%20Responsiveness.pdf (last accessed on March 19, 2009) 
288 
WHO, 25 Questions & Answers on Health & Human Rights, P.8-9, 2002, available at 
http://www.who.int/hhr/NEW378710MSOK.pdf (last accessed on March 19, 2009) 
289 
WHO, 'Linkage between Health and Human Rights', available at 
lmo://www.who.int/hhr/HHR%20Jinkages.pdf(last accessed on March 19, 2009) 
29° For example, lack of protection in freedom from discrimination, right to participation, individual autonomy, 
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implementing policies and legislations.291 
Promoting and protecting health requires explicit and concrete efforts to promote and 
protect human rights by everyone, including individuals, groups, nation states, and international 
communities. 
4.2.1 International Development of Health as Human Right 
Before the 19th century, health and human rights were scarcely a part of the international 
dialogue. The first health legislation was adopted in the 19th century, and the trend towards 
adoption of a right to health in the 20th century was marked by slow progress. 
The public health movement of the 19th century started over the outrage at unhealthy 
working conditions and living environments during the industrial revolution, and the spread of 
epidemic diseases. Realizing that sickness would load the social burden and good health would 
relieve the burden of social and economic concerns, policy makers became aware of the fact that 
public health measures and policies should be implemented to fight against diseases and ensure 
healthy living conditions. 
International health organizations have taken steps toward public health. A senes of 
International Sanitary Conferences was held in the 19th century?92 In 1907, founded by the 
Rome Agreement, an international office of public health was created, the Office International 
rights to participation, privacy and information. 
291 
WHO, 'Linkage between Health and Human Rights', available at 
h!!p://www.who.int/hhr/HHR%20linkages.pdf(last accessed on March 19, 2009) 
292 
Brigit C.A. Toebes, The Right to Health as a Human Right in International Law, P.13-14, Intersentia Publishers, 
1999 
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d'Hygiene Publique (OIHP). The main function of the OIHP was to disseminate information on 
public health matters, particularly on communicable diseases. The OIHP did not work well due 
to insufficient funding, and because it had to work with the health organization of the League of 
Nations until the creation of the UN293 . Later, the International Labor Organization (ILO) of 
1919 dealt with work-related health issues in the field of occupational health. The ad hoc 
Committee defined problems relating to workers' health to which international regulation was to 
be directed. 294 
Since this historic evolution, the issue of public health has been focused on the recognition 
of health as a human right on the national level. The national health policies were focused on 
improving the health of the public, and sanitary conditions were its first priority. However, in 
order to have sustainable public health, the issue of poverty should also be combated by 
providing accessible and affordable health related products and services. 
The notion of health as one of the social and economic rights was initiated at the United 
Nations Conference on International Organization held in San Francisco in 1945. Article 55 of 
the UN Charter stipulates that "the United Nations shall promote: b. solutions of international 
economic, social, health, and related problems; and international cultural and educational 
cooperation .... " 295 Later, the formulation of health as a human right was initiated and 
incorporated into various international human rights instruments, regional human rights 
293 
Brigit C.A. Toebes, The Right to Health as a Human Right in International Law, P.13-14, Intersentia Publishers, 
1999 
294 
Brigit C.A. Toebes, The Right to Health as a Human Right in International Law, P.13-14, Intersentia Publishers, 
1999 
295 
Article 55 of Charter of the United Nation, available at 
lY..ww.un.org/aboutun/charter/ (last accessed on March 19, 2009) 
- 122-
protections and customary international law. 
4.2.1.1 Sources 
The international human right to health can be found in large numbers of international human 
rights instruments, regional human rights instruments, customary international laws, and 
non-binding soft laws. 
4.2.1.1.1 Primary International Human Right Instruments 
Constitution ofthe WHO 1946296 
The Preamble of the Constitution ofthe WHO states: 
Health is a state of complete physical, mental and social well-being and not merely the 
absence of disease or infirmity. The enjoyment of the highest attainable standard of health 
is one of the fundamental rights of every human being without distinction of race, religion, 
political belief, economic or social condition .... 
Though it is striking to see the absolute, broad and idealistic character of the text, the WHO's 
definition of the right to health is still a breakthrough in the field of international human rights 
and a milestone in the further refinement and implementation of the right to health. 
Universal Declaration of Human Rights (UDHR) 1948297 
Article 25.1 ofUniversal Declaration ofHuman Rights (UDHR) 1948 affirms: 
Everyone has the right to a standard of living adequate for the health and well-being of 
himself and of his family, including food, clothing, housing and medical care and necessary 
social services, and the right to security in the event of unemployment, sickness, disability, 
widowhood, old age or other lack of livelihood in circumstances beyond his control. 
296 
WHO, WHO Constitution, 1946, available at 
lmp://www. who.int/governance/eb/who constitution en.pdf (last accessed on March 19, 2009) 
297 
UDHR, 1948, available at 
http://www.un.org/Overview/rights.html#a25 (last accessed on March 19, 2009 
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Article 25 of the UDHR has not adopted in the WHO's text. There is no separate article for the 
human right to health, but instead this right is combined with other social issues in very broad 
terms. Nevertheless, the UDHR is still a universally known and recognized human rights 
document. 
International Covenant on Economic, Social and Cultural Rights (ICESCR) 1966 
The right of health has been outlined in Article 12298 as follows: 
1. The States Parties to the present Covenant recognize the right of everyone to the 
enjoyment ofthe highest attainable standard of physical and mental health. 
2. The steps to be taken by the States Parties to the present Covenant to achieve the full 
realization of this right shall include those necessary for: 
(a) The provision for the reduction of the still birth-rate and of infant 
mortality and for the healthy development of the child; 
(b) The improvement of all aspects of environmental and industrial hygiene; 
(c) The prevention, treatment and control of epidemic, endemic, occupational 
and other diseases; 
(d) The creation of conditions which would assure to all medical service and 
medical attention in the event of sickness. 
There was considerable debate over whether to include the WHO definition in the covenant. 
Ultimately, it was decided not to include the definition so the terms of the right to health remain 
unclear. Questions as to the extent of the right to health still remain. The second part of 
Article 12 does mention health but as a broad concept, and establishes steps to achieve a right to 
health. 
The Committee on Economic, Social and Cultural Rights elaborated on the right to health in 
General Comment No.l4 in 2000. General Comment No.l4 described in more detail on the 
normative content of the right to health, including health care and the health determinant, the 
298 
International Covenant of Economic, Social and Cultural Rights (ICESCR), 1966, available at 
htm://www2.ohchr.org/english/law/cescr.htm (last accessed on March 19, 2009) 
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precondition of human health, the individual rights and the nation states' and even non-state 
actors' obligations towards the right to health?99 
Some of the preconditions of health determinants are also indirectly linked to the right to 
health and affect the enjoyment of that right. The ICESCR aims to ensure the protection of 
economic, social and cultural rights including the right to self-determination of all peoples in 
Article 1; the right to non-discrimination based on race, color, sex, language, religion, political or 
other opinion, national or social origin, property, birth or other status in Article 2; the equal right 
of men and women to enjoy the rights in the ICESCR in Article 3; the right to work in Articles 6 
and 7; the right to form and join trade unions in Article 8; the right to social security in Article 9; 
the right of protection and assistance to the family in Article 1 0; the right to an adequate standard 
of living in Article 11; the right to health in Article 12; the right to education in Articles 13 and 
14; and the right to cultural freedoms in Article 15.300 
4.2.1.1.2 Regional Human Right Protection 
The most famous regional human rights protection is laid out by three organizations: the Council 
of Europe, the Organization of American States (OAS) and the Organization of African Unity. 
These organizations have adopted human rights principles in the documents in which a right to 
health is set forth. 
299 
Committee of Economic, Social and Cultural Rights General Comment on The right to the highest attainable 
standard of health, 2000, available at 
http://www.unhchr.ch/tbs/doc.nsf!%28symbol%29/E.C.12.2000.4.En?OpenDocument (last accessed on March 19, 
2009) 
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International Covenant on Economic, Social and Cultural Rights, 1966, available at 
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Article 11 of the European Social Charter (ESC) -
The right to protection of health301 
With a view to ensuring the effective exercise of the right to protection of health, the Parties 
undertake, either directly or in cooperation with public or private organisations, to take 
appropriate measures designed inter alia: 
1. to remove as far as possible the causes of ill-health; 
2. to provide advisory and educational facilities for the promotion of health and the 
encouragement of individual responsibility in matters of health; 
3. to prevent as far as possible epidemic, endemic and other diseases, as well as accidents. 
Though the language in the provision is narrow and weak, the text of ESC describes clear 
state obligations requiring states to take measures as far as possible to protect health?02 
Convention on Human Rights and Biomedicine303 
The Convention contains specific provisions regarding the right to health as to consent, privacy 
and the right to information, the human genome, scientific research, organ and tissue removal 
from living donors for transplantation purposes, and prohibition of financial gain and disposal on 
parts of the human body. 
Article 3 of the Convention stipulates State obligations to ensure equitable access to health 
care, as "[p ]arties, taking into account health needs and available resources, shall take 
appropriate measures with a view to providing, within their jurisdiction, equitable access to 
health care of appropriate quality. "304 
301 
European Social Charter Article 11, 1996, available at 
http://conventions.coe.int/Treaty/EN/Treaties/Html/163.htm (last accessed on March 19, 2009) 
302 
European Social Charter Article 11, 1996, available at 
http://conventions.coe.int/Treaty/EN/Treaties/Html/163.htm (last accessed on March 19, 2009) 
303 
Convention on Human Rights and Biomedicine, 1997, available at 
http://conventions.coe.int/Treaty/en/Treaties/Html/164.htm (last accessed on March 19, 2009) 
304 
Convention on Human Rights and Biomedicine, 1997, available at 
http://conventions.coe.int/Treaty/en/Treaties/Html/164.htm (last accessed on March 19, 2009) 
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This provision does not include a broad base of the right to health, but focuses on access to 
health care instead. The provisional text also includes the state parties' obligation regarding 
health care which depends on the "health needs and available resources" of the state parties. 
american Convention on Human Rights and Protocol San Salvador, 1988 
The protocol that was adopted as the "Additional Protocol to American Convention on Human 
Rights in the area of Economic, Social and Cultural Rights" since 1988, is called the "Protocol of 
San Salvador." 
Article 10 states that 
1. Everyone shall have the right to health, understood to mean the enjoyment of the highest 
level of physical, mental and social well-being. 
2. In order to ensure the exercise of the right to health, the States Parties agree to recognize 
health as a public good and, particularly, to adopt the following measures to ensure that 
right: 
a. Primary health care, that is, essential health care made available to all individuals and 
families in the community; 
b. Extension of the benefits of health services to all individuals subject to the State's 
jurisdiction; 
c. Universal immunization against the principal infectious diseases; 
d. Prevention and treatment of endemic, occupational and other diseases; 
e. Education of the population on the prevention and treatment of health problems, and 
f. Satisfaction of the health needs of the highest risk groups and of those whose poverty 
makes them the most vulnerable. 305 
Article 10 (1) derived the term "physical, mental and social well-being" from the preamble ofthe 
WHO Constitution. This provision also states the obligations to undertake in the protection of 
the right to health. 
305 
Additional Protocol to the American Convention on Human rights in the Area of Economic, Social and Cultural 
Rights "Protocol of San Salvador", 1998, available at 
http://www.oas.org(juridico/english/Treaties/a-52.html (last accessed on March 19, 2009) 
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In addition, Article 11 proclaimed the right to a healthy environment: 
Article 11 states that 
1. Everyone shall have the right to live in a healthy environment and to have access to basic 
public services. 
2. The States Parties shall promote the protection, preservation, and improvement of the 
environment. 306 
]le African Charter on Human and Peoples' Rights 
The African Charter of Human and Peoples' Rights originally dealt with individual human rights, 
and collective rights, civil and political rights, and also a limited number of economic and social 
rights, such as the right to work, the right to health, and the right to education. 
307 
Article 16 of the Charter contains the protection with regards to health: 
1. Every individual shall have the right to enjoy the best attainable state of physical and 
mental health. 
2. State Parties to the present Charter shall take the necessary measures to protect the health 
of their people and to ensure that they receive medical attention when they are sick. 
308 
The language in the provision is similar to Article 12 ( 1) of the International Covenant on 
Economic, Social and Cultural Rights; however, the article does not enumerate steps in state 
obligations regarding the right to health. 
4.2.1.1.3 Customary International Law 
Customary international law, described in Article 38 of the Statute of the International Court of 
306 Additional Protocol to the American Convention on Human rights in the Area of Economic, Social and Cultural 
Rights "Protocol of San Salvador", 1998, available at 
http://www.oas.org/juridico/english/Treaties/a-52.html (last accessed on March 19, 2009) 
307 African Charter on Human and People's Rights, 1986, available at 
www.achpr.org/english/ info/charter en.html (last accessed on March 19, 2009) 
308 African Charter on Human and People's Rights, 1986, available at 
.www.achpr.org/english/ info/charter en.html (last accessed on March 19, 2009) 
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Justice, is one source of international law, which is understood as consisting of general practices 
accepted as law and binding on everyone, including individuals, groups, nation states and 
non-state actors309 in the international community without exceptions and irrespective of express 
consent. From this perspective, if the international human right to health norms go beyond 
human rights treaties and have become customary international law, this would broaden its 
application to non-state actors. 
Professor Andrew Clapham and Mariano Garcia Rubio confirm the existence of an opinio 
juris within the international community and consider the customary international human right to 
health using four criteria: (a) the wide acceptance of non-binding instruments dealing with the 
right to health; (b) the wide participation in multilateral treaties that establish the right to health; 
(c) the reference to such a right in national legislation, mainly at the constitutional level; and (d) 
the implementation of the right to health before municipal courts? 10 
4.2.1.2 Scope and Content ofthe Right to Health 
Human rights have a long history. "Health" is usually one of the first rights recognized as a 
human right. Health is a very broad and subjective concept. Health is influenced by cultural, 
geographic, and most importantly, socio-economic factors. 
The right to health is usually addressed in the negative, in other words, in violation, neglect 
309 
Processor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context of the Right to Health', P.20, 2002 available at 
~ww.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf(last accessed on March 19, 2009) 
310 
Processor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context of the Right to Health', P.22, 2002, available at 
~ww.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf(last accessed on March 19, 2009) 
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or abuse of other human rights which cause a health impact, such as torture. The actual basic 
concept of "health" in human rights has been generally absent from human rights discourse. 
~one 
The scope of the right to health is usually divided into individual health and public health.311 
Individual health usually refers to medicine and health care. Public health usually refers to the 
health of population, including the underlying precondition for health or health-related factors 
shared by the population as a whole. The term "public" health should be understood as 
"shared," or "use in common." When the conditions, situations, mediums or things shared or 
used in common are not healthy and pose a threat to the health of people, this should raise the 
protections due to public health. 
Content 
The traditional concept of human rights protection is to ensure that all people are born to be free 
and equal in dignity and rights.312 There are different perspectives over the term "the right to 
health." Different terms have been used, such as "right to health care," or "the right to health 
protection." But what does "health" mean in connection with the right to health? It is agreed 
that the right to health does not mean the right to have perfect health or to be healthy. Health is 
a broad and highly subjective matter; how then should health be defined in the right to health? 
3
1! Jonathan M. Mann, Sofia Gruskin, Michael A. Grodin, George J. Annas edited, Health and Human Rights: A 
Reader, P.8, Routledge , 1999 
Modem concept of health usually derives from two related disciplines: medicine and public health. While medicine 
generally focuses on the individual health, which concerns to medical and other health care services in the physical, 
mental and disability, in the contrast, public health has been focus in ensuring healthy conditions which emphasis 
mostly in the prevention of diseases, disability and premature death. 
312 
Jonathan M. Mann, Sofia Gruskin, Michael A. Grodin, and George J. Annas edited, Health and Human Rights: A 
Reader, P.9, Routledge, 1999 
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In the Preamble of the Constitution of the WHO, the term of health is still nebulous and left 
undefined. This definition has been criticized as too idealist and inappropriate.313 
There are other international agreements, regional human right instruments, and even 
national constitutions directly or indirectly recognizing and the right to health. Yet, the practice 
of the right to health is still waiting for further development. 
Human rights advocacies are trying hard to push for the realization of the right to health. 
Recently, they have challenged policy makers to gradually define the right to ~ealth and then to 
extend the concept314 ofthe right to health in various aspects. 
Brigit C. A. Toebes believes that the right to health underlies the economic, social rights 
safeguarding individuals from suffering social and economic injustices with respect to his/her 
health. She also points out that the right to health, as with other human rights such as civil and 
political rights and economic, social and cultural rights, are interdependent and indivisible from 
all human rights. 315 Some issues exerting health impacts are not part of the scope of the right to 
health.316 Toebes observes that the right to health can be divided into elements of health care 
313 
David P. Fidler, International Law and Public Health: Materials on and Analysis of Global Health Jurisprudence, 
P.302, Transnational Pub, 2000 
314 
Jonathan M. Mann, Lawrence Gostin, Sofia Gruskin, Troyen Brennan, Zita Lazzarini, and Harvey Fineberg, 
'Health and Human Right', Jonathan M. Mann, Sofia Gruskin, Michael A. Grodin, and George J. Annas edited, 
Health and Human Rights: A Reader, P.1 0, Routledge, 1999 
The modem concept of human rights has extended into cencems about the environment and global socioeconomic 
development, the practice into wider social involvement and participation to broaden the language and human rights 
concepts, the expansion of the protection from individuals v. states to other non-state actors, such as transnational 
business, and to combine the promotion and protection of human rights altogether. 
315 
Asbj0m Eide, Catarina Kause and Allan Rosas Edited, Economic, Social and Cultural Rights, 2nd Ed., P.170-171, 
Springer, 2001 
316 
Asbj0m Eide, Catarina Kause and Allan Rosas Edited, Economic, Social and Cultural Rights, 2nd Ed., P.175, 
Springer, 2001 
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and of underlying preconditions affecting health. 317 The scope and core content of the right to 
health from Toebes is as follows chart: 318 
SCHEME OF THE SCOPE AND CORE CONTENT OF THE RIGHT TO HEALTH 
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Professor David P. Fidler argues for the right to health illustrated in the concentric circles 
below. He conceptualizes this right as it pertains to violations of civil and political rights, such 
as torture;319 regulatory failure, involving failures by governments to regulate activities within 
For example, the right to health probably does not encompass a prohibition of torture per se, protection against 
arbitrary execution or the right to adequate housing per se, not to mention normal education at schools. 
317 
Brigit C. A. Toebes, The Right to Health as a Human Right in International Law, P.245, Intersentia Publishers, 
1999 
318 
Brigit C. A. Toebes, The Right to Health as a Human Right in International Law, P.288-289, Intersentia 
Publishers, 1999 
319 
David P. Fidler, International Law and Public Health: Materials on and Analysis of Global Health Jurisprudence, 
P.304, Transnational Pub, 2000 
Not all international experts concur. For example, the study ofToebes in the right to health in international law 
excludes the prohibition against torture and cruel, inhuman, or degrading treatment or punishment from the scope of 
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their boarders that can cause serious and foreseeable harm to health; access to health services and 
information, including supplies of safe water and basic sanitation; and access to health 
determinants, such as adequate food, housing, education and employment. The fact that the 
scope of the right to health remains uncertain in international terms, however, is one of the basic 
obstacles to its implementation. 
Access to Health 
Sourctii: Oavld F'. Fidler, lnternatlonBI Law and Globaf Public Heallh, 46 U. KAN. L. REv., 1, 43 
(1999). 320 
Some assert that the right to health means access to health care services. This argument 
raised a suggestion that in order to achieve a state of complete physical, mental, spiritual, and 
social well-being, an individual needs access to health care services. This concept is also 
reinforced by the WHO's concept of "health for all," meaning that nation states provide health 
care321 and protect the right to such care with no discrimination on any ground. Professor 
the right to health. 
320 David P. Fidler, International Law and Public Health: Materials on and Analysis of Global Health Jurisprudence, 
P.305, Transnational Pub, 2000 
321 David P. Fidler, International Law and Public Health: Materials on and Analysis of Global Health Jurisprudence, 
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David P. Fidler believes that the right does not address health services. Moreover, he points out 
that the progressive realization of health care service as a health right will have difficulties 
involving the questions ofthe economic resources of each country.322 
The UN adopts the broader term of the right to health. The term is defined with treaty 
provisions which proclaim not only as to the right to health care, but also the right to underlying 
preconditions for health. In the General Comment No.14 (2000) of the ICESER is established 
clearer normative content of the right to health contained in Article 12. The Committee 
contends that the right to health is not a right to be healthy, but rather takes into account the 
individual's biological and socioeconomic precondition and a nation state's available resources. 
The right contains both freedoms and entitlements regarding health. The freedom of the right to 
health includes the right to control one's health and body, including sexual and reproductive 
freedom and the right to be free from interference, such as free from torture, non-consensual 
medical treatment and experiments. The entitlements of the right to health, which are proposed 
in this dissertation, are to include a system of health protection which provides equality of 
opportunity for people to enjoy the highest attainable level ofhealth.323 
The core content of the right to health refers to the minimum essential level of the right. 
The key elements are set out in guidance for nation states. The comment underscores that the 
right to health is an inclusive right which not only obligates nation states to provide health care 
P.302, Transnational Pub, 2000 
The issue on the definition on the right to health as to a right to access health services remains controversial and 
even more chaiienging when the issue involves with the scarcity of economic resource of each country. 
322 David P. Fidler, International Law and Public Health: Materials on and Analysis of Global Health Jurisprudence, 
P.302, Transnational Pub, 2000 
323 
CESCR, General Comment No. 14, 2000, available at 
www.unhchr.ch/tbs/doc.nsf/(symboJ)/E.C.l2.2000.4.En?OpenDocument (last accessed on March 19, 2009) 
- 134-
based on their resources, but also to address the preconditions which closely relate to human 
health, such as access to safe and potable water and adequate sanitation, an adequate supply of 
safe food, nutrition and housing, healthy occupational and environmental conditions, access to 
health-related education and information, including information on sexual and reproductive 
health, and also participation in the health related decision making at the community, national 
and international levels324and conditions which are necessary for the realization of the highest 
attainable level ofhealth.325 
The committee also outlines elements for nation states as guidelines to protect and fulfill the 
right. The elements are AAAQ: availability, accessibility, acceptability and quality. 
"Availability" means that functioning public health and healthcare facilities, goods, services 
and programs, including the underlying determinants of health, such as safe and potable drinking 
water and adequate sanitation facilities, hospitals, clinics and other health-related buildings, 
324 CESCR, General Comment No. 14, P.3, 2000, available at 
www.unhchr.ch/tbs/doc.ns£'%28symboi%29/E.C.12.2000.4.En?OpenDocument (last accessed on March 19, 2009) 
325 CESCR, General Comment No. 14, P.2, 2000, available at 
~ww.unhchr.ch/tbs/doc.nsf/%28symboi%29/E.C.12.2000.4.En?OpenDocument (last accessed on March 19, 2009) 
326 WHO, 'The Right to Health', Fact Sheet, available at 
!Yww.who.int/entity/hhr/Right to health-factsheet.pdf (last accessed on March 19, 2009) 
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trained medical and professional personnel receiving domestically competitive salaries, and the 
availability of essential drugs327 in sufficient quantity within the nation state. 
"Accessibility" means that health facilities, goods and services must be accessible to 
everyone without discrimination, including water, pharmaceuticals, and shelter. Accessibility 
also encompasses physical accessibility, economic accessibility and information accessibility. 
Physical accessibility includes the physical accessibility of underlying determinants of health 
such as safe and potable water and sanitation facilities, whereby all health services must be 
within safe physical reach for all sections of the population. Economic accessibility means that 
all health services are affordable to all. Information accessibility refers to the right to seek, 
receive and impart information and ideas concerning health issues. "Acceptability" refers to state 
parties' obligation to ensure that all health facilities, goods and services are respectful of medical 
ethics and are culturally appropriate. Lastly, referring to "quality", the Committee specifies that 
states have to guarantee that all services are scientifically and medically appropriate and of good 
quality. 328 
Availability, accessibility, acceptability and quality of pharmaceuticals and medical services 
are the core content of the international human right to health which can solve and manage the 
disease burden caused by the ill preconditions of health determinants. In the fight against 
diseases, the lack of accessible and affordable pharmaceuticals and medical services, including 
medicines, vaccines, medical equipments and services, is urgently in need of attention. 
327 
CESCR Council, The Right to Highest Attainable Standard of Health, General Comment 14, 2000, available at 
www.unhchr.ch/tbs/doc.nsf/(symbol)/E.C.l2.2000.4.En?OpenDocument (last accessed on March 19, 2009) 
328 
WHO, 'International Covenant on Economic, Social and Cultural Rights, Health and Human Rights', available 
at 
www.who.int/hhr/Economic social cultural.pdf(last accessed on March 19, 2009) 
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Professor Paul Hunt, a Special Rapporteur of the Commission of Human Rights, divides the 
contour and content of the right to health into health care and the underlying determinants of 
health, freedoms and entitlements, which is very similar to and overlaps with the General 
Comment No.l4 of the CESCR. 
Hunt states that the right to health is an inclusive right which includes not only timely and 
appropriate health care, but also the underlying determinants of health. The right to health also 
contains both freedoms and entitlements. Freedoms include the right to control one's health, 
including the right to be free from non-consensual medical treatment and experimentation. 
Entitlements include the right to a system of health protection that provides equality of 
opportunity for people to enjoy the highest attainable standard ofhealth?29 
Judith Asher agrees that the right to health should not be seen as a right to be healthy. Nor 
should the right to health be viewed as a limitless right to receive medical care for any and every 
illness or disability. Instead, the right to health should be understood as a right to enjoyment of 
a variety of facilities and conditions which the state is responsible for providing as necessary for 
the attainment and maintenance of good health.330 
4.2.2 Right to Health in Accessible and Affordable Pharmaceutical Products 
Given these considerations, I believe that the right to health should be based on a foundation 
329 Commission on Human Rights, The Right of Everyone to the Enjoyment to the Enjoyment of the Highest 
Attainable Standard of Physical and Mental Health, E/CNA/2003/58, available at 
http://daccessdds.un.org/doc/UNDOC/GEN/G03/109/79/PDF/G0310979.pdf'?OpenElement (last accessed on March 
19, 2009) 
330 Judith Asher, The Right to Health: A Resource Manual for NGOs, 2004, available at 
http://shr.aaas.org/pubs/rt healthlrt health manual. pdf (last accessed on March 19, 2009) 
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invested in the protection of civil and political rights. 331 Civil and political rights are associated 
with ensuring people's liberties whereas economic, social and cultural rights are concerned with 
ensuring the basic needs in accordance with social justice; the right to health is an overlapping 
area between the two.332 Not only will the violation, neglect, and abuse of civil and political 
rights have impacts on the right to health, but in order to respect, fulfill and protect the right to 
health, the nation states must be able to ensure the protection and promotion of civil and political 
rights, then to implement and enforce economic, social and cultural rights. 333 This does not 
mean that the protection of civil and political rights is a prerequisite and priority for the right to 
health, but without the respect and recognition of civil and political rights, there can be no 
respect and recognition of human rights, and no nation states to provide for the protection, 
promotion and fulfillment of human rights.334 As Jack Donnelly puts it, "civil and political 
rights, by providing accountability and transparency, can help to channel economic growth into 
national development rather than private enrichment."335 Amartya Sen has also observed that, 
"among the most important freedom we can have is freedom from avoidable ill-health and from 
escapable mortality." Sen concludes that health improvement requires improvements in 
participatory politics in which "the public must see itself not merely as a patient, but also as an 
331 International Covenant of Civil and Political Rights, 1966, available at 
http://www2.ohchr.org/english/law/ccpr.htm (last accessed on March 19, 2009) and Andrew Clapham, Human 
Rights Obligations of Non-State Actors, P.1 0, Oxford University Press, 2006 
Though state dominated role of the international community has failed, development without an effective state is 
impossible. 
332 The UDHR 1948, a primary source of international human rights, does not make any distinction between the 
civil and political rights and economic, social and cultural rights. 
333 It seems that I fell into the debate after the Universal Declaration of Human Rights, on the issues on whether 
countries shall first have civil and political rights or economic, social and cultural rights. 
334 The violations of civil and political rights, such as lack of protection of the right to life, liberty, security of 
persons, freedom of movement, and not to torture or to cruel and unusual punishment, or arbitrary arrest and 
detention, usually, are accompanying with the violation of right to health. 
335 Debra L. Delaet, The Global Struggle for Human Rights: Universal Principles in World Politics, P. 107, 
Wadsworth Publishing , 2005 
Jack Donnelly continues to note that the interdependence between economic and social rights and civil and political 
rights is not inevitable. Human rights need to make conscious efforts to like these rights to foster interdependence. 
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agent of change. "336 Thus, the protection of the right to health depends on the protection of 
civil and political rights, but the civil and political rights are outside the circle of the right to 
health. Without the protection of civil and political rights, the right to health will be difficult to 
recognize and implement. 
Though many international legal experts have different views regarding the right to health, 
the definition of health should not be too restrictive. The international human right to health is 
a growing area of the law which adapts to the changing world and adjusts to its need. This 
dissertation suggests that the scope and content of the right to health should be clarified if we are 














336 Sofia Gruskin, Michael A. Grodin, George J. Annas, Stephen P. Marks edited, Perspectives on Health and 
Human Rights, P.l, Routledge, 2005 
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Both health care and social conditions are important determinants of health issues in 
practical terms; however, this dissertation proposes different views of the core of the right to 
health. The approach of the right to health is diagramed above. The core content of the right 
is divided into two categories: individual health and public health. Individual health is related to 
diseases, medical services and pharmaceuticals. Public health is related to the essential 
elements shared in common, such as the water, air, environment, disease and viruses. In the 
content of the right to health, there should not be divisions between each aspect of the right. 
The link between individual health and population health is closely interrelated. The traditional 
boundaries of the two have blurred due to a closer understanding of the links between them. 
Many scholars suggest that the right to health equals the right to health care, but this 
dissertation relegates health care to the secondary status as this research believes that the health 
care system is the tool or policy which nation states uses to provide available, accessible, 
acceptable and good quality care, mostly in the pharmaceutical and medical services to promote 
individual and public health. The health of the population can be strengthened by the 
increasing accessibility and affordability of medicines through health care. 337 The health care 
services, the second circle, may overlap with individual health, but they are outside the core 
content of the right. Such a health care service should be one of the infrastructures of a social 
welfare policy. Having the health care system will be more effective and efficient for 
populations to use to seek treatments, to maintain their health, to prevent and treat diseases, and 
337 
Jonathan M. Mann, 'Medicine and Public Health, Ethics and Human Rights', Jonathan M. Mann, Sofia Gruskin, 
Michael A. Grodin, and George J. Annas edited, Health and Human Rights: A Reader, P. 441, Routledge, 1999 
It is suggests that medicine and health care have limited influence of the right to health. Jonathan M. Mann points 
out that the major problem of the accessibility and affordability of the medicine arising from the socioeconomic 
status which effect greatly in the health gradient. It might be true, but the gap of socioeconomic status has vigorous 
impact on the accessibility and affordability of medicine and health care. 
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to increase the accessibility and affordability of health care services and pharmaceuticals. The 
health care services will have the goal of affecting the right to health more efficiently and 
effectively in the second concentric circle, but the benefit will still depends on each nation's 
resources and economic conditions. 
Nonetheless, above all the debates and discussions, the most critical components of the right 
to health are non-discrimination and equal treatment in the access to health care, the underlying 
determination of health, and other internationally prohibited grounds which impair the equal 
enjoyment of the right to health. 
4.2.3 Concluding Summary 
The right to health has been firmly embedded in a substantial numbers of UN human rights 
treaties. The UN treaties construe the right to health in broad terms. There are still many 
human right to health instruments which built their provisions upon the foundation of the earlier 
text but focus on specific groups, and these are characterized by more detail than the general 
human rights instruments. 
The above-mentioned regional human rights organizations have included a right to health in 
their instruments, some defining the right to health and some referring more generally to the right 
to health as the right to health care or to a healthy environment. In other cases, regional 
agreements do not explicitly recognize the right to health, but offer indirect protections through 
other health-related rights.338 However, the scope and content of the international human right to 
338 
Commission on Human Rights, The Right of Everyone to the Enjoyment to the Enjoyment of the Highest 
Attainable Standard of Physical and Mental Health, E/CNA/2003/58, 2003, available at 
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health remains unconfirmed. 
Health is one of the main concerns of a human being. The health issue has been a priority 
for decision makers; however, comparing the right to health to other human rights, progress 
towards developing rigorous standards for international human rights to health has been 
relatively slow. 
Due to the political sensitivity of the health issue, the right to health has begun to be firmly 
embedded into a number of international treaties, declarations and national constitutions, but the 
universal right to health is still waiting to be realized. As former United Nations Secretary 
General Kofi Annan once stated, "[i]t is my aspiration that health will be finally seen not as a 
blessing to be wished for, but as a human right to be fought for. "339 
4.3 Benefit of Pharmaceutical Science & Technology as Human Right 
Scientific and technological development and progress has become one of the most important 
factors in the development of human society. This development and progress has brought better 
conditions of life to the world population. 
Pharmaceutical science and technology has brought enormous benefits to human life and 
social progress. Benefits of pharmaceutical science and technology are a critical component of 
!illp://daccessdds.un.org/doc/UNDOC/GEN/G0311 09/79/PDF/G031 0979 .pdf?OpenElement (last accessed on March 
19, 2009) 
There are indirect protections of human rights to health, such as the American Declaration on the Rights and duties 
of Man, the American Convention on Human Rights, the Inter-American Convention on the Prevention, Punishment 
and Eradication of Violence against Women, and the European Convention for the Protection of Human Rights and 
fundamental Freedoms and its protocols. 
39 
WHO, 25 Questions & Answers on Health & Human Rights, 2002, available at 
hnp://www.who.int/hhr/NEW378710MSOK.pdf (last accessed on March 19, 2009) 
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the right to health. As a result of the burden of diseases and conditions described above, there 
is an urgent need to make full recognition of the enjoyment of pharmaceutical science and 
technology a part of the right to health. 
The privatization and commercialization of pharmaceutical science and technology does 
contribute to R&D in science and technology; however, they also change the focus of 
pharmaceutical-related science and technology from the life-saving and diseases-curing and 
prevention to pure capitalism. As one industry insider bluntly put it, "[i)'s about the consumers, 
not the diseases".340 
The right to protect the pharmaceutically-related inventions and the right to the enjoyment 
of the benefit of pharmaceutical science and technology both fall within the scope of human 
rights, but balancing the two interests has become a difficult task. 
The current international intellectual property rights341 system has provided some forms of 
protection on the supply side. The system ensures that the rights of the inventors, corporations 
34° Conference of Commercialization of Biotechnology R&D Results in Taipei, 15 Feb, 2008 
341 3dthree Organization, 'Intellectual Property and Human Rights: Is the Distinction Clear Now?: An Assessment 
of the Committee on Economic, Social and Cultural Right' General Comment No.17 (2005) on "The Right of 
Everyone to Benefit From the Protection of the Moral and Material Interest Resulting from any Scientific, Literary 
or Artistic Production of Which he is the Author'", P.1~2, 2006, available at 
www.3dthree.org/pdf 3D/3D GC17 IPHR.pdf(last accessed on March 19, 2009) 
There are arguments on whether intellectual property rights are protected in the scope of the human rights in Art15 
of ICESCR and Art 27 ofUDHR. These debates have been partly resolved by General Comment no. 17 (2005) by 
the Committee on Economic, Social and Cultural Rights. The General Comment No.17 (2005) points out that, 
"while under most intellectual property systems, intellectual property rights, often with the exception of moral rights, 
can be allocated, limited in time and scope, traded, amended and even forfeited, human rights are timeless 
expressions of fundamental entitlements of the human person.". It goes one and add "it is therefore important not to 
equate intellectual property rights with the human rights recognized in article 15 (c), but for some protection as long 
as available is suited to secure authors' moral and material interests from their productions. Commentators have 
argues that General Comment No.l7 is focusing on individual author's rights to scientific or literary production and 
fails to look at the current reality that most of the scientific inventions and literary products are almost wholly owned 
by corporation which might cause a problem when it comes to Art 15 (b) later. 
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or investors of the pharmaceutical products benefit from the protection of the moral and material 
interests resulting from their scientific, technological products are protected.342 By contrast, 
there is little attention on the demand side. The consumers or patients are not guarded by the 
right to enjoy the benefits of scientific and technological progress and its applications. 
The epidemic of SARS and HIV/AIDS, the terrorists' use of anthrax in 2002, and the 
increasing burdens of chronic diseases have awakened attention to the importance of the right to 
health. Though there are other factors that affect health, the accessibility and affordability of 
pharmaceutical-related products are surely on the list of priority for treating the sick and 
preventing diseases. 
4.3.1 Sources 
The first attention given to the link between human rights, science and technology appeared in 
Article 27 of the Universal Declaration of Human Rights (UDHR), 1948 and Article 15 of the 
International Covenant on Economic, Social and Cultural Rights (ICESCR), 1966. 
Article 27343 of UDHR reads: 
(1) Everyone has the right freely to participate in the cultural life of the community, to 
enjoy the arts and to share in scientific advancement and its benefits. 
(2) Everyone has the right to the protection of the moral and material interests resulting 
from any scientific, literary or artistic production of which he is the author. 
Article 15 ofiCESCR344, which elabor~tes ideas parallel to Article 27 ofUDHR with minor 
342 Some scientific or technological products; however, have been left out of the concept and scope of the protection, 
such as traditional medicine, medical knowledge, etc. 
343 Universal Declaration of Human Rights, Article 27, 1948, available at 
www.un.org/Overview/rights.html (last accessed on March 19, 2009) 
344 International Covenant on Economic, Social and Cultural Rights, 1966, available at 
www2.ohchr.org/english/law/cescr.htm (last accessed on March 19, 2009) 
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differences, reads as follows: 
1. The States Parties to the present Covenant recognize the right of everyone: 
(a) To take part in cultural life; 
(b) To enjoy the benefits of scientific progress and its applications; 
(c) To benefit from the protection of the moral and material interests resulting from any 
scientific, literary or artistic production of which he is the author. 
2. The steps to be taken by the States Parties to the present Covenant to achieve the full 
realization of this right shall include those necessary for the conservation, the 
development and the diffusion of science and culture. 
3. The States Parties to the present Covenant undertake to respect the freedom indispensable 
for scientific research and creative activity. 
4. The States Parties to the present Covenant recognize the benefits to be derived from the 
encouragement and development of international contacts and co-operation in the 
scientific and cultural fields. 
4.3.2 Scope and Content 
The drafting history of Article 27 of UDHR 1948 alluded to the lesson from the misuse of 
science and technology by the Hitler regime. 345 The provision also recognizes rights and claims 
related to science and technology in the human rights framework. Article 27 (1) recognized a 
right to benefit from scientific applications and the right to share in scientific advancement and 
its benefits. 346 
ICESCR 1966 was created with the same issue in mind, but it articulated more specific and 
binding human rights norms than UDHR 1948. ICESCR made the most relevant provisions of 
human rights analysis and IPRs in the context ofpharmaceuticals in Article 12 and 15. 
Article 12 of ICESCR established a foundation of international human rights to health as 
mentioned in chapter 2.3, and Article 15 of ICESCR binds state parties to having a system to 
345 International Covenant on Economic, Social and Cultural Rights, 1966, available at 
www2.ohchr.org!english/Iaw/cescr.htm (last accessed on March 19, 2009) 
346 International Covenant on Economic, Social and Cultural Rights, 1966, available at 
www2.ohchr.org!english/law/cescr.htm (last accessed on March 19, 2009) 
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balance between interests of the general public in accessing science and technology and the 
interests of authors and inventors of such science and technology. 
4.3.3 Concluding Summary 
The Committee of Economic, Social and Cultural Rights (CESCR) recogmzes the broad 
significance of the creation, ownership and control of knowledge-based science and technology 
that is protected in the form of IPRs. The allocation of IPRs has significant consequences that 
can affect the enjoyment of human rights in the commercialization and privatization of science 
and technology and the emergence of international IPR protections in the global trading system. 
The balancing of public and private interests works in favor of the IPRs protection of 
pharmaceuticals. Pharmaceutical science and technology were first invented to facilitate the 
innovations into the application of science to broadly benefit members of society from 
individuals, peoples, states and international communities in order to restore the physical and 
mental health of all people. However, due to commercialization and privatization, the 
international IPRs protection has led pharmaceutical science and technology into capitalism. 
Today, the human right to enjoyment of the benefit of pharmaceutical science and technology is 
judged by social and economic factors. The IPRs protection has traditionally offered incentives 
to inventors, but now, the system has become a safeguard mechanism for the returns on 
investment by pharmaceutical corporations, mostly by transnational pharmaceutical corporations. 
General Comment No.l7 of CESCR in 2005 considers that the right to enjoyment of the 
benefit from the invention by authors, in the form of IPRs, must be balanced with the enjoyment 
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of the benefits of scientific progress and its application,347 which is stated in Article 15.1 (b). 
However, this provision still lacks clarity in its definition, and the narrow scope of the right 
suggests slow progress. General Comment No.l7 only focuses on Article 15 (c), rather than the 
Article as a whole. There has been criticism of commentators for failing to take into account the 
complex nature of the relationship between science and technology with IPRs and cultural 
. ht 348 ng s. 
4.4 Disputed Hierarchy of International Law 
There has been vast discussion around whether the international trade laws have to comply with 
international human rights norms. The most important task under international human rights 
norms is to ensure the protection of the rights and applicable standards. 
In the case of pharmaceutical science and technology, the international trade laws in 
intellectual property rights create new opportunities for human beings to become and remain 
healthy; however, the intent to protect the interest of the pharmaceutical products has brought 
unforeseen problems and even threats and undesirable outcome to the international community. 
347 Committee on Economic, Social and Cultural Rights, Human Rights and Intellectual Property: Statement by the 
Committee on Economic Social and Cultural Rights, E/C.12/2001/15, 2001, available at 
http://www2.ohchr.org/english/bodies/cescr/docs/statements/E.C. 12.200 1.15HRintel-property.pdf (last accessed on 
March 19, 2009) 
348 3rdthree Organization, 'Intellectual Property and Human Rights: Is the Distinction Clear Now?: An Assessment 
of the Committee on Economic, Social and Cultural Right' General Comment No.17 (2005) on "The Right of 
Everyone to Benefit From the Protection of the Moral and Material Interest Resulting from any Scientific, Literary 
or Artistic Production of Which he is the Author"', P.3~4, 2006, available at 
www.3dthree.org/pdf 3D/3D GC17 IPHR.pdf(last accessed on March 19, 2009) 
The Chair of the Committee on Economic, Social and cultural Rights, Ms Dandan states the reasons for choosing 
Art.15 (c): Art 15 (c) was most urgent as there was a need to identify the human rights dimensions of IP policy. And 
the work of general comment on Art15 (a) and (b) has begun but is progressing slowly. 
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4.4.1 International Human Rights Norms and International Trade Laws 
The issue of the hierarchies between the international human rights law and international trade 
law has been vigorous discussed.349 Arguments arise as to whether the international trade law 
system can be and should be applied and interpreted in compliance with of the international 
human rights law obligations. The arguments are resolved by some commentators on the issue 
of whether the given human rights norms have achieved the status of jus cogens or obligations 
erga omnes. 350 
The obligations erga omnes and jus co gens are the obligations which are so important in the 
value that state actors have to honor the protection under international law. Obligations erga 
omnes, which mean "towards everyone"351 are a broader general principle which embraced jus 
cogens. In the case of Barcelona Traction (1970), ICJ defines the obligations erga omnes as 
those in which state actors owe a duty to the international community as a whole. "In the view 
of the importance of the rights involved, all States can be held to have a legal interest in their 
protection; they are erga omnes. "352 The Barcelona Traction case gives some examples of the 
types of rights which reached the status of erga omne to obligate the all states including "the 
outlawing of acts of aggression, and of genocide, as also from the principles and rules 
concerning basic rights of the human person, including protection from slavery and racial 
349 
James Harrison, The Human Rights Impact of the World Trade Organization, P.57, Hart Publishing, 2007 
This issue has draws much scholarly attention in recent times in ILC in the "Fragmentation oflntemational Law: 
Difficulties Arising from the Diversification and Expansion of International Law 
350 
James Harrison, The Human Rights Impact of the World Trade Organization, P.56, Hart Publishing, 2007 
351 
Andrew Clapham, Human Rights Obligation of Non-State Actors, P.96, Oxford University Press, 2006 
352 
Barcelona Traction, Light and Power Company, Limited (Belgium v. Spain)(New Application: 1962), available 
at 
httP://www. icj -cij. org/docket/index.php?sum=292&code=bt2&p I =3&p2=3&case=50&k= 1 a&p3=5 (last accessed 
on March 19, 2009) 
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discrimination"353 by giving separate right which gives rise to another to complain about the 
violation. Thus the International Court of Justice (ICJ) specifically confirms that every state 
can complain about the violation of international law when an obligation, which "owed to the 
international community as whole" or "owed to a group of states," is breached354; indicating 
examples as of the obligations erga omnes from slavery, genocide, racial discrimination. 
Although the ILC special Repportteur, James Crawford, points out that human rights obligations 
are either the obligations which are "owed to the international community as whole" or those 
which are "owed to a group of states". 355 He notes that, the classification of obligations is 
depends on the "the universality and significance" and moreover, he adds, human rights treaties 
are plainly, even if not always explicitly designed to protect a general common interests."356 
However, the content of "the principles and rules concerning basic right so f human rights" is not 
very clear. 
There are certain rights and obligations which have very important value to be protected 
under international law. The status of these rights and obligations are high above the 
international legal regime, and are referred to as "jus cogens". Jus Cogens obligations are a 
353 Barcelona Traction, Light and Power Company, Limited (Belgium v. Spain)(New Application: 1962), available 
at 
http://www.icj-cij.org/docket/index.php?sum=292&code=bt2&p 1 =3&p2=3&case=50&k= 1 a&p3=5 (last accessed 
on March 19, 2009) 
354 Andrew Clapham, Human Rights Obligation of Non-State Actors, P.96, Oxford University Press, 2006, and 
International Law Commission, Draft Articles on Responsibility of States for Internationally Wrongful Act, 2001, 
available at 
http://untreaty.un.org/ilc/texts/instruments/english/draft%20articles/9 6 200 l.pdf (last accessed on March 14, 2009) 
Article 48 Invocation of responsibility by a State other than an injured State 
1. Any State other than an injured State is entitled to invoke the responsibility of another State in accordance with 
paragraph 2 if: 
(a) The obligation breached is owed to a group of States including that State, and is established for the protection of a 
collective interest of the group; or 
(b) The obligation breached is owed to the international community as a whole. 
35 
Andrew Clapham, Human Rights Obligation of Non-State Actors, P.97, Oxford University Press, 2006 
356 
Andrew Clapham, Human Rights Obligation of Non-State Actors, P.97, Oxford University Press, 2006 
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subset of obligations erga omnes, which address to the hierarchically superior than obligations in 
obligations erga menes.357 
The Vienna Convention on the Law of Treaties 1969, Article 53358 "Treaties conflicting 
with a peremptory norm of general international law ('jus cogens')" provides, 
[A] peremptory norm of general international law is a norm accepted and recognized by the 
international community of States as a whole as a norm from which no derogation is 
permitted and which can be modified only by a subsequent norm of general international 
law having the same character. 
The principle of jus corgens is given the highest effect of the international legal norms, 
which binds every member of the international community. Any provision in treaties or 
convention is void when contradicting jus cogens. Any actor breaching the jus cogens norms 
cannot claim that he/she is acting pursuant to underlying valid treaty obligations, in the proposed 
issue, the international trade law. Thus, when any human right norms achieve jus cogens status, 
they will trump international trade laws. 359 
Unlike obligations erga omnes, examples of obligations jus cogens are not clearly identified. 
The settled lists of human rights norms which achieved the status of jus cogens may include: 
357 James Harrison, The Human Rights Impact of the World Trade Organization, P.59, Hart Publishing, 2007 
In other words, all obligations jus cogens are obligations erga omnes, but not all the obligations erga omnes are 
obligations jus co gens, 
358 The Vienna Convention on the Law of Treaties, Article 53, 1969, available at 
http://untreaty.un.org/ilc/texts/instruments/english/conventions/1 1 1969.pdf (last accessed on March 19, 2009) 
359 James Harrison, The Human Rights Impact of the World Trade Organization, P.58, Hart Publishing, 2007 
As the author indicated that in theory, if the WTO obligations have reached jus co gens, WTO obligations will trump 
human rights. However, it will be dangerous in the international law practice, especially in the case of WTO law. 
When the WTO law was negotiated by the influence of powerful non-state actors and certain powerful state actors 
and accompany with strong enforcement mechanism, it is difficult to say that once the trade norm will become jus 
cogens, when the norm has being accepted and recognized by the international community. 
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genocide, prohibition of slavery and slave trade, the murder or causing the disappearance of 
individuals, torture, prolonged arbitrary detention, systematic racial discrimination, or a 
consistent pattern of gross violation of international recognized human rights. Lacking 
consensus in the content of human rights in obligations jus cogens has diminished its value to 
solve conflicts and impact of the principle and leaves indeterminate its legal effect.360 
4.4.2 TRIPS and International Human Right to Health 
Article 3.2 of the WTO Understanding the Rules and Procedures Governing the Settlement of 
Dispute361 demands that the WTO agreement to interpret the exiting agreement in accordance 
with customary rules of public international law. 362 In addition, according to the Vienna 
Convention on the Law of Treaties (1969), Article 53, when there is a conflict with a peremptory 
norm of general international law ('jus cogens')", general international law will prevail. 
Whether the human right norms in health have achieved the status of jus cogens is another 
heavily debated argument. In the most settled list of jus cogens, the recognized obligations are 
limited to individual or state negative conducts including stated genocide, torture, and slavery. 
By contrast, the human right norms in health which are beyond the relationship of one individual 
or state actor to another encourage all actors in the international community to protect human 
rights in a positive way, which has been slow to progress. The positive realization of human 
rights is progressing and depends on a state actor's resources to inject the norms into the 
international community. It is very difficult to determine whether the human rights norms 
360 
James Harrison, The Human Rights Impact of the World Trade Organization, P.58-59, Hart Publishing, 2007 
361 
WTO, Understanding on Rules and Procedures Governing the Settlement of Disputes, Article 3.2, available at 
http://www.wto.org/englishldocs e/legal e/28-dsu e.htm (last accessed on March 19, 2009) 
362 
Andrew Clapham, Human Rights Obligation of Non-State Actors, P.166, Oxford University Press, 2006 
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depends on state resources to gradually realizing the right has been achieved in the status of jus 
cogens or not. 
Harrisons provides a similar argument in application to WTO laws. He states that human 
rights norms are obligations which are collective, i.e. owed to all parties in the treaty; but the 
WTO law obligations are reciprocal, i.e. bilateral or multilateral treaties among the member 
states. Some scholar suggests that when these two norms conflict, the human rights norm 
should prevail, but no consensus has been reached. 363 
Some commentators argue that international human rights are the most unique norms under 
international law; thus, at least there are some "core contents" which cannot be violated, even 
with insufficient agreement on the content of some international human rights norms.364 
Though there are still arguments regarding which human right norms have achieved the 
status of jus cogens, there are certain international human rights which should have be viewed as 
having reached this higher level of global recognition. The content of jus cogens grows just as 
human rights law, and with time and environmental changes, its content and protection expands. 
4.4.3 TRIPS and Convention of Biological Diversity 
The United Nations Convention on Biological Diversity marks the beginning of international 
cooperation in recognizing the importance of conservation and sustainable use of biological 
diversity for meeting the needs for food, health and other needs of future generation to access to 
363 James Harrison, The Human Rights Impact of the World Trade Organization, P.60 Hart Publishing, 2007 
364 James Harrison, The Human Rights Impact of the World Trade Organization, P.60 Hart Publishing, 2007 
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and share both the genetic resources and essential technologies. 365 Biological diversity is 
essential to TM, because 90% of TM and TM knowledge involves the use of plants. In order to 
have sustainable use, research and development of TM, there must also be biological diversity of 
genetic resources. 
Convention on Biological Diversity, 1992 
The Earth Summit for the adaptation of the Convention on Biological Diversity (CBD) was held 
in Rio de Janeiro in 1992. CBD embodies the international recognition and acceptance of the 
importance biological diversity. Members started trying to set up principles as to the 
bio-resources as the sole property of sovereign states and to establish that they have the freedom 
to use and trade them, but in a sustainable manner. The Convention also embodies how 
national governments can play a role in ensuring sustainable biodiversity regimes within which 
commerce, resources management and environmental institutions are utilized to prevent 
destruction, extinction, or alienation of biological resources. 366 
The recognition of "property rights" is one such set of incentives under the Convention and 
is aimed at encouraging beneficiaries to continue efforts of conservation and sustainable use of 
biological resources. The "sharing of benefits" that arise from commercialization of genetic 
resources in source countries is another incentive to encourage conservation efforts. 367 
365 Regulatory Situation of Herbal Medicines: A Worldwide Review, by WHO, P.l, 1998, available at 
http://whqlibdoc. who.int/hq/1998/WHO TRM 98.1.pdf (last accessed on March 19, 2009) 
366 CBD, Historical perspectives on the occasion of the lOth Anniversary of the entry into force of the Convention 
on Biological Diversity, available at 
http://www.cbd.int/doc/publications/CBD-1 Oth-anniversary.pdf (last accessed on March 19, 2009) 
CBD, 1992, Article 15, Access to Genetic Resources, available at 
http://www.biodiv.org/convention/articles.shtml?a=cbd-15 (last accessed on March 19, 2009) and 
Padmashree Gehl Sampath, Regulating Bioprospecting: Institutions for Drug Research, Access, and Benefit-Sharing, 
P.35-36, United Nations University Press, 2005 
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CBD implicitly recognize the existence, value and importance of TK in Article 8 G)368, In 
Situs Conservation, which reads as follows: 
Each Contracting Party shall, as far as possible and as appropriate ... 
Subject to its national legislation, respect, preserve and maintain 
knowledge, innovations and practices of indigenous and local communities embodying 
traditional lifestyles relevant for the conservation and sustainable use of biological diversity 
and promote their wider application with the approval and involvement of the holders of 
such knowledge, innovations and practices and encourage the equitable sharing of the 
benefits arising from the utilization of such knowledge, innovations and practices. 
The CBD also provides a scheme of granting incentives at a local level suggesting that 
indigenous and local communities have a right over knowledge, innovations and practices, 
subject to national legislation. It includes that national governments have to provide 
participatory mechanisms for the exercise of the right so that communities can share the benefits 
The CBD reinforces the concept of national sovereignty of genetic resources within country's territory. CBD Article 
15 also requires nationai governments to identify the priority in biodiversity conservation and set up legal rules and 
institutions to govern the bioprospecting. 
368 Including the following provisions: 
--Preamble, paragraph 12: Recognition of the close dependence of indigenous and local communities on biological 
resources and the desirability of sharing equitably benefits arising from the use of traditional knowledge, 
innovations and practices relevant to the conservation ofbiological diversity and the sustainable use of its 
components ( 
--Preamble, paragraph 13: Recognition of the vital role that women play in the conservation and sustainable use of 
biological diversity and the need for their full participation at all levels of policy-making and implementation 
-- Article 1: The objectives of the Convention, namely, the conservation of biological diversity, the sustainable use 
of biological resources and the equitable sharing ofbenefits from the use of these resources 
--Article 8 (j): The undertaking of Parties to respect, preserve and maintain TK, innovations and practices relevant 
to the conservation and sustainable use of biological diversity; to promote their wider application with the approval 
and involvement of the holders of such knowledge; and to encourage the equitable sharing of benefits arising from 
the application of such knowledge, innovations and practices 
-- Article 10 ( c )Protecting and encouraging customary use of biological resources in accordance with traditional 
cultural practices 
--Article 17.2: The exchange of information relevant to the conservation and sustainable use ofbiological diversity 
to include, inter alia, indigenous and traditional knowledge 
--Article 18.4: In cooperation for the development and use oftechnologies, the inclusion of indigenous and 
traditional technologies relevant to the pursuit of the objectives of the Convention 
- 154-
[rom the commercialization of their resources. Many countries are now implementing Article 8 
G) through their national plans, strategies and programs. A number of governments have 
adopted specific laws, policies and administrative arrangements for protecting traditional 
knowledge, emphasizing that prior informed consent must be obtained before bio-prospecting. 369 
CBD also refers to traditional knowledge as including "indigenous and traditional 
technologies" in Article 18.4, which reads as follows: 
The Contracting Parties shall, in accordance with national legislation and policies, 
encourage and develop methods of cooperation for the development and use of technologies, 
including indigenous and traditional technologies, in pursuance of the objectives of this 
Convention. For this purpose, the Contracting Parties shall also promote cooperation in the 
training of personnel and exchange of experts. 
Conjoining Article 8G) and Article 18.4, "traditional knowledge, innovations and practices" 
means not only the protection of such knowledge, innovation and practices by appropriate legal 
and administrative means of protections, but also the respecting, preserving and maintaining of 
such knowledge, innovation and practices in accordance with Article 8 G). 
CBD Article 15 ( 1 ), Access to Genetic Resources, establishes property rights, from open access 
369 CBD, 1992, Article 8 G): Traditional Knowledge, Innovations and Practices, Introduction, available at 
http://www.biodiv.org/programmes/socio-eco/traditional!default.shtml (last accessed on March 19, 2009) and 
CBD, Article 8 G): Traditional Knowledge, Innovations and Practices, Article 8 G) after COP 7, available at 
http://www.biodiv.org/programmes/socio-eco/traditional/akwe.aspx (last accessed on March 19, 2009) 
In the seventh meeting of the conference of the Parties in 2004, the COP 7 adopted Akwen: kon guidelines for 
governments to initiate a legal and institutional review. The COP7 also considered using sui generis systems for the 
protection of traditional knowledge, innovations and practices. The issues are considered as follows: 
-Consider non-intellectual-property-based sui generis forms of protection; 
- Further develop, as a priority issue, elements for sui generis systems; 
-Review the relevance and applicability of the Bonn Guidelines; 
- Make recommendations regarding the international regime on access and benefit-sharing; 
-Assess the role of databases and registers in the protection of traditional knowledge; and 
-Explore, existing as well as new forms of intellectual property protection. 
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to materials at an international level, to a common property resource at the national level, on 
genetic resources, stating that "[r]recognizing the sovereign rights of States over their natural 
resources, the authority to determine access to genetic resources rests with the national 
governments and is subject to national legislation." Some sub-provisions of Article 15 provide 
the designing mechanisms to regulate the access.370 
However, realization of biodiversity conservation is far more complex, because the 
Convention's most important points are a departure from earlier international environmental 
agreements in that they recognize that conservation and the sustainable use of biological 
diversity can only be tackled when the subject matter is defined within an economic context. 
CBD Article 80) calls for respect, preservation and maintenance of traditional knowledge that is 
associated with biodiversity at the national level and contains an obligation to support and further 
advance TK in the context of conserving biological diversity; it does not contain a legal basis for 
creating an individual right nor any legal protection in the sense of establishing, exclusive, 
enforceable proprietary rights over the traditional knowledge.371 Moreover, the CBD embodies 
the concept of benefit-sharing in both general and specific ways in several provisions,372 but 
there are still big gaps in between.373 Yet, unlike the WTO, the provisions in the CBD impose a 
37° CBD, 1992, Article 15, available at 
http://www.cbd.int/convention/convention.shtml (last accessed on March 19, 2009) 
371 
Padmashree Gehl Sampath, Regulating Bioprospecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, P. 36, United Nations University Press, 2005 
Though CBD has recognized TK and provided mechanisms and broad-based measures on biological diversity, it 
does not specifically prioritize the measures nor it provides nor does it provide details, thus leaving member states 
with a lot of flexibility to implement its framework. 
372 Provisions relate to benefit sharing: Article I, "fair and equitable sharing of benefits"; Article 16, access and 
transfer of technology; and Article 19, handling ofbiotechnology and distribution of its benefits. 
373 
Padmashree Gehl Sampath, Regulating Bioprospecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, P. 38-39, P.50-51, United Nations University Press, 2005 
Although countries will be compensated for the use of genetic resources, the Convention does not codify the 
relationship between the generation of revenues through such activities and biodiversity conservation in a direct way. 
Secondly, the Convention does not define "appropriate" compensation for the use of genetic resources. Lastly, 
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weak, fragile obligation on the proprietors, mostly pharmaceutical companies, to ensure the 
exchange of the genetic resources, and the associated traditional knowledge are under the 
protection of the provisions of the convention and guaranteed equitable returns. 
The biggest problem of the CBD is that it "lacks contextualization to local eco-political 
circumstances and its integration across local, regional, commercial and environmental frontiers 
has been lax. "374 CBD left optimal national legal frameworks for bio-prospecting. The lack 
of clarity of the terms in CBD and the diverse political ambitions of countries had led to less than 
full implementation of its provisions.375 Not only has the policy on the meaning and import of 
theses provisions been polarized among countries of the South and the North, but the issues are 
made even more complicated by the TRIPS Agreement. TRIPS deals with the intellectual 
property rights within the Member States, including the pharmaceuticals, public health, access, 
traditional knowledge and benefit sharing that are the subject of the CBD. The issues fall on 
the relationship between TRIPS and CBD, the regulation of bio-prospecting on drug research 
though specific forms of benefit-sharing is mentioned, the Convention does not provide guidelines as to which form 
of benefits should be shared under what circumstances, which leave a lot of rooms for countries to deliberate 
amongst themselves. 
The language and interpretation in Article 15 of benefit-sharing is ambiguous, especially the prior informed consent 
(PIC) and Mutually Agreed Terms (MAT), scholars fear that the PIC process and benefit-sharing provisions may end 
up as a 'rent-seeking' process. Moreover, developing countries ask transfer of technology as reads in CBD Article 16, 
but developed countries only respond with the obligation to provide or facilitate access of and transfer of 
technologies related to access, conservation, and sustainable use of the genetic resources or traditional knowledge. 
Accompanying with the economic value of the drug research based on the genetic resources and traditional 
knowledge, developing source countries argue for the benefit sharing on the intellectual property rights lead to the 
exploitation of the resources or traditional knowledge, but developed, user countries tend to think that the payment 
shall be related to the potential or actual harm caused, which is the use of the genetic resources or traditional 
knowledge. This issue has not been settled. 
374 Padmashree Gehl Sampath, Regulating Biopropecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, P.3, United Nations University Press, 2005 
375 Padmashree Gehl Sampath, Regulating Biopropecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, P.45, United Nations University Press, 2005 
"One ofCBD's problems lies in the way in which its worthwhile goals are to be implemented. They are vague, 
ambiguous or impotent. As a result, it is very ambitious attempt to integrate 'previously distinct policy goals' in the 
CBD is on the verge of a failure. Key provisions such as Article 8 G), Article 15 and Article 16 are being used out of 
context and in isolation from the rest of the Convention: Many of reasons lie in the politics that divide 
genetic-resource-rich source (yet developing) countries and technology-rich (but developed) countries." 
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based on genetic resources and traditional knowledge. There are also splits of stakeholders, the 
resources rich countries, towards the access and benefit sharing on genetic resources and 
traditional knowledge. One group of countries stands for the conservation of the genetic 
resources and traditional knowledge and another group focuses on benefit sharing. How to 
balance the interests in between and how to reach the needs and expectation of genetic resources 
or TK holders has become a tough task. The design of successful legal instruments for the 
protection and realization of the economic potential and economic commercial value of genetic 
resources and traditional knowledge depends on how to get a consensus between these three 
main interests groups for the R&D in the pharmaceutical sectors.376 
Another major difficulty faced by CBD, in common with many international treaties, is that 
CBD obligations bind states as contracting parties but confer no rights and obligations on private 
entities such as research institutes, pharmaceutical companies and indigenous communities?77 
Without specific and effective national laws and regulations, governments have little power to 
enforce the provisions in the Convention. Currently, the access and benefit-sharing are left to 
contracts between the bio-prospectors, mostly firms and scientific institutes, and public 
authorities in the sources countries. This contractual approach has several disadvantages which 
act against the original purpose of the Convention.378 
376 
Padmashree Gehl Sampath, Regulating Biopropecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, P.4-5, United Nations University Press, 2005 
377 
Sohpia Twarog and Promila Kapoor edited, UNCTAD, Protecting and Promoting Traditional Knowledge: 
Systems, National Experiences and International Dimensions, P. 99, 2004, available at 
www.unctad.org/en/docs/ditctedlO en.pdf(last accessed on March 19, 2009) 
378 
Sohpia Twarog and Promila Kapoor edited, UNCTAD, Protecting and Promoting Traditional Knowledge: 
Systems, National Experiences and International Dimensions, P. 99, 2004, available at 
www.unctad.org/en/docs/ditcted10 en.pdf (last accessed on March 19, 2009) 
The original right holders of genetic resources and traditional knowledge often is not included in the contract, thus, 
they have no information and participation in the negotiation in the terms of contract and profit results wherefrom. 
Moreover the agreements are made as "package", where have little bargaining power on it. 
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So far, most of the developing countries, mainly TM/TMK holder countries, have not yet 
enacted laws to implement the resolution passed at the CBD. Although with the recognition of 
traditional medicine by most countries would help to improve the traditional medicine and 
knowledge and allow those countries to work closely to tackle some problems of intellectual 
property rights relating to traditional knowledge and medicine, the majority of the problems still 
exists. 
The purpose of CBD is to promote more equitable use and exchange of genetic resources 
under ethical and legal norms to share the benefits among interested parties. It tries to reach a 
balance between the two sides for both the needs of technologically advanced countries and 
biologically endowed countries. Companies within pharmaceutical, crop-protection, seed and 
biotechnology industries appear to be the most likely to acknowledge the CBD.379 However, 
most companies are increasingly using contractual agreements380 to clarify their own rights and 
379 Saraha A. Laird, Biodiversity and Traditional Knowledge: Equitable: Partnerships in Practice, P.279, Earthscan 
Pubns Ltd, 2002 
Companies are responding the awareness of CBD by changing business practice. 
The most common responds include: 
-A decrease in corporate collecting activities; consolidation of collecting programmes into fewer countries, or ever 
solely domestic-collecting activities; 
- Greater recourse to material from ex-situ collections, such as culture collections and compound libraries, in place 
of samples acquired through field-collecting activities; 
-An increased role for intermediaries as brokers of access and benefit-sharing relationships, as well as suppliers of 
samples; 
- The increasing use of material transfer agreements to clarify the terms of exchange; and 
-The development of basic standards of benefit-sharing best practice to guide staff within companies-for example, 
through policies and internal guidelines. 
380 
Saraha A. Laird, Biodiversity and Traditional Knowledge: Equitable: Partnerships in Practice, P.286, Earthscan 
Pubns Ltd, 2002 
Most of the contractual agreements are used for identifying parties, defme the subject matter, specify uses and 
compensation, technological or in-kind basis, regulate rights over intellectual property in the event to development 
and marketing of products and define the period of the agreement and conditions for termination and provision 
containing breach of contract and the choice of law. The forms and terms of contracts may be varied, for example, 
contracts for the sale of raw material, material transfer agreements, licensing regimes and memoranda of 
understanding. 
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'b'l' . 381 respons1 1 1t1es. It is common to see provisions comprising a "package" of monetary and 
non-monetary benefits, and most of the time the right holders cannot negotiate fair terms for 
access and benefit-sharing. 382 
CBD established the obligation of protection and conservation of genetic resources, but 
leaves the legislation and content of this obligation to member states. Many member states 
have ratified the CBD, but do not have national laws governing access to TM/TK and the sharing 
of benefits from its use, leaving TM/TK and genetic resources in the public domain.383 
The Link and Interaction between TRIPS and CBD 
TRIPS Article 27.3 (b) and the provision of the CBD dealing with access to TK and 
benefit-sharing interact in two major ways. First, the interaction between intellectual property 
rights and traditional knowledge raises the issue of whether current intellectual property rights 
system can provide a satisfactory mechanism for protecting TK, and whether current intellectual 
property rights systems dealing with on biotechnological inventions aid the appropriation of 
traditional knowledge.384 The second interaction relates to the CBD Article 16, transfer of 
381 WIPO engages in the works of the Draft Intellectual Property Guidelines for Access and Benefit-Sharing 
Contracts. 
382 Professor Anil K. Gupta prepared, WIPO-UNEP Study on the Role of Intellectual Property Rights 
in the Sharing of Benefits Arising from the Use of Biological Resources and Associated Traditional Knowledge, P.64, 
available at 
www.wipo.int/tk/en/publications/769e unep tk.pdf (last accessed on March 19, 2009) 
Mgbeoji states that the contract model neglects the immense asymmetry in the negotiating power of commercial 
firms and local people, accompanying by the problems of privacy of contract and places undue trust in the 
bureaucracy overseeing licensing arrangements. 
383 Sophia Twarong and Promila Kapoor edited, UNCTAD, Protecting and Promoting Traditional Knowledge: 
Systems, National Experiences and International Dimensions, P.99, 2004, available at 
www.unctad.org/en/docs/ditctedlO en.pdf(last accessed on March 19, 2009) 
CBD established the obligation of protection and conservation of genetic resources, but leaves the legislation and 
content of obligation to member states. Many member states have ratified fir the CBD, but do not have national 
legislations governing the access to TK and the sharing of benefits from its use, the TK and genetic resources, then 
remains in the public domain. 
384 Padmachree Gehl Sampath, Regulating Biopropspecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, P.43, United Nations University Press, 2005 
Some of the genetic sources countries, communities and NGOs have been concerned about that intellectual property 
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technology, including biotechnology. It is unclear whether transfer of technology is a form of 
benefit sharing as defined in CBD Article 16 (1)385 . 
The intellectual property protection on some potential medicinal plants or some other genetic 
resources may make possible capitalization and provide incentives to some groups of users, but 
not as to the rest of genetic resources which has less economic value. In the mean time, CBD 
Article 16 ( 5)386 does recognize that cooperation to ensure the protection of intellectual property, 
but the protection of intellectual property cannot undermine the objectives of the CBD. The 
most discussed potential conflicts involve the relationship between the demands of drug research, 
compensation, and the prohibition on unsustainable use of genetic resources. Groups, 
communities, or source countries have different perceptions on whether genetic resources or 
traditional knowledge based on medicinal products should be protected under the intellectual 
property rights system and to what extent. 
Without resolving these issues, such as the roles, the rights and responsibilities for the users 
and providers of TM, it will be more difficult to protect and promote TM systems, hindering their 
ability to contribute to drug research and public health. 
system, especially TRIPS, encourages privatize and patent the genetic resources itself or traditional knowledge 
without any obvious intellectual contribution, and not even compensation. Cases are many, the famous 
misappropriation ones such as, patent on traditional knowledge on the uses of turmeric, ayahuasca and neem. 
385 CBD, 1992, Article 16 (1 ), available at 
http://www.biodiv.org/conventionlarticles.shtml?a=cbd-16 (last accessed on March 19,2009 
Each Contracting Party, recognizing that technology includes biotechnology, and that both access to and transfer of 
technology among Contracting Parties are essential elements for the attainment of the objectives of this Convention, 
undertakes subject to the provisions of this Article to provide and/or facilitate access for and transfer to other 
Contracting Parties of technologies that are relevant to the conservation and sustainable use of biological diversity or 
make use of genetic resources and do not cause significant damage to the environment. 
386 CBD, 1992,Article 16 (5), available at 
http://www.biodiv.org/convention!articles.shtml?a=cbd-16 (last accessed on March 19, 2009) 
The Contracting Parties, recognizing that patents and other intellectual property rights may have an influence on the 
implementation of this Convention, shall cooperate in this regard subject to national legislation and international law 
in order to ensure that such rights are supportive of and do not run counter to its objectives. 
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The relationship between TRIPS and CBD is defined by three interpretations. The first 
holds that there is inherent conflict between the two. Another view perceives no such conflict, 
finding instead mutual support for each framework's provision. Finally, a third interpretation 
views no inherent conflict, but sees the potential for conflict in implementation, requiring 
international action to ensure that TRIPS and CBD are implemented in a mutually-supportive 
fashion. 387 
CBD Article 8 contains the general principle that the sui generis right should not interfere 
with the minimum standards of intellectual property rights and should not result in the 
complications that may result in less compliance with the terms of the Agreement. Sampath 
believes that CBD Article 8 (a)388 includes the general accepted "public interest" principle, 
which allows the member states to adopt laws, regulations and measures necessary to the 
protection of public health. 389 
Many source countries propose that TRIPS can implement the CBD in the content of 
genetic resources and TK protection. Because the TRIPS Agreement was adopted after CBD 
and is more specific in its terms regarding intellectual property protection, under Article 30 of the 
Vienna Convention of the Law of Treaties, 1969, it will prevail if there is a conflict in intellectual 
387 Padmachree Gehl Sampath, Regulating Biopropspecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, United Nations University Press, 2005 
388 CBD, 1992, Article 8 (a), available at 
http://www.biodiv.org/convention/articles.shtml?a=cbd-08 (last accessed on March 19, 2009) 
Each Contracting Party shall, as far as possible and as appropriate: 
(a) Establish a system of protected areas or areas where special measures need to be taken to conserve 
biological diversity; 
389 Padmachree Gehl Sampath, Regulating Biopropspecting: Institutions for Drug Research, Access, and 
Benefit-Sharing, United Nations University Press, 2005 
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property protection.390 
4.4.4 Concluding Summary 
Since there is no content addressed to issues of the right to the enjoyment of the benefit of 
scientific progress and its application directly, the enjoyment of the benefit and application of 
pharmaceuticals remains untouched by international instrument. 
Due to difficulties in formulating these rights, the international community has consistently 
delayed developing a system for the specific definition, scope, and enforcement of the right to 
enjoy the benefits of scientific progress and the application of pharmaceutical research. 
With economic globalization and the increasing privatization and commercialization of 
pharmaceutical-related science and technology, it has become more difficult to achieve the goal 
of accessibility and affordability of pharmaceuticals. 
The IPRs system is turning away from its original intent to encourage R&D in order to have 
more inventions to benefit the human populations, and today the system has evolved to serve the 
commercial and economic interests of global pharmaceutical corporations. IPR system should 
include human rights norms to safeguard the benefit of the inventors and the users of the 
inventions and the sustainable development of bio-prospering and benefit sharing of bio-diversity. 
The type and level of protections should be applied in a manner that will broadly benefit 
members of society both individually and collectively, especially in the context of 
390 Vienna Convention ofthe Law ofTreaties, 1969, available at 
htt_p://untreaty.un.org/ilc/texts/instruments/english/conventions/1 1 1969.pdf (last accessed on March 19, 2009) 
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pharmaceuticals. A right to benefit from science and technology assumes that both individuals 
and communities will have to be easy access.391 
Dr Margaret Chan, Director-General of the WHO, has noted that "[p]ublic health cannot 
move forward without innovation. The need for innovation is constant." She also notes that 
"the price of medicines and other products can be prohibitive, effectively blocking access to 
care. "392 She acknowledges that the price of medicines is one of the several factors which 
influence the availability, accessibility, acceptability and quality of pharmaceuticals. Appropriate 
funding and incentive mechanisms are needed to research and develop accessible, available, 
acceptable and quality pharmaceuticals, especially for the diseases disproportionately affecting 
the populations of developing countries. The international human right to health will be 
difficult to realize without equitable access to life-saving and health-promoting interventions for 
the price of medicine. 393 
4.5 Conclusion 
"Health" is a human rights issue that covers a very wide range of other issues. The definition of 
'the right to health' has been seen in many international treaties, declarations and documents, 
however, how to recognize, respect, protect and fulfill the right to health in the availability, 
accessibility of pharmaceuticals still remains complex and contentious. 
391 Audrey R. Chapman, WIPO Panel Discussion on Intellectual Property and Human Rights, 1998, available at 
www. wipo.int/tk/enlhr/paneldiscussion/papers/pdfi'chapman.pdf (last accessed on 1 Mar 2008) 
392 WHO, Dr. Margaret Chan, Director-General of the World Health Organization, Opening Remarks at the second 
session of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property, 2007, 
available at 
www.who.int/dg/speeches/2007/20071105 igwg/en/print.html (last accessed on March 19, 2009) 
393 WHO, Dr. Margaret Chan, Director-General of the World Health Organization, Opening Remarks at the second 
session of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property, 2007, 
available at 
www.who.int/dg/speeches/2007/20071105 igwg/en/print.html (last accessed on March 19, 2009) 
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While the conceptual uncertainty and political sensitivity of the international human right to 
health has left the sick and the needy behind, we, as actors in the international community, 
should give consideration to both the protections of R&D and the human right to accessible, 
available, acceptable and good quality pharmaceutical-related products. The IPRs system 
serves a social function. The IPRs protection should serve the objective of protecting 
individual well-being to the extent of the highest attainable level ofhealth. 
Chapter 5: Change 
5.1 The Changing World and the Expansion of International Human Rights Law 
The global economy has influenced the status of health and also affects many human rights and 
health issues. Globalization promotes the transnational activities of individuals, nation states 
and non-state actors. As this process occurs, international human rights are also developing to 
adapt to this globalized world. 
5 .1.1 Expanding Scope of International Human Rights Law 
The traditional concept of human rights is that they are universal, indivisible and interdependent, 
interrelated, 394 and cultural. 395 
394 WHO, 25 Questions & Answers on Health & Human Rights, P.7, 2002, available at 
http://www.who.int/hhr/NEW378710MSOK.pdf(last accessed on March 19, 2009) 
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Human rights protection is universal regardless of cultural differences,396 and applies to all 
human being around the world, regardless of whom they are or where they live. Human rights 
inhere in each human being. The rights protect individuals and groups from violation and 
interference by acts or omissions. They treat all people as equal by following the principle that 
all human beings are born free and equal in rights and dignity. 397 
The principle of indivisibility recognizes that no human being is inherently inferior to any 
other. Economic, social and cultural rights must be respected and recognized as being on the 
same footing as civil and political rights. The principle of interdependence recognizes the 
difficulty of realizing human rights when any human right is neglect, isolated, or discriminated 
against without justification. Human rights are interrelated to one another. The right to a safe 
and healthy life is more important to most people than others, and efforts to realize international 
human rights should be made only after considering all rights as a whole, but allowing for 
prioritization as necessary in accordance with human rights principles.398 
Due to the positive character of economic and social rights, the civil and political rights 
protections are included in most nation states' constitutions; by contrast, the economic, social and 
395 Sompong Sucharitkul, 'A Multi-Dimensional Concept of Human Rights in International Law', 62 Notre Dame L. 
Rev. 305, 1987 
396 United Nations, Frequently Asked Questions on a Human Rights-Based Approach to Development Cooperation, 
P.5, 20066, available at 
http://www.ohchr.org/Documents/Publications/FAQen.pdf(last accessed on March 19, 2009) 
International human rights are universally recognized and cannot allow culture difference in the respect, protection 
and fulfillment, but in the practical implementation and adaptation to different cultural contexts. 
397 Sompong Sucharitkul, 'A Multi-Dimensional Concept of Human Rights in International Law', 62 Notre Dame L. 
Rev.305, 1987 
398 Sompong Sucharitkul, 'A Multi-Dimensional Concept of Human Rights in International Law', 62 Nortre Dame 
L.Rev.305, 1987 
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cultural rights are generally framed in much softer terms. 399 Some parts of economic, social 
and cultural rights have not yet established internationally-recognized measures and steps to be 
included in the constitutional contexts. Socio-economic factors influence this process to a great 
extent, and even though some human rights have been recognized, often nation states cannot 
move forward because of a lack of resources. 
5.1.2 The Expanding Right Holders of International Human Rights 
Traditionally, human rights protection is between the individual and state governments. Human 
rights are primarily the rights of individuals.400 Each nation state should be responsible for 
respecting and promoting human rights. By ratifying the international human rights treaties, 
nation states will be obligated under international law to enrich their domestic national laws. 
International and national obligations require transparent, effective and accessible mechanisms of 
accountability for the protection of human rights. 401 
On the other hand, human rights primarily create obligations on nation states. The Vienna 
Declaration and Programme of Action adopted at the World Conference on Human Right, " .. .it 
is the duty of States, regardless of their political, economic and cultural systems, to promote and 
protect all human rights and fundamental freedoms."402 
Within the context of globalization, human rights protection should not be limited to only 
399 Christian Tomuschat, Human Rights: Between Idealism and Realism, P.38, Oxford University Press, 2004 
400 Sompong Sucharitkul, 'A Multi-Dimensional Concept of Human Rights in International Law', 62 Notre Dame L. 
Rev. 305, 1987 
401 Paul Hunt, 'Neglected Diseases, Social Justice and Human Right: Some Preliminary Observations', 2003, P.5, 
2003, available at 
http://www.who.int/hhr/working paper4 neglected%20diseases.pdf (last accessed on March 19, 2009) 
402 WHO, 25 Questions & Answers on Health & Human Rights, P.7, 2002, available at 
http://www.who.int/hhr/NEW37871 OMSOK.pdf (last accessed on March 19, 2009) 
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individuals but should also include collective groups of people. 403 When the violation of 
individual rights cumulates into the violation of peoples' rights, there should be collective or 
group's right404 to hold the state actors or non-state actors responsible and/or accountable. 
Applying this principle to the right to health, the right should not be limited to individual 
human rights only, but when the health problems or conditions have become so pervasive as to 
constitute a violation against an entire group, collective rights should exist to combat the 
violation. When a threat to individual health may cumulate into a threat to public health, when 
the individual's illness has turned into an epidemic or outbreak of infectious diseases or serious 
chronic diseases or pollution of the health determinants, here, the core of the right to health is 
violated. Moreover, when the pharmaceuticals or medical services are not affordable and 
accessible, the issue will then become a public health concern. The individual problems can add 
up to collective problems. 
5.1.3 The Expanding Subjects oflnternational Human Rights Law 
As mentioned, human rights primarily focus on the relationship between individuals and nation 
states. Globalization has affected not only state actors but also non-state actors, particular 
. 1 . 405 transnatwna corporatiOns. The promotion and protection of human rights should not be 
403 The term collective or group rights usually refer to the rights of peoples and groups. Human rights claims are 
more effective by peoples and groups. 
404 The later developed concept of collective, groups' or peoples' rights have been reflected in some regional human 
ri~hts regimes404, but not yet in international human rights instruments. 
40 Office of the United Nations High Commissioner for Human Rights, Globalization-Business and Human 
Rights, available at 
http://www2.ohchr.org/english/issues/globalizationlbusiness/index.htm (last accessed on 1 Mar 2008) 
The international community intervenes of the human rights protection mostly in the situations of natural disasters to 
make the goods and services available under the special conditions. And also 
Andrew Clapham, Human Rights Obligations of Non-State Actors, 2006, P.8 
As Professor Andrew Clapham emphasis, "[a]nalysing globalization highlights change and developments in various 
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bounded by the frontiers of national states. Both state actors and non-state actors should be 
responsible and accountable for creating, promoting and maintaining international human right 
norms. 
As the promotion and realization of international human right norms progresses, greater 
.. 1 .. 'd406 mtematwna cooperatiOn Is requue . The international cooperation of every actor in this 
international community might be able to progressively achieve realization the right on a global 
scale. 
5.1.4 Concluding Summary 
The emerging global economy has brought explosive changes and challenges to the world. The 
process of globalization has changed the interaction of individuals and groups across certain 
boundaries. The most problematic issue might be that the application and practice of the 
current international human rights does not meet with the demands of the globalized world. 
The former Secretary-General ofthe United Nations, Kofi Annan, has underscored that 
the pursuit of development, the engagement with globalization, and the management of 
change must all yield to human rights imperatives rather than the reverse. Respect for 
human rights, as proclaimed in the international instruments, is central to our mandate. If 
we lose sight of this fundamental truth, all else will fail. 407 
sectors- but human rights abuses are committed by legal entities, not by an abstract phenomenon named 
globalization." 
406 WHO, 25 Questions & Answers on Health & Human Rights, 2002, P.l5, available at 
http://www.who.int/hhr/NEW378710MSOK.pdf(last accessed on I Mar 2008) 
As reflected in Article 2 of ICESER, which states that nation states need to "take steps, individually and through 
international assistance and cooperation, especially economic and technical, to the maximum of its available 
resources, with a view to achieving progressively the full realization of the rights recognized [herein]???" 
Additionally, "international action for the achievement of the rights ... includes such methods as ... furnishing of 
technical assistance and the holding of regional meetings and technical meetings for the purpose of consultation and 
study organized in conjunction with the Governments concerned." 
407 WHO, 25 Questions & Answers on Health & Human Rights, P.24,2002, available at 
http://www.who.int/hhr/NEW37871 OMSOK.pdf (last accessed on March 19, 2009) 
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Globalization is increasing the flow and movement of money, goods, services and people 
across national borders. It also has also complicated the relationship between state actors and 
non-state actors. The process of globalization has brought benefits to many people and 
countries in the form of a better life and awareness of human rights protection. However, the 
effect of the process has also been to deny many people equality in the access to markets, 
information and essential goods, such as life saving pharmaceuticals and medical equipment. 
It has been recognized that the development of human rights protection needs a more 
friendly and favorable environment; however, the expanding scope and application of 
international human rights protections have not received a very clear profile. Not only must the 
concept of international human rights be expanded, but new entities or power associations must 
be included in order to build a proper framework and a network of institutions. 
International law is living, growing, and developing, especially in the area of international 
human rights protection. International human rights protections must prepare to face the 
changing and challenging globalized world. 
5.2 Responsibility and Accountability in the International Human Rights to Health 
Legal recognition of the right to health will give rights to the holders and legal responsibility and 
accountability to the obligors. Legal responsibility is closely linked to the notion of entitlement. 
Action or omissions done by either state actors or non-state actors which cause harmful 
consequences or damages could result in responsibility and accountability. The legal 
recognition of the human right to health is the prerequisite of legal responsibility. With the 
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legal recognition of the right to health, persons and peoples will be able to claim human 
rights-based remedies in cases of violations of or neglect to the right to health. 
The primary human rights obligation rest with the state actors, as state actors are subjects of 
international law and the decision makers in international law. State actors have human rights 
responsibility and accountability to ensure protection and prevent threats from others, including 
both other state actors and non-state actors. The realization of the international human rights 
still requires international co-operation between state actors and non-state actors.408 
5 .2.1 State Actors 
State actors which ratify the treaties for human rights protection in the right to health assume 
responsibility and accountability. Article 2 of International Covenant of Economic, Social and 
Cultural Rights imposes obligations on nation states specify that "states are a party to take 
steps ... with a view to achieving progressively the full realization of the rights recognized in the 
present Covenant."409 The provision sets out the general legal obligation of States in relation to 
the various covenant rights, including the right to health in Article 12. The General Comment 
No.3 of the Committee of ICESCR in 1990 also confirms that state parties have core obligation 
to ensure the satisfaction of at the very least, minimum essential level of protection for each of 
the rights. 410 
408 Sompong Sucharitkul, 'The Right to Food and Freedom from Hunger in the Past Sixth of a Century', P.4, 1993 
http://dialnet. unirioja.es/servlet/articulo?codigo=20214 72 (last accessed on March 20, 2009) 
The protection of human rights in the common concern and primary responsibility of every State as well as the 
collective obligation of the international community. 
409 International Covenant on Economic, Social and Cultural Rights (ICESCR), 1966, available at 
http://www.unhchr.ch/html/menu3/b/a cescr.htm (last accessed on March 19, 2009) 
410 ICESCR, General Comment No.3, 1990, available at 
http://www. unhchr.ch/tbs/doc.nsf/(Symbol)!94bdbaf59b43a424c 12563ed0052b664 ?Opendocument (last accessed on 
March 19, 2009) 
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Nation states' accountability and responsibility based on international human rights is 
confirmed in the General Comment No.14 of the Committee on Economic Social and Cultural 
Rights.411 The comment addresses the state governments' obligation first to require state actors 
to respect, protect and fulfill the obligation. The duty to respect the right to health requires 
states to refrain from interfering directly or indirectly with the enjoyment of the right to health, 
both in the context of pharmaceuticals and in other contexts affecting preconditions to health. 
The duty to protect requires states to take measures in preventing non-state actors from 
interfering with the right to health in health services such as pharmaceuticals. The duty to 
fulfill requires states to adopt appropriate legislative and administrative measures in promotion 
and full realization of the right.412 
It is obvious that both states and non-state actors must act vigorously in international human 
rights protection in the context of health. In the neglect or non-compliance with human rights 
norms, the term "abusing" is usually used instead of"violation."413 
In the General Comment No.l4 of the Committee on Economic Social and Cultural Rights, 
the term "violation" is used for non-state actors. Moreover, the General Comment makes clear 
that states' obligation includes omission or failure to regulate the activities of individuals, groups 
or corporations to prevent them from violating the right to health. 
411 ICESCR, General Comment No.l4, 2000, available at 
http://www. unhchr.ch/tbs/doc.nsf/(Symbol)/40d00990 1358b0e2c 1256915005090be?Opendocument (last accessed 
on March 19, 2009) 
412 CESER, The Right to the Highest Attainable Standard of Health, General Comment No.14, available at 
www.unhchr.ch/tbs/doc.nsf/(symbol)/E.C.12.2000.4.En?OpenDocument (last accessed on March 15, 2009) 
413 Professor Andrew Clapham and Mariano Garcia Rubio, The Obligation of States with Regard to Non-State 
Actors in the Context of the Right to Health, 2002, P.l, available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf(last accessed on March 15, 2009) 
"Violation" usually refers to the misconduct by governments, so as to avoid greater recognition and undue status to 
non-state entities. 
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State Responsibility held by the State Itself 
The right to health requires health policies to ensure the accessibility, availability, acceptability 
and quality facilities, goods and services related to the underlying determinants of health. The 
section addressing accessibility (affordability) states in part that payments for health-care 
services, as well as services related to the underlying determinants of health, has to be based on 
the principle of equity, ensuring that these services, whether privately or publicly provided, are 
affordable for all, including socially disadvantaged groups.414 
The accessible, available, acceptable and of quality medicine is the main issue related to 
trade. Professor Paul Hunt recommends that states are obligated to ensure that pharmaceutical 
products are:415 
- Available: state has to have health policy in making medicine available within its territory by 
using, where appropriate TRIPS flexibilities, such as compulsory licenses and parallel imports. 
- Accessible: state has to ensure that essential medicine is not only available in the jurisdiction, 
but also accessible to all. The accessibility has four dimensions: non-discrimination, physical 
accessibility, economic accessibility (affordability) and information. 
- Quality: states need to have monitoring system to ensure good quality of medicines, 
and to prevent counterfeit, contaminated and sub-standard drugs. 416 
414 CESER, General Comment No.14, available at 
http://www. unhchr.ch/tbs/doc.nsf/(Symbol)/40d00990 1358b0e2c 1256915005090be?Opendocument (last accessed 
on March 20, 2009) 
415 Paul Hunt, The Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental 
Health, Mission to the World Trade Organization, 2004, P.1 0-11 
http://www. unhchr.ch/Huridocda!Huridoca.nsf/(Symbol)/E.CN .4.2004.49 .Add.1.En?Opendocument (last accessed 
on March 20, 2009) 
416 ICESER, General Comment No.14, P.3, available at 
www. unhchr.ch/tbs/doc.nsf/(symbol)/E.C.12.2000.4.En?OpenDocument (last accessed on March 19, 2009) 
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States have an obligation to take steps necessary for the development and diffusion of 
science for the prevention, treatment and control of diseases. State responsibility in promoting 
the highest attainable physical and mental health is achieved through the establishment of health 
care system. 
It is individual nation state's responsibility to provide for health care needs through the 
public sector through adequate funding of health delivery systems. This would substantially 
enhance the health budget. The share of general government budget expenditure allocated to 
health care varies. From as low as 5% in several countries in Africa, Asia and the WHO 
Eastern Mediterranean Region to well over 20% in some countries in Americas, great inequality 
exists between these health expenditure ratios. One-third of low income countries allocated 
over 10% of their national budget to health in 2003.417 The influxes of capital often reach as 
high as 20% from external sources thorough global health partnerships such as the Global Fund 
to Fight AIDS, Tuberculosis and Malaria and the Global Alliance for Vaccine and Immunization, 
and from bilateral donors. However, with no assurance of aid predictability over the long term, 
sustainability is a major concern.418 
State Responsibility on State-Empowered Non-State Actors 
State actors have responsibility and accountability to regulate and enforce international human 
rights laws on their people or entities. The international law of state responsibility has been 
417 WHO and HAl, Medicine Prices: A New Approach to Measurement, 2003, Working Draft for Field Testing and 
Revision, available at: 
http://whglibdoc.who.int/hq/2003/WHO EDM PAR 2003.2.pdf(last accessed on March 19, 2009) 
In most developed countries, health insurance covers a major part of medicine costs; however, in some African and 
Asian countries, because the pharmaceutical price is so high, the medicine and health spending could dominate 
around 80% of a household's income. 
418 World Health Statistics 2006, P. 16, also available at 
www.who.int/whosis/whostat2006.pdf 
- 174-
developed to cover state-empowered non-state actors, especially for the privatized state 
corporations which retain public or regulatory functions. 
Article 5 of Articles of State Responsibility of International Law Commission (ILC)419 
refers to the increasing phenomena of non-state actors exercising governmental authority, mostly 
in the situations of formerly state-controlled corporations which have been privatized but still 
retain certain public or regulatory functions.420 Article 5 reads as: 
The conduct of a person or entity which is not an organ of the State under article 4 but 
which is empowered by the law of that State to exercise elements of the governmental 
authority shall be considered an act of the State under international law, provided the person 
or entity is acting in that capacity in the particular instance. 
The Commentary also explained the intended scope of Article 5: 
(2) The generic term 'entity' reflects the wide variety of bodies which, though not organs, 
may be empowered by the law of a State to exercise elements of governmental authority. 
They may include public corporations, semi-public entities, public agencies of various 
kinds and even, in special cases, private companies, provided that in each case the entity 
is empowered by the law of the State to exercise functions of a public character 
normally exercised by State organs, and the conduct of the entity relates to the exercise 
of the governmental authority concerned. For example in some countries private 
security firms may be contracted to act as prison guards and in that capacity may 
exercise public powers such as powers of detention and discipline pursuant to a judicial 
sentence or to prison regulations. 
Therefore, states will be responsible for the acts and omission of the non-state actors at the 
international level when the behavior constitutes an internationally wrongful act and the entity 
was acting in that capacity in the particular instance. Nation states will be responsible for the 
419 International Law Commission, Draft Articles on Responsibility of States for Internationally Wrongful Acts, 
200 I, available at 
http://untreaty.un.org/ilc/texts/instruments/english/draft%20articles/9 6 200 l.pdf (last accessed on March 19, 2009) 
420 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of States with Regard to Non-State 
Actors in the Context of the Right to Health', P.5, 2002, also available at 





acts of the empowered non-state actors where they carry out governmental activities, but not 
when those activities are un-related to the governance responsibilities of the actors.421 
Article 5 of the ILC covers entities that have been privatized or granted governmental 
powers by internal, domestic law. The internal law in question must specifically authorize the 
conduct as involving the exercise of public authority. Whether the non-state actors are involved 
with the right to health within the scope of Article 5 depends on the domestic law, history and 
tradition of the state. For example, when the health care has been considered governmental and 
empowered by domestic law, then the act or omission of the non-state actors will be considered 
to be a denial of the right to health attributed to the state under the law of state responsibility.422 
Non-State Actors under State's Control 
When the non-state actors is under the state's actual or direct control, there will be state 
responsibility for all acts or omission of the state-controlled non-state actors if there is evidence 
that the non-state actors were exercising public powers or the state was using its ownership 
interest in, or control of the non-state actors to achieve certain result. 
The commentary of Article 8 in the ILC Draft Articles on Responsibility of States for 
421 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of States with Regard to Non-State 
Actors in the Context of the Right to Health', P.6, 2002, available at · 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf(last accessed on March 19, 2009) 
422 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of States with Regard to Non-State 
Actors in the Context of the Right to Health', P.6, 2002, available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf(last accessed on March 19, 2009) 
However, in the context of a practical approach to the private sector and the right to health, it is unlikely to prove a 
useful avenue to pursue for an organization such as the World Health Organization. Speculating on whether a 
particular society has a tradition ofgovernmental provision of health care, and searching for the pertinent internal 
law which has empowered a large company to operate would clearly distract from the main message of"health for 
all". 
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Internationally Wrongful Acts, 2001, reads: 
The conduct of a person or group of persons shall be considered an act of a State under 
international law if the person or group of persons is in fact acting on the instructions of, or 
under the direction or control of, that State in carrying out the conduct.423 
When the violations or abuses are attributed to the state by the non-state actors, the state 
might be responsible under international and entitled to sanction, just as when the state is the 
actor. When state fails to provide or prevent the human rights violation or human rights abuses 
by the non-state actors, the state might be responsible when human rights bodies exists, such as 
the six UN human rights treaty bodies, or the regional human rights courts, then the state can be 
held responsible and failed in its international human rights obligations.424 
State Responsibility on Non-State Actors within Its Jurisdiction 
State responsibility for health is not only to abstain from violating human rights to health of itself, 
but also to ensure the conditions which enable individuals and other entities to realize their rights 
as fully as possible. Every entity, including individuals and organs of society, shall strive to 
respect, protect and fulfill the international human right to health. 
As mentioned, state actors have responsibility and accountability to regulate and enforce 
international human rights laws. Some countries impose human rights obligations directly on 
423 International Law Commission, Draft Articles on Responsibility of States for Internationally Wrongful Acts, 
2001, available at 
http://untreaty.un.org/ilc/texts/instruments/english/draft%20articles/9 6 2001.pdf (last accessed on March 19, 2009) 
and Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of States with Regard to Non-State 
Actors in the Context of the Right to Health', P.7, 2002, available at 
www. who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf (last accessed on March 19, 2009) 
424 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of States with Regard to Non-State 
Actors in the Context of the Right to Health', P. 7, 2002, available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf (last accessed on March 19, 2009) 
The omission ofthe human rights obligation, sorts of indirect accountability, is often overlooked as one considers 
the ability of the human rights regime to deal with the accountability of the non-state actors. 
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non-state actors, while some others pass legislations for that purpose. 425 
Non-state actors are increasing their influence in relation to economic, social and cultural 
rights. It is the obligation of the state actors to ensure that no individual's or people's rights are 
violated in any way by any discriminatory behavior or undue damage these non-state actors may 
be causing. State actors should set up laws and regulations to control the conduct of non-state 
actors, including: multinational corporations, including pharmaceutical companies; national 
private sector companies; health insurance providers; providers of private health care; medical 
research institutes; international and national NGOs. However, some problems arise due to a 
nation state's inability or unwillingness to ensure that non-state actors conform to international 
human rights.426 
5.2.2 Non-State Actors-Transnational Corporations 
Nation states' international human rights obligations have been featured and established in 
international law and international human rights systems. However, the issue of international 
human rights responsibility and accountability of non-state actors is not totally settled. 
In the wake of the global economic downturn, transnational corporations sell their products 
or services everywhere in the world, and they are able to negotiate with national governments. 
Their power has been so influential that when the industry is the major industry of nation states, 
425 Holger Hestermeyer, Human Rights and the WTO: The Case of Patent and Access to Medicines, P.94-95, Oxford 
University Press, 2007 
426 Andrew Clapham, Human Rights Obligations of Non-State Actors, P.4, Oxford University Press, 2006 
Caroline Thomas suggests that "the globalization is privileging the private over the public sphere and over the 
commons. It is eroding the authorities of states differentially to set the social, economic and political agenda 
within their respective political space. It erodes the capacities of states in different degrees to secure the livelihoods 
of their respective citizens by narrowing the parameters of legitimate state activities". 
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they influence the negotiation of treaties between nation states. While the non-state actors are 
exercising their powers and influences on the forming or negotiation on the international law, 
non-state actors essentially participate in the rule making activities. Acting in tandem with the 
state actors to exercise negotiation power, the non-state actors are like invisible hand of control 
behind the veil of the decision making.427 "[I]ndividuals are increasingly as powerless towards 
big corporations as they are towards the states and that human rights can be violated by both 
states and corporations. "428 The growing sphere of influence 429 and the role of non-state actors 
in the international community have been more crucial than ever under international law. 
The United Nation General Assembly has a Declaration on the Rights and Responsibility of 
Individuals, Groups and Organs of Society to Promote and Protect Universally Recognized 
Human Rights and Fundamental Freedoms in 1999. The declaration stresses that the 
international community shall fulfill human rights protection jointly and separately without any 
distinction. Individuals, groups, institutions and NGOs also have important roles and 
responsibilities to use as appropriate to the promotion of the rights of everyone to a social and 
international order in which the rights and freedom set forth in the Universal Declaration of 
Human Rights (UDHR) and other human rights instruments are honored. In the UDHR calls on 
"every individual and every organ of the society" to strive to promote and respect the rights and 
427 Holger Hestermeyer, Human Rights and the WTO: The Case of Patent and Access to Medicines, P.94-95, Oxford 
University Press, 2007 
428 Holger Hestermeyer, Human Rights and the WTO: The Case of Patent and Access to Medicines, P.94-95, Oxford 
University Press, 2007 
429 UN Global Compact Office and the Office of the UN High Commission for Human Rights, Embedding Human 
Rights in Business Practice, P.l7, available at 
http:/ /www.ohchr.org/Documents/Publications/Embeddingen.pdf (last accessed on March 19, 2009) 
"The concept of sphere of influence is not defined in detail by international human rights standards; it will tend to 
include the individuals to whom the company has a certain political, contractual, economic or geographic 
proximity." All corporations have sphere of influences, no matter how large or small, local or transnational, though it 
is obvious that large transnational corporations tend to have more sphere of influences. 
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freedoms it contains and to secure their effective recognition and observance. The concept of 
"every organ of the society" covers non-state actors, such as corporations.430 General Comment 
No.14 also makes clear that non-state actors have responsibilities and can violate those 
responsibilities due to failure to fulfill their obligations.431 
The UN Sub-Commission for the Protection and Promotion of Human Rights, states some 
international human rights to health in these relevant paragraphs: 
12. Transnational corporations and other business enterprises shall respect civil, cultural, 
economic, political and social rights and contribute to their realization, in particular the 
rights to development; adequate food and drinking water; the highest attainable standard 
of physical and mental health; adequate housing; education; freedom of thought, 
conscience and religion; and freedom of opinion and expression; and refrain from actions 
which obstruct the realization of those rights. 
14. Transnational corporations and other business enterprises shall carry out their activities in 
accordance with national laws, regulations, administrative practices and policies relating 
to the preservation of the environment of the countries in which they operate as well as in 
accordance with relevant international agreements, principles, objectives, responsibilities 
and standards with regard to the environment as well as human rights, public health and 
safety; and shall generally conduct their activities in a manner contributing to the wider 
goal of sustainable development. 
Looking at Professor Chris Okeke's criteria, transnational corporations (TNCs) should be 
subjected to human rights responsibility and accountability since they enjoy having rights, 
possess duties and are empowered to vindicate their rights. The most difficult problems remain 
with how TNCs and other business enterprises shall contribute to the realization of the rights to 
43° CESER, 'Declaration on the Right and Responsibility of Individuals, Groups and Organs of Society to Promote 
and Protect Universally Recognized Human Rights and Fundamental Freedoms, 1999, available at 
http://www.unhchr.ch/huridocda!huridoca.nsf/(Symbol)/ A.RES.53 .144.En?OpenDocument (last accessed on March 
19, 2009) and UN Global Impact Office and UN OHCHR, Embedding Human Rights in Business Practice, P.15, 
available at 
http:/ /www.ohchr.org/Documents/Publications/Embeddingen.pdf (last accessed on March 20, 2009) 
431 CESER, General Comment No.14, P.l2-13, 2000, available at 
www.unhchr.ch/tbs/doc.nsf/(symbol)/E.C.l2.2000.4.En?OpenDocument (last accessed on March 20, 2009) 
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the highest attainable standard of physical and mental health, human rights and public health. 
Pressure from advocates is directed at imposing a duty to corporate entities to respond to the 
right to health and bear the accountability and responsibility. The most common case is neglect 
of the human rights violation or omission of non-state actors by the state actor. Lately, there 
has been a focus on corporate social responsibility in the areas of labor rights and environmental 
protection432 and trying to extend that responsibility to other areas of human rights. 
Nicola Jligers divides this issue into respect, protection and fulfillment in the environmental 
law, labor law and consumer protection. The draft norms on the responsibility of transnational 
corporations and other business enterprises with regard to human rights also focus on the right to 
equal opportunity and non-discriminatory treatment; the right to security of persons; the rights of 
workers; consumer protection; environmental protection; and economic, social and cultural 
rights. To fulfill their corporate duty to respect the right to health, a company is required to 
abstain from operations which may cause environmental problems in the working environment 
which may cause the health problem to employees and the people residing on the land. 
Negligence or intentional disregard for these protections, including allowing unsafe or unhealthy 
products to enter the marketplace, violates this duty. For corporations, the duty to protect the 
right to health relies on the underlying determinants of the right to health, such as food and 
nutrition, housing, access to safe and portable water and adequate sanitation, safe and healthy 
432 UN Global Compact Office and the Office ofthe UN High Commissioner for Human Rights, Embedding 
Human Rights in Business Practice, P.99-118, available at 
http://www.ohchr.org/Documents/Publications/Embeddingen.pdf (last accessed on March 20, 2009) 
"Human rights and supply chain management in the pharmaceutical sector", the case study of how Novo Nordisk 
integrated human rights, including labor rights, into its supply chain management and the human rights dimension of 
the work. 
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working conditions and the environment. This duty may require corporations to adopt 
guidelines433 in order to ensure the activities of business partners will not lead to violations of 
other individuals' right to health. For example, a corporation may meet its obligation to fulfill 
right by providing its employees with health care services and hospitals. 434 Nicola Jager 
focuses on the duty of a corporation to facilitate realization of the right to health of its employees 
rather than a general obligation to fulfill the right to health to everyone. 
As mentioned, relying on state actors to ensure TNCs comply and non-violate with human 
rights norms might be more difficult than among all non-state actors because TNCs are often 
more economically powerful than the state actors in the trading of benefits to attract investment. 
Some of the state actors are not likely to enforce or regulate TNCs, fearing that it will chill 
investment. Moreover, though the TNC's home state should bear the responsibility to regulate 
and enforce the international human rights norms, the enforcement is usually weak, because of 
the interested relationships between the state and the TNCs. 
Furthermore, when there is violation of human rights by TNCs, sanctions on the nationality 
state of the TNCs will not be effective. The effectiveness of sanctions has been criticized 
hardily, but over all, it appears that the political gain of sanctions is usually out weighted by the 
pain of civilian suffering and the wrongdoer TNCs remains untouched while innocent peoples 
are gratuitously harmed.435 
433 The guidelines are usually referred as "code of conduct". 
434 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of States with Regard to Non-State 
Actors in the Context of the Right to Health', P.16, 2002, also available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf (last accessed on March 20, 2009) 
435 Sofia Gruskin, Michael A. Grodin, George J. Annas, and Stephen P. Marks edited, Perspectives on Health and 
Human Rights, P. 369~370, Routledge, 2005 
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TNCs currently favor voluntary codes of conduct, guidelines, and sectoral initiatives to 
reflect their tackle on the human rights protection. 
OECD Code of Conduct 
OECD has elaborate Guidelines for TNCs. Transnational corporations shall bear a voluntary 
heavy moral responsibility when engaging activities, however, the "OECD Code of Conduct" 
was constituted only as a recommendation. 
Moral/Social Responsibility 
The classic concept of corporate responsibilitl36 was composed by Milton Friedman, who 
famously declared: "The social responsibility of business is to increase its profits." The primary 
corporate accountability is to shareholders to maximizing the profit and only constraint the 
conduct pursuit of profits legally comply the law.437 
The Sub-Commission on the Promotion and Protection of Human Rights has adopted a set 
of draft norms, based on existing international standards that seek to identify which human rights 
apply directly to companies. The "Norms of the Responsibilities of Transnational Corporations 
and Other Business Enterprises with regard to Human Rights" focuses on the right to equal 
opportunity and non-discriminatory treatment; the right to security of persons; the right of 
436 The moral obligation of business has been discussed since late 1990s, the term sometimes called, 'code of 
conduct', 'business ethics', 'corporate sustainability', 'good corporate citizenship' or 'corporate social 
responsibility' . 
437 Doreen McBamet, 'Human Rights, Corporate Responsibility and New Accountability', Tom Campbell and 
Seumas Miller edited, Human Rights and the Moral Responsibility of Corporate Public Sector Organization, P.64, 
Springer , 2004 
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workers; consumer protection; environmental protection; and economic, social and cultural 
rights.438 
However, the norms are not legally binding, but provide a guideline and explanation for 
companies to understand human rights in the hope that corporations will undertake, embrace and 
incorporate the norms into their policies. 
UN Global Compact 
The United Nation' Global Compact is a voluntary initiative asking participating companies to 
embrace, support and enact, within their sphere of influences, policies concerning human rights, 
1 b . h . 1 . d . . h 439 a or ng ts, envuonmenta protectiOn, an antl-corruptwn measure, among ot ers. Principle 
one and two of the UN Global Compact focus on human rights protection. However, the 
measures are voluntary and lack binding power. 
Human Rights Guidelines for Pharmaceutical Companies in Relations to Access to Medicines440 
This guideline confirmed that having accessible and affordable pharmaceutical products is vital 
to the right to the highest attainable standard of health. It also confirmed state actors as the 
primary actor to provide health care system to its people, but also addressed non-state actors, 
such as pharmaceutical corporations, requiring them to share responsibilities to increase access 
438 Commission on Human Rights, Sub-Commission on the Promotion and Protection of Human Rights, Norms on 
the Responsibility of Transnational Corporations and Other Business Enterprises with regard to Human Rights, 2003 
http://www.unhchr.ch/huridocda/huridoca.nsfi(Symbol)!E.CN.4.Sub.2.2003.12.Rev.2.En (last accessed on March 20, 
2009) 
439 UN Global Compact, available at 
www.unglobalcompact.org/AboutTheGC/TheTenPrinciples/index.html (last accessed on March 20, 2009) 
440 General Assembly ofthe UN Special Rapporteur on the Right to the Highest Attainable Standard of Health (UN 
document:A/63/263. dated 11 August 2008), 2008, available at 
http://www2.ohchr.org/english!issues/healthlright/docs/Guidelinesfm:pharmaceuticalcompanies.doc (last accessed on 
March 20, 2009) 
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to medicines. 441 
However, although this guideline addresses on the concerns on management, monitoring 
and accountability, corruption, public policy influence, advocacy and lobbying, clinical trials, 
neglect diseases, patent and licensing, pricing, discounting and donations and ethical promotion 
and marketing,442 this guideline is only a recommendation to pharmaceutical companies, with no 
binding power. Moreover, the guideline guides pharmaceutical companies to provide more 
accessible pharmaceutical products, but does not address what responsibility and accountability 
pharmaceutical companies have to the international human right to health and the inaccessible 
and unaffordable pharmaceutical price effects caused by the non-violation of pharmaceutical 
industry-negotiated TRIPS agreement. 
Both the states and non-state actors prefer voluntary initiative to legal binding commitment. 
However, voluntary initiatives have been criticized as ineffective in the field of human rights 
protections. Good developments require stakeholders to be accountable for specific result for 
violation and neglect. Some advocates focus on the need to give "teeth" to international 
instruments by moving social responsibility towards legal obligations or even accountabilities in 
some field of protection to uphold international standards, which could have imminent effects on 
the human population. 
441 CESCR, General Assembly of the UN Special Rapporteur on the Right to the Highest Attainable Standard of 
Health (UN document:N63/263. dated 11 August 2008), 2008, available at 
http://www2.ohchr.org/english/issues/healthlright/docs/Guidelinesfm:pharmaceuticalcompanies.doc (last accessed on 
March 20, 2009) 
Pharmaceutical companies, including innovator, generic and biotechnology companies, have human rights 
responsibility in relationship to access to medicines and enhance shareholder value. 
442 CESCR, General Assembly of the UN Special Rapporteur on the Right to the Highest Attainable Standard of 
Health (UN document:N63/263. dated 11 August 2008), 2008, available at 
http://www2.ohchr.org/english/issues/healthlright/docs/Guidelinesforpharmaceuticalcompanies.doc (last accessed on 
March 20, 2009) 
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5.2.3 Conclusion 
The right to health obligates nation state actors to be responsible and accountable to ensure that 
there is a health care system delivering right to health outcomes. State actors also acquire 
responsibility and accountability which fail to ensure the powerful transnational corporations 
respect human rights responsibilities. 
Nation states are also obligated to live up to international obligations in human rights to 
ensure that their own action, and those of other actors under its control, do not violate or 
contravene human rights norms. 
Trade globalization has brought the world closer, and offers opportunities for access to 
previous closed markets for products and services. However, it also has an impact on the 
realization of human rights, especially the right to health, including a healthy environment, labor 
rights, and access to affordable medicines. 
The human rights to health in the context of pharmaceutical products might be an issue for 
both state actors and non-state actors. As pharmaceutical product expenses also contribute to 
the health care expenditure, without accessible and affordable pharmaceutical products, state 
actors will have problem providing accessible and affordable health care to their people. 
Moreover, though pharmaceutical transnational corporations might receive subsidies from 
some nation states, pharmaceutical companies are not empowered or under direct control by state 
actors in order to impose responsibility and accountability. Even if pharmaceutical companies 
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are empowered or under direct control by state actors, other state actors are not able to pursue 
international liability to pharmaceutical companies when there is absent for injuries 
consequences arising out of Acts not prohibit by international law by acting in compliance of 
international law, but the effect in inaccessible and affordable pharmaceutical products.443 
Furthermore, the existing responsibility and accountability of non-state actors focus on 
direct violation on human rights by tortious act, environmental pollution and consumer 
protection. However, when the pharmaceutical prices are so inaccessible and unaffordable, 
there is an emergent questions of what responsibility and accountability can be imposed on 
transnational pharmaceutical corporations when there is no direct violation of laws. 
5.3 Conclusion 
Too often, economic power trumps politics in the development of international norms in 
response to globalization. There must be new ways to understand transnational justice and 
global law. Andrea Bianchi suggests that transnational civil society networks and 
1 . . d d' f h . h 444 non-governmenta orgamzat10ns create our un erstan mg o uman ng ts. However, in the 
legal approach, non-state actors exist as actors within the international community, but operate 
independently of binding obligations, responsibilities and accountability under international law. 
International law is lively, growing and expanding, but subject to restrictions. We need to 
examine all the actors under international law, though not give the same "status" to all actors. 
States have obligations not only to their own population, but also have obligations to take 
443 Sompong Sucharitkul, 'State Responsibility and International Liability under International Law', 18 Loy. L.A. 
Int'l & Comp. L.J. 821, 1996 





steps through international assistance and cooperation toward the full realization of the right by 
all people. In the spirit of United National Charter Article 56445 , the State parties should 
recognize the essential role of international cooperation and comply with the commitment to take 
joint and separate action to achieve the right. 
The protection of international human rights is a trend of progression. Although there are 
different kinds of human rights, the ultimate goal of the protections is to respect, fulfill and 
protect human dignity. The international community has taken steps towards further realization 
of international human rights and international co-operation in needed by everyone in the 
international community. 446 
THE LAYERS OF CAPACITY NEEDED FOR THE FULFILMENT OF HUMAN RIGHTS 
Although the right to health is sometimes recognized, there are difficulties in implementing 
445 United Nation, Charter of United Nation, available at 
http://www.un.org/aboutun/charter/index.html (last accessed on March 19, 2009) 
Article 56 
All Members pledge themselves to take joint and separate action in co-operation with the Organization for the 
achievement of the purposes set forth in Article 55. 
446 CESCR Council, The Nature of States Parties Obligations, General Comment 3, 1999, available at 
http://www. unhchr.ch/tbs/doc.nsf/(symbol)/CESCR +General+comment+ 3 .En?OpenDocument (last accessed on 
March 19, 2009) 
In the General Comment 3 ofCESCER, the Committee addressed the attention on the State parties' international 
obligation to take steps, individually and through international assistance and cooperation, especially economical 
and technical towards the realization of the right to health. 
447 Human Rights, 'Health and Poverty Reduction Strategies', P.17, 2005, available at 
http://www.who.int/hdp/publications/human rights.pdf(last accessed on March 20, 2009) 
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and enforcing the right due to the character of the right to health, which unlike other economic, 
social and cultural rights depends on the state's available resources. There is insufficient 
attention given to how international law might be implemented within the changing context of 
globalization with regards to health. The free-market based economy has driven both state 
actors and non-state actors into more difficulties with the attempts to ensure economic, social and 
cultural rights in the field of health. 
The health of its population is one nation state's responsibility to the extent of its capacity, 
which depends on its resources, but with the issues of infectious and chronic diseases, the public 
and individual health become the concerns of everyone. In fighting against diseases, the 
socioeconomic inequalities have adverse effects on health. In the rapid wake of globalization 
and privatization, attention must be paid to both nation states and non-state actors448 in order to 
fully grasp the essential influences that contribute to the right to health. 
448 Sofia Gruskin and Daniel Tarantola, 'Health and Human Rights', Sofia Gruskin, Michael A. Grodin, George J. 
Annas, and Stephen P. Marks edited, Perspectives on Health and Human Rights, P.29, Routledge, 2005 
Non-state actors can involve within the right to health by themselves or governments could delegate their roles and 
responsibilities to non-state actors, for example, biomedical research institutions, international foundations, health 
insurance companies, care providers, health management organizations and the pharmaceutical industry. In the 
situations of the delegated responsibilities, the accountability of non-state actors is poorly defmed and inadequate 
monitored in most cases. 
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Chapter 6: Enforcement 
6.1 Implementation and Enforcement 
Legal enforcement mechanisms have been the central focus of many human rights advocates. 
State parties are the primary obligors to safeguard human rights by implementing and enforcing 
the rights following treaty provisions. International human rights instruments have committees 
to deal with disputes and violations. Some covenants explicitly state that state parties may use 
other procedures for the settlement of disputes in accordance with the agreement. Other 
regional agreements even provide inter-state dispute mechanisms to the relevant regional body or 
court.449 
Implementation of international human rights is usually complicated. The codified treaties 
have stronger binding power on state parties, and declarations typically have weaker binding 
power, whereas customary international law can have either strong or weak binding power. 
6.1.1 International Human Rights Treaties and Regional Agreements 
Treaties are binding on the countries that ratify them, but are sometimes subject to reservations. 
The key international human rights treaties are the International Covenant on Economic Social 
and Cultural Rights 1966 (ICESCR), and the International Covenant on Civil and Political Rights 
1966 (ICCPR),450 both of which elaborate on the Universal Declaration of Human Rights 1948 
(UDHR). Besides these core documents, other international human rights treaties451 focus on 
449 Andrew Clapham, Human Rights Obligations of Non-State Actors, P.92, Oxford University Press, 2006 
450 International Bill of Human Right: After World War II, the international communities adopted Universal 
Declaration ofhuman Rights 1948 (UDHR). Two separate treaties were created in 1966: the International Covenant 
on Economic, Social and Cultural Rights (ICESCR) and the International Covenant on Civil and Political Rights 
(ICCPR). The West argued for civil and political rights prior social and economic rights. The East argued that food, 
health, education was paramount and civil and political rights should be later. 
451 WHO, International human rights treaties/conventions, available at 
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either specific groups or categories of populations, such as racial minorities,452 indigenous 
populations,453 women,454 children,455 disabilities,456 migrants,457 or on specific issues, such as 
torture,458 genocide,459 and victims of crime.460 
The civil and political rights are generally included in the constitutional text or other legal 
orders demanding that the state abstain from violating certain rights. Thus, victims of unlawful 
governmental interference can claim violation under the legal system in which these infractions 
took place. Nation states have been more reluctant to incorporate economic, social, and cultural 
rights, though these rights are being incorporated progressively through recognition by an 
increasing number of countries. 
State actors are the primary party responsible for the protection of human rights. State 
actors must implement and enforce these rights. The international human rights mechanisms 
monitor, promote and coordinate the rights with the state actors. State actors will be held 
http://www.who.int/hhr/readings/treaties/en/index.html (last accessed on March 20, 2009) 
452 International Convention on the Elimination of All Forms ofRacial discrimination, 1963, available at 
http://www.unhchr.ch/html/menu3/b/9.htm (last accessed on March 20, 2009) 
453 Convention Concerning Indigenous and Trial Peoples in Independent Countries, 1989 
454 Convention on the Elimination of All Forms against Women 1979 
http://www2.ohchr.org/english/law/cedaw.htm (last accessed on March 20, 2009) 
455 Convention on the Rights of Child, 1989, available at 
http://www.unhchr.ch/html/menu3/b/k2crc.htm (last accessed on March 20, 2009) 
456 Convention on the Rights of Persons with Disabilities, 2007, available at 
http://www.un.org/disabilities/convention/conventionfull.shtml (last accessed on March 20, 2009) 
457 International Convention on the Protection of the Rights of All migrant Workers and Members their Families, 
1990 
http://www2.ohchr.org/english/law/cmw.htm (last accessed on March 20, 2009) 
458 Convention against Torture and other Cruel, Inhuman or Degrading Treatment or Punishment, 1984, available at 
http://www2.ohchr.org/english/law/cat.htm (last accessed on March 20, 2009) 
459 Convention on the Prevention and Punishment ofthe Crime of Genocide, 2003, available at 
http://www. unhchr.ch/Huridocda!Huridoca.nsf/(Symbol)/E.CN .4.RES.2003 .66.En?Opendocument (last accessed on 
March 20, 2009) 
46° Convention for the Suppression of the Traffic in Persons and of the Exploitation of the Prostitution of Others, 
1949, available at 
http://www2.ohchr.org/english/law/trafficpersons.htm (last accessed on March 20, 2009) 
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accountable if they fail to give effect to the rights. 
The human rights mechanisms are divided into two categories: charter-based mechanisms 
and treaty-based mechanisms. 
The treaty-based human rights mechanisms are derived from provlSlons contained in 
specific legal instruments, and these mechanisms hold more narrow mandates, address unlimited 
audiences in the countries that have ratified them, and base their decision-making on consensus. 
This group includes the Committee against Torture, the Committee on Economic, Social and 
Cultural Rights, the Committee on the Elimination of Racial Discrimination, the Committee on 
the Protection of the Rights of All Migrant Workers and Members of their Families, and the 
Committee on the Right of the Child, and Human Rights Committee.
461 
State parties are required to submit progress reports to the treaty bodies and their 
populations. The monitoring bodies meet regularly to review state parties' reports and to 
engage in a "constructive dialogue" with governments on how to live up to their human rights 
obligations. At the end of each session, the treaty body makes concluding observations which 
include recommendations to the government. Other specialized agencies can also facilitate the 
dialogue between the state parties and treaty monitoring bodies.
462 
The charter-based human rights mechanisms are derived from the provisions contained in 
461 United Nations Documentation Research Guide, Human Rights, available at 
http://www.un.org/Depts/dhVresguide/spechr.htm (last accessed on March 20, 2009) 
462 WHO, 25 Questions & Answers on Health & Human Rights, P.l2, 2002, available at 








the Charter of the United Nations, and these mechanisms hold broad human rights mandates, 
address an unlimited audience and take action based on majority voting. This group includes the 
Human Rights Council, the Commission on Human Rights, and the Sub-commission on the 
Promotion and Protection of Human Rights. 463 
The bodies appoint special reporters, independent experts and working groups to monitor 
and report on human rights issues or human rights conditions in specific countries. 464 
There are other regional arrangements of human rights protection within regional 
intergovernmental organizations. The organizations monitor, promote, protect and coordinate 
the human rights in those regions. Examples of the regional human rights protection 
instruments include the African Charter on Human and People's Rights in African region, the 
American Convention of Human Rights in American region, and the European Convention on 
the Protection of Human Rights and Fundamental Freedoms in the European region. The Asian 
Pacific regional organization is still under development.465 
While these international mechanisms are monitoring at an international level, they still 
have limited capacity to ensure effective and systematic monitoring. None of the international 
treaties contains international monitoring mechanisms for nation states or individual to file 
complaints. This can be done more easily at the national level. Civil society can reveal and 
463 United Nations Documentation Research Guide, Human Rights, available at 
http://www.un.org/Depts/dhVresguide/spechr.htm (last accessed on March 20, 2009) 
464 United Nations Documentation Research Guide, Human Rights, available at 
http://www.un.org/Depts/dhVresguide/spechr.htm (last accessed on March 20, 2009) 
465 WHO, 25 Questions & Answers on Health & Human Rights, P.l3, 2002, available at 
http://www.who.int/hhr/NEW378710MSOK.pdf(last accessed on March 20, 2009) 
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highlight problems through coalitions and networks.466 However, relying on the nation states to 
comply with the protections of the right to health poses some obstacles. For those nation states 
as the obligor for the right, the only monitoring mechanism is the state's own reporting procedure, 
and if there are failures of implementation and compliance with the right to health, the reports 
will not be effective in improving compliance with the right. Most of the times, state parties do 
not file reports or the content of the reports are self-serving, unhelpful or reflect an unwillingness 
to improve the condition. Therefore, there are proposals suggesting that an individual 
complaint procedure be added for furtherance of the realization of the right.467 
6.1.2 Non-Binding International Human Rights Instruments 
The non-binding international human right to health instruments are usually in the form of 
declarations, comments, and resolutions. Even though non-binding, they offer guidelines for 
actors in the field of international law. With the wide acceptance of the soft laws, sometimes 
these laws can be seen as initial evidence of the customary character of the norm and may be 
evidence of customary obligations for all states where there is a degree of state practices468 that 
later might form into part of customary international law. 
The main human right declaration is the Universal Declaration of Human Rights 1948. 
Other declarations469 are focused on specific groups, such as women,470 disabled persons,471 or 
466 WHO, Third Informal Consultation on Health and Human Rights, P.7, 2002, available at 
http://www.who.int/hhr/information/en/Human Rights Day2002report.pdf(last accessed on March 20, 2009) 
467 David P. Fidler, International Law and Public Health: Materials on and Analysis of Global Health Jurisprudence, 
P.307, Transnational Pub, 2001 
468 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context of the Right to Health', P.20, 2002, available at 
www. who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf (last accessed on 1 March 20, 2009) 
469 WHO, International declaration, norms and standards, available at 
http://www.who.int/hhr/readings/declarations/en/index.html (last accessed on March 20, 2009) 
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specific issues on the right to development,472 individually recognize human rights,473and the 
use of scientific and technological progress.474 Consensual policy475 and regional documents476 
are non-binding, and include sl,lch formats as declarations and programs of action. 
Declarations from international organizations provide guidance on some policy 
implementation, but declarations are non-binding; however, norms and standards instituted 
therein could become binding as customary international law. 
6.1.3 Customary International Human Rights Law 
According Article 38 of the Statute of International Court of Justice, the source of international 
law include international convention; international custom, as evidenced by general practices 
accepted as law; the general principle recognized in civilized nations; judicial decisions; and the 
teachings of the most highly qualified publicists of the various nations.477 
470 Declaration on the Elimination ofViolence against Women, 1993, available at 
http://www.unhchr.ch/huridocdalhuridoca.nsfi(Symbol)/ A.RES.48.1 04.En (last accessed on March 20, 2009) 
471 Declaration on the Rights of Disabled Persons, 1975, available at 
http://www.unhchr.ch/html/menu3/b/72.htm (last accessed on March 20, 2009) 
472 Declaration on the Right to Development, 1986, available at 
http://www.unhchr.ch/html/menu3/b/74.htm (last accessed on March 20, 2009) 
473 Declaration on the Right and Responsibility of Individuals, Groups and Organs of Society to Promote and 
Protect Universally Recognized Human Rights and Fundamental Freedoms, 1999, available at 
http://www.unhchr.ch/huridocda/huridoca.nsf/(Symbol)/A.RES.53.144.En (last accessed on March 20, 2009) 
474 Declaration on the Use of Scientific and Technological Progress in the Interests of Peace and for the Benefit of 
Mankind 1975, available at 
http://wwwl.umn.edu/humanrts/instree/s2dustp.htm (last accessed on March 20, 2009) 
475 WHO, International conference documents and follow ups, available at 
http://www.who.int/hhr/readings/conference/en/index.html (last accessed on March 20, 2009) 
476 WHO, Regional Instruments Related to Human Rights, available at 
http://www.who.int/hhr/readings/regionallen/index.html (last accessed on March 20, 2009) 
477 Statute of the International Court of Justice, available at 
http:/ /www.icj-cij .org/documents/index.php?p 1 =4&p2=2&p3=0&PHPSESSID=cd318d9c693d2ae6ec2c3963fc64ac 
f2#CHAPTER II (last accessed on March 20, 2009) 
Article 38 
1. The Court, whose function is to decide in accordance with international law such disputes as are submitted to it, 
shall apply: 
a. international conventions, whether general or particular, establishing rules expressly recognized by the contesting 
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For the formation of customary international law, objectively there is a state practice, 
understood as material acts accomplished by states, and subjectively it is believe that such a 
practice is rendered obligatory by the existence of a rule of law requiring it. The frequency or 
even habitual character of the acts may be considered to be motivated by consideration of 
courtesy, convenience, or tradition, but this frequency by itself is not enough to constitute 
custom. 478 Customary international obligation may also be evidenced through a normative 
instrument. 4 79 
Abi-Saab argues that if a nation state may create custom through practice, it may also 
generate customary international law through a written instrument that does not necessarily 
constitute a treaty. Treaties create convention obligations to their member states, but treaties 
may also create customary obligations for all nation states, for both parties and non-parties to the 
treaty, through further practice. 480 
Non-binding instruments, such as the resolutions of international organization, may be 
states; 
b. international custom, as evidence of a general practice accepted as law; 
c. the general principles of law recognized by civilized nations; 
d. subject to the provisions of Article 59, judicial decisions and the teachings of the most highly qualified publicists 
of the various nations, as subsidiary means for the determination of rules oflaw. 
2. This provision shall not prejudice the power of the Court to decide a case ex aequo et bono, if the parties agree 
thereto. 
478 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context ofthe Right to Health', P.20, 2002, available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf(last accessed on March 20, 2009) 
It is the traditional theory on customary international law developed by the International Court of Justice (ICJ) in the 
North Sea Continental Shelf case. 
479 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context of the Right to Health', P.20, 2002, available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf (last accessed on March 20, 2009) 
480 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context of the Right to Health', P.21, 2002, available at 




binding on every actor in the international community later, when the standards contained in the 
resolution have matured into customary international law. 481 Treaties and non-binding 
international instruments seem to form customary international law in many fields. Through 
general practices by nation states, treaty obligations may become customary international law 
and customary obligations applicable to non-party states.482 
The key element of the formation of customary international law is the general acceptance 
that follows the state practices. Generally, a state's acceptance and recognition form customary 
international law; state practices also help to form the customs in some way. The content and 
criterion of the custom are also created by the state practices. 483 
Once the norms form into customary international law, that custom will bind every actor in 
the international community. If the international human rights norm is mostly practiced 
between nation states and individuals, once the norms ripen into customary international law, the 
norms will then bind individuals, groups, nation states and non-state actors. However, this 
approach requires time to develop, and further discussion is needed regarding the status of 
non-state actors in international human rights law. 
6.1.4 Concluding Summary 
481 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context of the Right to Health', P.21, 2002, available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf (last accessed on March 20, 2009) 
482 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context of the Right to Health', P.21, 2002, available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf(last accessed on March 20, 2009) 
483 Professor Andrew Clapham and Mariano Garcia Rubio, 'The Obligation of State with Regard to Non-State 
Actors in the Context of the Right to Health', P.21, 2002, available at 
www.who.int/hhr/Series 3%20Non-State Actors Clapham Rubio.pdf (last accessed on March 20, 2009) 
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International human rights instruments bind the signatory parties through the application of the 
domestic law of each nation state. International human rights treaties or declarations could form 
into customary international law and bind all actors, including non-signing parties, individuals 
and even non-state actors by customary international law, and therefore compel them to abide by 
the norms of international human rights. 
The right to health has been firmly embedded in a substantial number of UN human rights 
treaties. The UN treaties construe the right to health in broad terms. There are still many 
human rights to health instruments which built their provisions upon the earlier texts but focus 
on specific groups, and these are characterized by more detail than the general human rights 
instruments. 
The above-mentioned regional human rights organizations have included a right to health in 
their instruments, some defining the right to health and some referring more generally to the right 
to health as the right to health care or to a healthy environment. In other cases, regional 
agreements do not explicitly recognize the right to health, but offer indirect protections through 
other health-related rights.484 However, the scope and content of the international human right 
to health remains unconfirmed. 
Most of these regional human rights instruments obligate nation states as the parties 
484 Commission on Human Rights, The Right of Everyone to the Enjoyment to the Enjoyment of the Highest 
Attainable Standard of Physical and Mental Health, E/CNA/2003/58, 2003, available at 
http://daccessdds.un.org/doc!UNDOC/GEN/G03/l 09/79/PDF/G031 0979 .pdf?OpenElement (last accessed on March 
20, 2009) 
There are indirect protections of human rights to health, such as the American Declaration on the Rights and duties 
of Man, the American Convention on Human Rights, the Inter-American Convention on the Prevention, Punishment 
and Eradication of Violence against Women, and the European Convention for the Protection of Human Rights and 





primarily responsible and accountable for the right to health. Notably, Article 27 to 29 of the 
African Charter485 clearly obligates not only the nation states, but everyone in the international 
community, including each individual, group and non-state actor, to be responsible and 
accountable for human rights protection. 
The international human right to health is still developing and growing. Once the right is 
confirmed by customary international law as binding on all actors within the international 
community, the issue will focus on which parties can claim to hold the right, which parties may 
be obligated by it, and to what extent. 
6.2 Proposed Resolution to Balance the Interests 
The imbalance of economic power also greatly affects the realization of the right to health. 
International cooperation and assistance is crucial. Professor Paul Hunt also points out that it is 
important to have international cooperation in realization of the right to health. Developing 
countries have firm obligations arising from the right to health and the developed countries have 
the responsibility to offer assistance to developing countries to emerge from poverty and the 
burden of diseases to realize the right to health for their populations.486 Non-state actors are 
also encouraged or imposed obligations and/or accountabilities to the right to health. 
In order to balance the interests of both transnational pharmaceutical corporations and 
patients/consumers of pharmaceutical products, this dissertation concludes that the financial 
485 African Charter on Human and People's Right, available at 
http://www.achpr.org/english/ info/charter en.html (last accessed on March 20, 2009) 
486 The Right to Health: An Interview with Professor Paul Hunt, 2004, available at 
http://projects.essex.ac.uk:/ehrriv2N 1/Hunt.pdf (last accessed on March 20, 2009) 
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factor is the determinable element underlying this controversy. 
This dissertation proposes to use tiered pncmg systems for pharmaceutical products 
according to the gross domestic product (GPD) or gross domestic income (GDI) to set the price 
of pharmaceutical products in each country, and also a sui generis intellectual property system 
for pharmaceutical products. 
Since TRIPS sets a minimum standard for pharmaceutical products, but not global patent 
law, pharmaceutical industry-based state actors try to negotiate for stronger protection by 
bi-lateral agreements, free trade agreement to strengthen and insure their investment.487 A sui 
generis intellectual property system for pharmaceutical products can offer special protection to 
register, monitor and enforce the intellectual property holder's right in each national state, 
globally. Since pharmaceutical products are so unique in their ability to determine life or death, 
there is a need for a special category for the fruits of the R&D, and these fruits must be given 
special protection. Pharmaceutical companies are not charity, and they need incentives to 
engage in more R&D. Through the global pharmaceutical products system, pharmaceutical 
companies could have more protection on their investment, and could save substantial sums of 
money lost to patent litigation, parallel imports, and grey market pharmaceuticals, and transfer 
the costs to deduct the pharmaceutical products' price to make them accessible and affordable to 
populations. The organization will also manage traditional medicine and medical knowledge, 
to prevent taking of the knowledge without just compensation. 
The patients/consumers will be willing and able to pay for the price of such pharmaceuticals, 
487 It is the so called, "TRIPS-Plus" Agreements. 
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